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ABSTRACT
Activating mutations of ras genes are frequently found in human cancers. Since Ras
proteins and their functions play an important role in tumorigenesis, it is important to develop
targeted anticancer therapeutics against Ras-related human cancers. We observed that in addition
to tumorigenic ability, oncogenic H-Ras possesses a novel proapoptotic ability to facilitate the
induction of apoptosis by histone deacetylase inhibitors (HDACIs), such as FR901228 and
trichostatin A (TSA). HDACIs make up a new class of structurally diverse anticancer agents and
have been shown to exhibit antimetastatic and antiangiogenic activities toward malignantly
transformed cells. We detected that expression of oncogenic H-Ras potentiated intracellular
reactive oxygen species (ROS) in human and mouse cells to enhance HDACI-induced ROS,
thereby contributing to the induction of selective apoptosis and caspase activation.
The first part (Part I) of this dissertation focuses on the understanding of Ras proteins, their
role in normal and transformed cell physiology, and current treatment options against Ras-related
human cancers, as well as the role of HDACIs and ROS in anticancer therapeutics. The next three
parts (Part II-IV) focus on revealing the mechanisms for the novel pro-apoptotic ability of
oncogenic H-Ras that allow HDACIs to induce selective apoptosis of the oncogenic H-Ras
expressing cells. Results in Part II & III verify the pro-apoptotic activity of oncogenic H-Ras in
the increased susceptibility of human cancer cells to HDACIs. The caspase pathways, the B-Raf
and extracellular signal regulated kinase pathway, p21Cip1 and p27Kip1, and core histone contents
are regulated differently by FR901228 in oncogenic H-Ras–expressed cells than their counterparts
in parental cells, contributing to the increased susceptibility to the induction of selective apoptosis.
Results in Part IV describe the role of reactive oxygen species in the pro-apoptotic ability of
iv

oncogenic H-Ras to enhance the cell susceptibility to HDACIs. Intracellular ROS was
cooperatively up-regulated by oncogenc H-Ras and HDACI treatment to induce selective
apoptosis of oncogenic H-Ras-expressing cells. The last section (Part V) summarizes the findings
with their importance and discusses future directions.
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PART-I
BACKGROUND AND OVERVIEW
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ras oncogene in human cancer
Cancer and Oncogene
Cancer is characterized by uncontrolled cell growth and differentiation where a normal
cell becomes progressively transformed to a malignant one. This transformation results from
sequential acquisition of mutations in the cellular genome that causes changes in the gene
functions responsible for maintaining a balance between cell proliferation and cell death. These
mutational damages can cause (i) activation of oncogenes, which stimulate proliferation or
protect against cell death, and (ii) the inactivation of the tumor suppressor genes, which would
normally inhibit proliferation. These genetic changes in tumor tissue lead to excessive cell
proliferation as compared to cell death. In normal tissue, on the other hand, a strict balance
between cell proliferation and cell death is always maintained.
Oncogenes are activated proto-oncogenes that promote cellular transformation. Normally
their products will perform different essential functions inside a cell such as transmission of
growth-promoting signals from cell surface to the nucleus (e.g. src, ras), transcription regulation
(e.g. myc, c-jun), or regulation of cell death (e.g. bcl2). These genes are dominantly acting since
only one copy of the gene has to undergo mutation to produce a change in cellular control. On
the other hand, both copies of the tumor suppressor gene (e.g. Rb, p53) must be lost, mutated or
inactivated for malignant transformation.
The next hurdle for an aspiring cancer cell after overcoming the controls on cell birth and
cell death is telomere erosion that sets the limit for endless cell division. Telomeres are nontranscribed regions at the end of chromosomes that shortens with every cell division. This
process induces replicative senescence and blocks cell division. Telomerase, the enzyme that
2

repairs the eroded telomeres, is expressed in limited fashion in somatic cells; therefore the
somatic cells are allowed only a limited number of cell divisions (1). Telomerase upregulation
has been observed in most of human malignancies and helps the cancer cells to maintain
telomere length in order to become immortal (2). Once immortalized, these continuously
dividing cells need enough supplies of nutrients and oxygen to maintain a high rate of
proliferation. To meet this demand a solid tumor may start the process of angiogenesis by
stimulating the release of several growth factors e.g. vascular endothelial growth factor (VEGF)
from tumor cells as well as the surrounding normal cells (3,4).
Much of the current molecular research is directed towards identifying genes that are
altered in various types of tumors and elucidating the role of these genes in carcinogenesis. A
family of genes that is frequently found to harbor a mutation in human tumors is that of the ras
oncogenes.

ras oncogene
ras is a family of genes that is widely activated in human cancer. In fact ras was the first
oncogene to be discovered in human cancer (from a bladder tumor) (5). In humans there are
three functional genes in this family; H-ras, K-ras, and N-ras. The Ras genes encode four highly
similar 188-189 amino acid proteins with molecular weights of 21,000 (H-Ras, N-Ras, K-Ras4A
and K-Ras4B). The two forms of K-Ras diverge solely in their COOH-terminal 25 amino acids
as a consequence of alternate exon utilization (Figure 1). Mutated ras genes in human tumors can
be detected by their ability to transform NIH/3T3 cells into immortalized cells (NIH/3T3
transfection assay). In early research, this assay was used in combination with nude mouse
3

tumorigenicity test to reveal the positions at which activating point mutations occurred. Such
point mutations are mostly seen in codons 12, 13 and 61 of the three ras genes. The most
frequent alteration is a codon 12 G Æ T transversion causing a glycine Æ valine amino acid
substitution (6). Currently the incidence of mutated ras genes in various human tumors can be
easily detected by detecting point mutations with the help of various biochemical assays such as
selective hybridization with synthetic oligodeoxynucleotide probes specific for a known
mutation, RNase mismatch cleavage or by sequence analysis after PCR amplification of the ras
gene segments known to contain point mutations. These assays have provided information on the
presence and incidence of mutated ras genes in a variety of tumor types. Specific associations
have been found between the various ras oncogenes and particular types of human cancer (Table
1). K-ras mutations are found mainly in pancreatic and colonic carcinomas, H-ras mutations are
frequent in bladder carcinomas, and N-ras mutations are linked primarily to lymphoid
malignancies and melanomas. Some tumor types, like thyroid tumors, seem to lack any
specificity and activating mutations are seen in all three ras oncogenes (7,8).

Regulation of Ras functioning
Post-translational modifications
Ras proteins are small GTPases and act as signal transduction molecules at the inner
surface of plasma membrane in response to various extracellular stimuli. After their synthesis,
cytoplasmic Ras proteins must undergo post-translational modification (lipid processing) at their
C terminus that facilitates their association with the plasma membrane in order to carry out
4

intracellular functions. Hence, post-translational modification of Ras proteins is the key
determinant of their functioning. The C terminus is highly divergent among the Ras family
members and contains the membrane-targeting sequences (Figure 1). Three enzymes that
sequentially modify the C-terminal CAAX motif of Ras proteins catalyze post-translational lipid
processing, where C is cysteine, A is usually an aliphatic residue and X is any amino acid
(Figure 1). First a farnesyl isoprenoid lipid is attached to Ras proteins by the enzyme
farnesyltransferase (FTase). In the presence of FTase inhibitors, both K-Ras-4A and N-Ras can
become prenylated by geranylgeranyl transferase (9). This prenylation reaction is followed, in
the endoplasmic reticulum, by the proteolytic cleavage of the last three amino-acid residues
(AAX) by Ras-converting enzyme-1 (RCE1), and by the carboxymethylation of the now
terminal Cys residue by isoprenylcysteine carboxyl methyltransferase-1 (ICMT1). The Cterminal Lys residues in K-Ras-4B are sufficient to anchor it in the membrane, whereas H-, Nand K-Ras-4A require a palmitoylation step in which a palmitoyl moiety is attached to the Cterminal upstream Cysteine residues by palmitoyltransferase (PTase) before their insertion in the
membrane is stabilized (10,8).
GTPase cycle and GAP- and GEF-mediated regulation
At inner surface of the plasma membrane Ras proteins serve as binary molecular switches
to transduce extracellular ligand-mediated stimuli into the cytoplasm to control signal
transduction pathways that influence cell growth, differentiation and apoptosis. As shown in
figure 2, biological activity of Ras is controlled by a regulated GDP/GTP cycle. The binding of
GTP to Ras proteins locks them in their active states, which enables high affinity interactions
5

with downstream targets that are called effectors. Subsequently, a slow intrinsic GTPase activity
cleaves off the gamma-phosphate, leading to Ras functional inactivation and thus the termination
of signaling. Since the intrinsic GDP/GTP exchange and GTP hydrolytic activity of Ras is very
low, two types of regulatory proteins modulate cellular control of GDP/GTP cycling. Guanine
nucleotide exchange factors (GEFs) or GTP-releasing proteins/factors (GRPs/GRFs), such as
RasGRF and son of sevenless (SOS), promote formation of the active GTP-bound state whereas
Ras GTPase activating proteins (GAPs), such as p120GAP or neurofibromin (NF1), promote
formation of the inactive GDP-bound state. Oncogenic Ras mutant proteins are locked in the
active GTP-bound state, as point mutations at 12, 13 or 61 codons render them insensitive to
GAP stimulation leading to constitutive, deregulated activation of Ras function (11).

Downstream effector signaling
In general, Ras mediated signaling involves its activation and recruitment to the plasma
membrane following receptor Tyrosine kinase (RTK) stimulation by growth factors (GF).
Activated Ras then initiate several signal-transduction cascades by engaging effector molecules
from multiple effector families to mediate its various functions (Figure 2). Ras effectors are
proteins that interact with RAS-GTP/activated Ras.
Raf and the MEK/ERK cascade. Raf is a key effector of Ras. The mammalian Raf protein
family consists of three Serine/Threonine kinases: Raf-1, A-Raf and B-Raf (11). Raf-1 was the
first bona fide mammalian Ras effector to be identified. It mediates the signal from Ras to
nucleus through mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase
(ERK) kinase (MEK), ERK1/2, and the E26-transcription factor proteins (ETS). MAPK
6

signaling has been shown to be both sufficient and necessary for Ras-induced transformation of
murine cell lines. In addition, activating mutation of B-Raf is found in human cancers, in nonoverlapping frequencies with Ras mutations (for example, in melanoma and colon cancer). This
further emphasizes an important role for aberrant Raf–MEK–ERK signaling in oncogenesis
(12,8).
Ras signals through PI3K. Another Ras effector is p110 catalytic subunit of the class I
phosphoinositide

3-kinases

(PI3Ks)

which

generate

the

second

messenger

lipid

phosphatidylinositol (3,4,5) triphosphate or PIP3 upon activation. PIP3 recruits phosphatidyl
inositol-dependent kinase 1 (PDK1) and Ser/Thr kinase AKT/Protein kinase B to the plasma
membrane, where PDK1 phosphorylates and activates AKT. The anti-apoptotic effects of Ras
have been mainly attributed to the pro-survival activities of activated PI3K signaling through a
pathway that involves the Ser/Thr kinase AKT/protein kinase B and the transcription factor
nuclear factor-κB (NF-κB), both of which have crucial roles in preventing anoikis (detachment
induced cell death or suspension induced apoptosis). High activity of PI3K is seen in many
tumor cells and in most cases this is attributed to the loss of the phosphatidylinositol 3 kinase
phosphatase with tensin homology (PTEN) lipid phosphatase. PTEN catalyzes the removal of the
D3 phosphate from PIP3 to terminate downstream signaling, and is now thought to be the most
commonly mutated tumor suppressor in humans, after p53 (8,13).
Ras signals through RAL–GEFs. Ras interacts with guanine nucleotide-exchange factors for
the Ras-like (RalA and RalB) small GTPases (Ral guanine nucleotide-dissociation stimulator
(RalGDS) and RalGDS-like protein (RGL)). RAL–GEFs serve as a link between the RAS and
the Ral family of GTPases. Recent studies in human cells have suggested that activation of the
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RalGEF–Ral pathway alone, but not the PI3K or the Raf pathways, is sufficient to promote Ras
transformation of human kidney epithelial cells (14). RAL signaling has been implicated in
tumor cell growth and cell survival, regulation of endocytosis or excocytosis, actin organization,
cell migration, and gene expression (15,8).
Additional Ras effectors. Several other Ras effectors have been described, which include a
number of proteins with diverse roles in cell physiology. These include phospholipase C-ε
(PLCε), T-cell lymphoma invasion and metastasis-1 (TIAM1), Ras interaction/interference
protein-1 (RIN1), ALL (acute lymphoblastic leukaemia)-1 fused gene on chromosome 6 (AF-6,
also known as afadin) proteins, and the Ras association domain-containing family (RASSF)
proteins (8).

Targeting oncogenic Ras in human cancer treatment
Current Ras-related anticancer approaches mainly focus on targeting RAS proteins or
RAS effector pathways (16). Blocking Ras function by inhibiting the enzymes that catalyze posttranslational modification of Ras proteins in order to prevent its association with plasma
membrane was one of the earliest strategies adopted. This led to the development of
farnesyltransferase inhibitors (FTIs) that simulate the CAAX motif of Ras proteins and compete
with Ras for its post-translational processing enzymes, thus blocking the first step of Ras
modification (prenylation) and thereby inhibiting its activity (17). However later on it was found
that in the presence of FTase inhibitors, K-Ras and N-Ras can become prenylated by
geranylgeranyl transferase thereby rendering them refractory to inactivation by FTIs (9).
Alternative strategy to block Ras function involved pharmacological inhibition of enzymes that
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catalyzes other steps of the Ras processing pathway such as Ras-converting enzyme-1 (RCE1)
and isoprenylcysteine carboxyl methyltransferase (ICMT1). However due to extensive number
of other CAAX-terminating proteins that serve as substrates, these two enzymes may not be
selective for Ras proteins. Additional approaches have been developed over the years such as
inhibition of Ras expression by anti-sense RNA-based technology, the use of anti-Ras
ribozymes, or application of anti-Ras retroviral therapy to counter Ras function (8).
Approaches focusing on targeting Ras effector pathways involve developing inhibitors of
downstream effector of Ras such as MEK, Akt, and mTOR. For example, inhibition of MEK by
CI-1040 has been shown to inhibit the growth of some cell lines expressing Q61R NRAS (18).
However, despite substantial effort, there are currently no agents that effectively counter the
biochemical consequences of oncogenic Ras.
Recent studies have shown the pro-apoptotic activity of oncogenic H-Ras(V12) that
allows HDACI FR901228 to induce selective apoptosis of mouse embryo fibroblast 10T1/2 cells
(105,106). However, mechanisms behind the pro-apoptotic activity of oncogenic H-Ras are not
clear. Histone deacetylase inhibitors (HDACIs) are a new class of anticancer agents and growing
evidence indicates that transformed cells are much more sensitive than normal cells to growthinhibitory and apoptotic effects of (44,47).
Expression of oncogenic Ras has also been shown to elevate intracellular ROS (64). ROS
have broad range of responses inside the cell depending upon magnitude of level and duration of
exposure. Excessive accumulation of intracellular ROS may cause cell death. Cells with
activating mutation of ras genes will be under increased ROS stress and will be more susceptible
to further oxidative insults than normal cells, leading to cell death. Hence any agent that directly
9

or indirectly causes ROS accumulation will preferentially kill cancer cells. For example,
HDACIs have been shown to cause increased intracellular ROS leading to apoptosis (84).
Excessive accumulation of intracellular ROS caused by oncogenic Ras and HDACI treatment
may cause selective apoptosis of cells harboring activating mutation of ras genes.

Apoptosis in cancer
Apoptosis
Apoptosis is a genetically encoded, highly regulated natural process for removing
unwanted cells such as those with potentially harmful mutations, aberrant sub-stratum
attachment, or alterations in cell-cycle control. Defective apoptosis can disrupt the delicate
balance between cell proliferation and cell death and can lead to diseases such as cancer. Hence
evasion of apoptosis has been recognized as one of the six essential alterations in cell physiology
that dictate malignant growth and is a hallmark of most, and maybe all, types of cancer (19).
Defective cell cycle regulation, growth factor autonomy, defective senescence, sustained
angiogenesis, and metastasis and tissue invasion are other five fundamental hallmarks of cancer.
Moreover, defective apoptosis can also interfere with the anticancer drugs, which act primarily
by inducing apoptosis. Hence, over the years many efforts have been made to design the drugs,
which can restore apoptosis in order to treat cancer (20).
Apoptotic cell death phenotype is characterized by features such as cytoplasmic
shrinkage, membrane blebbing, nuclear fragmentation, intranucleosomal DNA fragmentation,
phosphatidylserine exposure due to changes in the plasma membrane, and finally fragmentation

10

into membrane enclosed apoptotic bodies sequestered by macrophages or other engulfing cells
(21,22).

Mechanism of Apoptosis
The core machinery of apoptosis in mammals consists of a large family of cysteine
proteases, termed caspases, Apaf-1 and BCL2-family members. Activation of caspases is
responsible for the cleavage of vital components of the cell leading to the formation of
characteristic morphological features of apoptosis (described above) (23).
Apoptotic signaling pathways that activate caspases can be divided into two components
— those that involve the mitochondria (intrinsic pathway) and those that signal through death
receptors (extrinsic pathway) (Figure 3)
The intrinsic pathway involves the release of cytochrome c from the intermembrane
space of the mitochondria due to mitochondrial membrane permeabilization (MMP). Though
exact mechanism of MMP is not yet clear, defective inner transmembrane potential (ΔΨm) has
been observed before, during and after MMP (24). The mitochondrial respiratory chain produces
energy, which is stored as an electrochemical gradient or the ΔΨm, negative inside of about 180200 mV. This energy source pumps protons (H+) that drive ATP synthesis. Loss of ΔΨm is a
result of the ion equilibration across the inner membrane. This loss of ΔΨm could lead to
swelling of the matrix as water enters, which can result in sufficient swelling to break the outer
membrane to produce MMP. MMP contributes to cell death in several different ways; in
apoptosis by releasing cytochrome c, in caspase independent cell death by releasing factors like
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apoptosis inducing factor (AIF) (25) and Htra2/Omi (26) and, by disrupting mitochondrial
functions that are essential for cell survival such as electron transport chain (27).
Once in cytosol, cytochrome c interacts with apoptotic protease-activating factor 1
(APAF1) and, together with dATP (2'-deoxyadenosine 5'-triphosphate), forms a multimeric
complex that recruits and activates caspase 9, leading to the activation of downstream executer
caspases and the death response (20).
In the extrinsic pathway, ligands such as tumour-necrosis factor (TNF), FAS ligand (also
known as CD95L), or TNF-related apoptosis-inducing ligand (TRAIL, also known as APO2
ligand (APO2L) or TNF ligand superfamily member 10 (TNFSF10)) interact with and activate
their respective death receptors (TNF receptor 1 (TNFR1), FAS (also known as CD95) and death
receptor 4 (DR4, also known as TRAIL receptor 1 (TRAILR1)) or DR5 (also known as
TRAILR2), respectively. Activated receptors then initiate recruitment of the FAS-associated
death domain (FADD) and the activation of the protease caspase 8, which then cleaves and
activate downstream executer caspases (28). The death receptor pathway also contributes to the
mitochondrial cytochrome c release through the activation of caspase 8 and its down stream
target BID (29). Caspase 8 induces BID-cleavage leading to the formation of truncated BID
(tBID), which then translocates from cytoplasm to mitochondria and causes cytochrome c
release. Finally both mechanisms converge into cleavage and activation of executioner caspases
3, 6 and 7, which carry out the proteolysis of death substrates (Figure 3) (23).
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Caspases
Caspases are a family of cysteine proteases that are responsible for the execution of
apoptosis. As the name implies (‘c’ stand for cysteine and ‘aspase’ is for aspartate) these
enzymes cleave the protein after an aspartic acid residue. Each caspase is initially synthesized as
a pro-caspase and requires a cleavage at specific site (which also is an aspartate) by another
caspase to generate active enzyme. Multiple caspases are involved in mammals during different
phases of apoptosis (23). Currently, 11 human caspases have been identified: caspase 1-10 and
caspase 14. The protein initially named caspase 13 was found to be the bovine homologue of
caspase 4. Caspase 11 and 12 are murine homologues of human caspase 4 and 5. Caspases are
classified in several ways. Most important of those is the function-based classification where all
caspases fit into three subfamilies i.e. initiators of apoptosis and inflammation (caspase 1, 5, 11),
initiators of apoptosis (caspase 2, 8, 9, 10, 12) and effectors /executors of apoptosis (caspase 3, 6,
7) which are activated by initiator caspases (21).

Regulation of Apoptosis
Apoptotic signaling pathways are tightly regulated by pro and anti-apoptotic mechanisms
and the balance between them may govern the orderly demise of the cell. Proteins of BCL2
family members (30) that localize to the mitochondria can either prevent or cause the release of
cytochrome c from the mitochondria to either inhibit or promote apoptosis. For example, antiapoptotic BCL2 family members BCL2 and BCL-XL inhibit programmed cell death by
preventing the release of cytochrome c, whereas pro-apoptotic BCL2 family members (such as
BAK, BAX, BAD and BID) promote the release of cytochrome c. Inhibitor of apoptosis proteins
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(IAPs) are another important protein family that regulates apoptosis. IAPs bind to and inhibit
both intrinsic and extrinsic caspases and thereby block apoptotic signaling (31). IAPs in turn are
regulated by another mitochondrial released protein called SMAC (second mitochondria-derived
activator of caspase (32), also known as DIABLO, direct IAP-binding protein with low pI (33)).
SMAC is released from mitochondria once the cell has received a death signal. SMAC then
binds to IAP and antagonizes their anti-apoptotic activity.
Other important regulators of apoptosis are MDM2 and p53. On sensing DNA damage,
p53 induces cell-cycle arrest and apoptosis. Importance of disrupting the p53 pathway in cancer
development can assess by the fact that p53 is mutated and inactivated in half of all cancers
analyzed. MDM2 can also inactivate p53 mediated apoptotic pathway by binding to p53 and
causing its degradation by the proteasome (34).
Protein components and regulators of the apoptosis signaling pathways are possible drug
targets for modulating apoptosis and are promising targets for cancer drug discovery. Some of
the apoptosis targets that are currently being explored for cancer drug discovery include the
tumor-necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors, the BCL2
family of anti-apoptotic proteins, inhibitor of apoptosis (IAP) proteins and MDM2 (20).

Histone deacetylase inhibitors in cancer research
Acetylation, Deacetylation, and Chromatin Remodeling
While the base sequence of DNA provides the genetic code for proteins, remodeling of
the chromatin proteins around which the DNA is wrapped is the fundamental epigenetic
mechanism along with DNA methylation for regulating gene expression. All of the human
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genome is packaged into chromatin which is a complex structure made up of DNA, histones, and
non-histone proteins. The basic repeating unit of chromatin is the nucleosome, composed of
approximately 146 bp of DNA wrapped around the histone octamer composed of two copies of
each of four core histones, H2A, H2B and H3 and H4 (Figure 4). In addition to the core histone
molecules, the linker histone H1 is also contained in chromatin, which in combination with other
proteins helps in DNA condensation. Histones are small basic proteins consisting of a globular
domain and a more flexible and charged NH2-terminus (histone “tail”) that protrudes from the
nucleosome (35,36). Chromatin remodeling involves the reversible post-translational
modification of amino acids in the histone tails by acetylation of lysines, methylation of lysines
and arginines, phosphorylation of serines, and ubiquination and sumoylation of lysines (Figure
4). These modifications affect the histones' ability to bind DNA and each other, which in turn
affects gene expression. It has been hypothesized that histone modifications acting alone or in
combination represent a ‘‘code’’ that can be read and translated into biological functions by nonhistone proteins forming complexes involved in the regulation of gene expression (37-39).
Among these various covalent modifications of histone tail histone acetylation has been
the most studied and appreciated. The acetylation status of histones and non-histone proteins is
determined by two groups of enzymes, histone deacetylases (HDACs) and histone acetyltransferases (HATs). HATs add acetyl groups to lysine residues and acetylation of histone in
general promotes a more relaxed chromatin structure, allowing transcriptional activation.
HDACs remove the acetyl groups from lysine residues and consequently promote chromatin
condensation and hence can act as transcription repressors (40).
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The correlation between histone acetylation and transcriptional activation is due to
intrinsic HAT activity of several groups of transcriptional co-activator proteins. These include
GCN5-related N-acetyltransferase, MYST, and cAMP response element binding protein
(CREB/p300) families (41). HATs are recruited to sites in the promoter region of genes by
DNA-binding transcription factors and they function in association with protein complexes that
can include an array of other HATs, transcription coactivators and co-repressors. HATs also
target non-histone protein substrates, in particular TFs such as p53, GATA-1, E2F, estrogen
receptor (ER), and various cell-cycle regulatory proteins with variable functional consequences
(40).
In humans, 18 HDAC enzymes have been identified and classified into four classes,
based on homology to yeast HDACs (42,43). Class I HDACs are related to yeast RPD3
deacetylase and can be further divided into classes Ia (HDAC1 and -2), Ib (HDAC3) and Ic
(HDAC8). They have high homology in their catalytic sites. Class I HDACs are primarily
nuclear in localization and ubiquitously expressed. Class II HDACs are related to yeast Hda1
(histone deacetylase 1) and include class IIa, consisting of HDAC4, -5, -7 and -9, and class IIb,
consisting of HDAC6 and -10, which contain two catalytic sites. Class II HDACs have tissuespecific expression and can be primarily cytoplasmic in location and/or migrate between the
cytoplasm and nucleus. All HDACs under class I and II are zinc-dependent enzymes and their
activity is inhibited by compounds such as varinostat or trichostatin A (TSA). Members of class
III HDAC, also called a sirtuins, require NAD+ for their enzymatic activity. Among them,
SIRT1 is orthologous to yeast silent information regulator 2. Unlike class I and class II
deacetylases, the enzymatic activity of class III HDACs is not inhibited by compounds such as
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vorinostat or TSA. Class IV HDAC is represented by HDAC11, which has conserved residues in
its catalytic center that are shared by both class I and class II deacetylases. Apart from histone,
the HDACs have many non-histone proteins substrates such as hormone receptors, chaperone
proteins and cytoskeleton proteins, which regulate cell proliferation and cell death (Table 2).
Hence these enzymes may more properly be referred to as "lysine deacetylases" (43).

Histone deacetylases and Cancer
HATs and HDACs are involved in acetylation and deacetylation not only of chromatin proteins,
disruption of which can lead to altered regulation of transcription of genes (epigenetic
regulation), but also of non-histone proteins controlling cell-cycle progression, differentiation,
and/or apoptosis. Hence altered expression or mutation of genes that encode HATs and HDACs
can disrupt the highly ordered differentiation program leading to proliferation of undifferentiated
cells and cancer.
Alterations in both HATs and HDACs are found in many human cancers. Genes encoding
HATs have been found translocated, amplified, overexpressed, and/or mutated in many human
cancers. For example, loss of heterozygosity in p300 gene has been described in 80% of
glioblastomas whereas loss of heterozygosity in CREB binding protein locus has been observed
in a subset of lung cancers (44). Structural mutations in HDACs associated with cancers are rare.
However, overexpression of different HDACs has been reported in various cancers. HDAC2 and
HDAC3 proteins are increased in colon cancer samples (45). Again in many cases of lymphomas
and leukemias HDACs are functionally recruited in oncogenic translocation protein complexes
(46).
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Histone deacetylase inhibitors
HDACIs are a new class of structurally diverse anticancer agents and have been shown to
exhibit antimetastatic and antiangiogenic activities toward malignantly transformed cells in vitro
and in vivo (47,42). They selectively alter gene transcription by chromatin remodeling and by
changing the structure of proteins in transcription factor complexes. HDACs have many nonhistone proteins as their target substrate apart from histones, which regulate cell proliferation and
cell death thus HDACI-induced transformed cell death involves both transcription-dependent and
transcription-independent mechanisms (Table 3) (42,47,48).
HDACIs are structurally diverse group of molecules derive from both natural sources (e.g TSA,
FK228) and from synthetic route (e.g. MS-275, Tubacin). With few exceptions they all have
been divided into chemical classes including hydroxamates such as Trichostatin A (TSA),
aliphatic acids such as phenyl butyrate, benzamides such as MS-275, and electrophilic ketones
such as trifuoromethyl ketones, and depsipeptides such as FK228 (Table 3) (47).
FR901228
FR901228, also known as FK228 and romidepsin (NSC-630176), (E)-(1S,4S,10S,21R)7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos16-ene-3,6,9,19,22-pentanone, is a bicyclic depsipeptide isolated from Chromobacterium
violaceum cultures (49,50). FR901228 has been shown to exhibit strong activity inhibiting Class
I histone deacetylases, mild activity inhibiting Class II, assayed in vitro (51). Some studies have
suggested that Class I HDACs are important in regulating proliferation and survival in cancer
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cells (42,52). Selective inhibition of Class I HDACs by FR901228 has been postulated to play
an important role in the selectivity of FR901228 in control of cancer cells. As such, FR901228
is a pro-drug and has a stable molecular hydrophobic structure that facilitates its entry through
the cell membrane into cells. Its internal disufide bond can be reduced by intracellular
glutathione to form two active, free sulfhydryl groups to chelate the zinc in the HDAC active site
(53). Increased intracellular glutathione is associated with multidrug resistance; therefore,
FR901228 is potentially effective for treating tumor cells with glutathione-mediated drug
resistance.
Trichostatin A (TSA)
Trichostatin A (TSA) was first isolated from cultures of Streptomyces hygroscopicus as
antifungal antibiotics active against Trichophyton species (54). It was the first natural product
hydroxamate discovered to inhibit HDACs. It is an inhibitor of class I and II HDACs. TSA, has
relatively high reactivity and instability, and has been extensively used as a tool for the study
HDAC function. TSA contains a cap group, an aliphatic chain and a terminal hydroxamic acid
functional group. TSA act as substrate mimics and inhibit the HDAC by inserting its aliphatic
chain into catalytic site of the enzyme. This insertion and binding in the catalytic site blocks
substrate access to the active zinc ion and, thereby, inhibits the deacetylase activity (40).
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The cellular effects of HDACI
HDACIs have been shown to induce growth arrest, differentiation, cell death and
inhibition of angiogenesis. Normal cells are almost always considerably more resistant than
tumor cells. Mechanisms of their action are complex and not completely understood. Effects of
HDACIs can be attributed to the accumulation of acetylated histones and many nonhistone
proteins that have been shown to involve in regulation of gene expression, cell proliferation, cell
migration, and cell death. For example HDACIs can affect transcription by inducing acetylation
of histones, transcription factors and other proteins regulating transcription and thereby
selectively altering the gene expressions. Up to 20% of all known genes are affected by HDACI
(48). The cyclin-dependent kinase (CDK) inhibitor p21 (WAF1/CIP1) and p27 (KIP1) are the
most common genes induced by HDACIs which are responsible for HDACI-mediated cell cycle
arrest in both normal and transformed cells (43).
HDACIs have been shown to induce transformed cell death by activating the intrinsic and
extrinsic apoptotic pathway, mitotic failure, autophagic cell death, polyploidy, and senescence,
and reactive oxygen species–facilitated cell death (43). In addition, HDACI such as TSA, FK229
have been shown to block tumor angiogenesis by inhibition of transcription factors of
angiogenesis namely hypoxia inducible factors (HIF) (43). HDACI also cause hyper-acetylation
of HSP90 and its inactivation, leading to the degradation of proteins that require the chaperone
function of HSP90 leading to inactivation of anti-apoptotic pathway (55). The response to
HDACI depends upon on the nature of HDACI, concentration and time of exposure, and the cell
context (cell type, cell stage, and normal or pathological state of the cell).
HDACI have shown synergistic or additive antitumor effects with a wide range of
antitumor reagent, including chemotherapeutic drugs (e.g. cisplatin, VP-16), HSP90 inhibitor
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(e.g. 17-ally-amino-demethoxy geldanamycin), proteasome inhibitor (e.g. bortezomib), kinase
inhibitors (e.g. phosphatidylinocitol 3 kinase inhibitor LY294002, MEK1/2 inhibitor PD184352)
and radiotherapy (42,52).

Clinical development of HDACI
Various HDACIs are in phase I/II clinical trials with the main aim being to
analyze/exclude unwanted toxicity and to find optimal doses/schedules. At least 14 different
HDACI are in some phase of clinical trials as monotherapy or in combination with various other
antitumor agents such as gemcitabine, radiation, etc, in patients with hematologic and solid
tumors (Table 3) (43).
Resistance has been observed in clinical trials with some HDACIs in different tumors.
However the basis of resistance to HDACIs is not well understood. High level of Bcl-2 and
thioredoxin (Trx), which has been associated with resistance of transformed cells to
chemotherapy, may play a role in the resistance to HDACIs (43). Resistance to FK228 has been
associated with upregulation of multiple drug resistance protein1 (MDR1) and P-glycoprotein
(P-gp) that mediate FK228 efflux (56).

Reactive oxygen species in cancer research
Reactive oxygen species (ROS)
These are oxygen containing chemical species with reactive chemical properties
generated inside the cell as the consequence of respiration and enzymatic activities. ROS include
O2-derived free radicals such as superoxide anion radical (O2-) and the hydroxyl radical (·OH),
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which contain an unpaired electron, and nonradical derivatives of O2 such as hydrogen peroxide
(H2O2) (57,58).
Mitochondria represent the major source of intracellular ROS. During oxidative
phosphorylation, electrons are delivered through the respiratory chain, and a proton gradient is
established across the inner mitochondrial membrane as energy source for ATP synthesis. One
important biochemical event associated with this metabolic process is the production of
superoxide. It is estimated that approximately 2% of the total mitochondrial O2 consumption
results in O2- production which is subsequently converted to hydrogen peroxide (58,59).
Metabolism of O2 to water is catalyzed by cytochrome c oxidase in the inner mitochondrial
membrane and sequential addition of electrons to oxygen during electron transport generates
various ROS (Figure 5). Some electrons may escape from the mitochondrial electron transport
chain, such as from the reaction of O2 with the ubisemiquinone (Q) site of complex III (Figure
5), and react with molecular oxygen to form superoxide. O2- can react with itself by spontaneous
or enzymatic (e.g., superoxide dismutase, SOD) dismutation to form H2O2. H2O2 then reacts with
reduced iron (FeII) to generate the reactive hydroxyl radical (•OH).
Apart from mitochondrial production ROS can also be synthesized by enzymes such as
NADPH oxidases, also called as NOX proteins, synthesized by phagocytic cells to battle against
bacterial infection (60).
Under normal physiological conditions production of intracellular ROS in kept in a state
of redox homeostasis by cellular antioxidant defense system to prevent possible deleterious
effect of ROS. Antioxidant system consists of enzymes as well as nonenzymatic antioxidants.
Enzymes such as superoxide dismutase, glutathione peroxidase catalyze the conversion of O2- to
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H2O2, which is then converted to water and O2 by catalase (61). Nonenzymatic antioxidants, like
vitamin E, vitamin C, β-carotene, glutathione, and coenzyme Q function to quench ROS (62). In
addition, cells have secondary antioxidant defenses consist of protease systems specialized for
the removal of oxidatively modified proteins as well as DNA repair or lipid repair enzymes.
However, sometimes production of ROS exceeds the endogenous cellular capacity for their
detoxification by antioxidant system and/or utilization leading to a nonhomeostatic state referred
to as “oxidative stress” (60).

ROS in carcinogenesis
Growing evidence suggests that cancer cells in general are under increased oxidative
stress compared to normal cells (63). This is mainly due to elevated ROS generation associated
with active metabolism and oncogenic stimulation in cancer cells which in turn contributes to
cancer progression. Oncogenes have been shown to cause increased ROS generation. Oncogenic
H-Ras, for example, increases ROS generation which in turn mediate some of the biological
effects of oncogenic Ras such as, mitogenesis in fibroblasts (64), the generation of genomic
instability (65), and malignant transformation (66). Several studies have indicated that the Rasinduced membrane NADPH-oxidase complex plays an important role in producing ROS for Rasinduced transformation phenotypes (66-69). In addition, oncogenic Ras-increased ROS may
cause DNA damage, contributing to Ras-induced mutagenesis in cells lacking the tumor
suppressor p53 (70). The oncogene c-myc has also been shown to increase ROS generation,
which induces DNA damage and mitigates p53 function leading to genetic instability (71).
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Another possible mechanism for increased ROS production in cancer cells may involve
malfunction of the mitochondrial respiratory chain. Metabolically active cancer cells require a
high level of ATP supply to maintain their active biochemical functions associated with
uncontrolled cell growth and proliferation. This energy demand places a further stress on the
mitochondrial respiration chain, and is likely to contribute to increased ROS generation. In
addition, any mutation in mitochondrial DNA (mtDNA) which codes for 13 components of the
respiration complexes can adversely affect functioning of mitochondrial respiratory chain
leading to excessive ROS generation. In fact, mtDNA mutations are frequently detected in
cancer cells and have been shown to correlate with increased ROS contents (63,72).
ROS have broad range of responses inside the cell depending upon magnitude of level
and duration of exposure. Recent studies have shown active involvement of ROS in the
regulation of signal-transduction pathways (73) and during oncogenic signaling in cellular
transformation and cancer (74,65). In general, low levels of ROS are mitogenic and promote cell
proliferation, while intermediate levels cause transient or permanent cell cycle arrest and induce
cell differentiation. Excessive production of ROS may inflict damage to various cellular
components including DNA, protein, and lipid membranes and can induced cell apoptosis or
necrosis (75).
ROS mediated nuclear DNA damage may results in genetic instability whereas damage to
mitochondrial DNA will affect mitochondrial electron transport chain leading to further increase
in ROS generation. Protein oxidation by ROS may affect redox equilibrium due to inhibition of
enzymes involved such as catalases and peroxidases, which in turn impair the cells ability to
clear ROS causing, further increase in oxidative stress. However the most important consequence
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of ROS-mediated damage is lipid peroxidation, which refers to the addition of oxygen to
unsaturated fatty acids to form organic hydroperoxides (ROOH). The oxidation of membrane
phospholipids decreases the fluidity of the biological membranes and increases the membrane
permeability. In mitochondria, where much of the ROS is generated, membrane damage by
oxidation may cause release of cytochrome c and activate apoptotic cascades. Various studies
have shown the role of reactive oxygen species in inducing apoptosis (76-78). However, in some
cases massive cellular oxidation by high levels of ROS may lead to necrotic cell death instead of
apoptosis or a combination of these two (63,79).

ROS generating agents in cancer research
As cancer cells are under increased ROS stress, they are more susceptible to further
oxidative insults than normal cells, leading to cell death. Hence any agent that directly or
indirectly causes ROS accumulation will preferentially kill cancer cells. This provides the basis
for selective therapeutics against cancer. Increase in ROS stress to cause selective killing of
cancer cells can be achieved by direct exposure of cells to ROS-generating agents or by
inhibition of antioxidant system of the cell or by appropriate combination of the above.
Various agents have been shown to cause increased ROS generation leading to apoptosis
of cancer cells such as, arsenic trioxide, anthracyclines and cisplatin (78,80,81). Some anticancer
agents target the antioxidant enzyme of the cell leading to excessive accumulation of ROS.
Estrogen derivative 2-ME, for example, was shown to inhibit SOD resulting in accumulation of
cellular superoxide (O2−) and cell death (83). One effective strategy could be the use of
appropriate combination of ROS-generating agents and inhibitors of antioxidant system leading
25

to severe oxidative stress and cell death. Combination of the ROS-generating agent ATO and
SOD inhibitor 2-ME, for example, have been shown to cause ROS accumulation synergistically
leading to effective killing of cancer cells (78).

HDACI as ROS generating agent
Recently HDACIs, a new class of selective anticancer drugs, have been shown to cause
cell death by increasing ROS production. HDACIs such as, FK228, Varinostat, TSA and MS275 causes accumulation of ROS in transformed cells upon treatment leading to apoptosis which
can be prevented by use of free radical scavengers such as N-acetylcysteine (84,85,43).
Mechanism involved in HDACI-induced ROS increase is not yet clear; few studies have
suggested this increase in ROS is due to the inhibition of antioxidant system of the cell. HDACIs
have been shown to deplete cellular glutathione (86). HDACIs have also been shown to upregulate thioredoxin-binding protein-2, resulting in suppression of thioredoxin, which is a major
intracellular scavenger of ROS, and leading to excessive accumulation of intracellular ROS (43).

Urinary Bladder Cancer
Incidence and etiology of bladder cancer
Urinary bladder cancer is one of the most common cancers and ranks fifth among all
cancers in the Western world. It accounts for 336,000 new cases and 132,000 deaths annually
worldwide (87). In US, it is the fourth and eighth most common malignancy in men and women,
respectively, and the number of diagnosed cases is increasing annually (88). Cigarette smoking is
the major risk factor, contributing to approximately 50% of all bladder cancers, followed by
petrochemical and other industrial exposures (89).
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Transitional cell or urothelial carcinoma is the most common type of bladder cancer,
accounting for more than 90% all bladder cancers. Other types include adenocarcinomas, small
cell carcinomas and squamous cell carcinomas. The urothelium lines the inner surfaces of almost
the entire urinary tract, including the renal pelvis, ureter, bladder and proximal urethra. Since
urothelium is the permeability barrier between urine and blood, it is constantly exposed to
potential carcinogens. Although urothelium covers entire urinary tract, bladder urothelium is
mostly affected by tumors, presumably owing to prolonged exposure to carcinogens.
Urothelial carcinomas are separated clinically into superficial tumors, also referred to as
low-grade non-invasive papillary tumors, and muscle invasive tumors. Superficial tumors
account for about 80% of urothelial carcinomas and are often multifocal and recurrent, with
limited potential to become muscle-invasive. They originate from simple and nodular urothelial
hyperplasia. Muscle invasive tumors on the other hand, derive from flat, high-grade carcinoma in
situ (CIS) lesions and account for the rest 20% of urothelial carcinomas (87).
Full-blown urothelial carcinomas contain numerous genetic and epigenetic abnormalities,
including chromosomal aberrations (e.g. aneusomies, deletions and amplifications), activation of
oncogenes (e.g. H-ras), inactivation of tumor-suppressor genes (e.g. p53,Rb) and alterations in
the tumor microenvironment (89).

Activation of the Ras signaling pathway
Accumulating evidence indicates that key components of this signaling pathway such as
H-ras and upstream receptor tyrosine kinases (RTKs) are frequently activated in human
urothelial carcinomas (Table 4).
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H-ras: H-ras was the first human oncogene identified in urothelial carcinomas (Reddy et. al.,
1982). H-ras activation in urinary carcinomas involves direct H-ras gene mutations (at codons
12, 13 and 61) as well as protein overexpression due to alternative splicing of the last intron of
the H-ras gene (90). Recent studies indicate that H-ras mutations occur in 30–40% of urothelial
carcinomas whereas overexpression of H-Ras is seen in over half of human urothelial
carcinomas — a much higher frequency than that of H-ras mutations (Table 4) (87,91). The role
of H-Ras activation in urothelial tumorigenesis has been verified with the help of transgenic
mouse models. The targeted expression of an activated H-Ras in the urothelium of transgenic
mice induced early-onset urothelial proliferation. In the transgenic mice, but not in wild-type
controls, urothelial hyperplasia then evolved to low-grade non-invasive papillary tumors that
resemble the human disease, indicating a pivotal role of H-Ras activation in urothelial
carcinomas (92).

Receptor tyrosine kinases: In addition to activated H-Ras, several RTKs that function upstream
of Ras are constitutively active in urothelial carcinomas leading to activation of Ras signaling
pathway (Table 4). For example, mutations in the fibroblast growth factor receptor 3 (FGFR3)
gene occur in about 70% of the low-grade non-invasive papillary tumors (93). Forced expression
of FGFR3 mutants in NIH-3T3 cells resulted in cellular transformation and mitogen-activated
protein kinase (MAPK) activation, resembling the transfection effects observed with activated HRas (94).
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Targeting the RTK–Ras signalling pathway
Since RTK–Ras signalling pathway is widely involved in bladder cancer, components of
this pathway can be exploited as therapeutic targets.
Targeting the RTK. Inhibitory antibodies against RTKs, particularly those target EGFR family
proteins, have shown potent tumor-inhibitory activity in cultured cells and animal tumor models,
and are being evaluated in clinical trials (95). Several small molecules have been identified based
on in vitro screening assay, such as SU5402, SU6668, PD173074 and CHIR-258, that all inhibit
FGFR3. Besides the small molecule approach, monoclonal antibodies raised against FGFR3
have been developed that show inhibitory effects on urothelial tumor cell-lines (96,87).
Targeting Ras protein. As described in the previous section (Targeting oncogenic Ras in human
cancer) various strategies can be employed to counter oncogenic Ras in urothelial carcinomas. In
addition, combination of farnesyl- and geranylgeranyl-transferase inhibitors, which exhibit high
toxicity when used systemically, could be administered intravesically to treat bladder urothelial
carcinomas, giving lower systemic toxicity. Treatment of oncogenic H-Ras-bearing urothelial
tumors in animal models with Farnesyltransferase inhibitors (FTIs) has been found to
significantly increase the tumor response to radiation (97).

HDACIs in bladder cancer
Since bladder cancer contains numerous epigenetic abnormalities in addition to various
genetic defects, epigenetic modifiers such as HDACIs can be of great therapeutic importance.
HDACIs can be used as monotherapy or in combination with existing therapies for bladder
cancers such as surgical treatment or existing chemotherapeutic agents for bladder cancers, such
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as methotrexate, vinblastine, doxorubicin or cisplatin (89). Several HDACIs have been evaluated
recently for their therapeutic application in bladder cancer. The most important among them is a
novel depsipeptide, FK228, which has been shown to be a potent chemotherapeutic agent for
urothelial carcinoma in vivo with minimal undesirable side effects. It exhibited growth inhibitory
effects on five different transitional cell carcinoma cell lines in a dose- and time-dependent
manner (98,99). Recent studies have suggested that FK228 pretreatment increases the sensitivity
of tumor cells to adenoviral gene therapy vectors (100,101). Besides FK228, other HDACIs,
such as TSA and MS-275, have also been shown to block bladder cancer cell cycle in vitro and
induce apoptosis (98,102). Belinostat, a novel histone deacetylase inhibitor has shown growth
inhibitory effect on a number of bladder cancer cell lines (103). HDAC inhibition with sodium
butyrate and TSA has been shown to increase the sensitivity of tumor necrosis factor-related
apoptosis-inducing ligand-resistant bladder tumor cells (104).
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Table 1: Incidence of ras mutations in human cancer

TISSUE

H-Ras
(%)

K-Ras
(%)

N-Ras
(%)

Adrenal gland
Biliary tract
Bone
Breast
Central nervous system
Cervix
Endometrium
Eye
Gastrointestinal tract
Haematopoietic and lymphoid tissue
Kidney
Large intestine
Liver
Lung
Oesophagus
Ovary
Pancreas
Prostate
Salivary gland
Skin
Small intestine
Stomach
Testis
Thymus
Thyroid
Upper aerodigestive tract
Urinary tract

1
0
2
1
0
9
1
0
0
0
0
0
0
1
1
0
0
6
16
5
0
4
0
0
4
9
30

0
32
1
5
1
8
14
4
19
5
1
32
7
17
4
15
60
8
4
2
20
6
5
15
3
4
4

5
1
0
1
2
1
0
1
0
12
0
3
4
1
0
4
2
1
0
19
25
2
4
0
7
3
3

Modified from Nature Reviews Molecular Cell Biology 9, 522
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Table 2: Nonhistone protein substrates of HDACs

Function

Proteins

DNA binding
transcriptional
factors

p53, c-Myc, AML1, BCL-6, E2F1, E2F2, E2F3, GATA-1,
GATA-2, GATA-3, GATA-4, Ying Yang 1 (YY1), NF-κB
(RalA/p65), MEF2, CREB, HIF-1 , BETA2, POP-1, IRF-2,
IRF-7, SRY, EKLF

Steroid receptor

Androgen receptor, estrogen receptor , glucocorticoid
receptor
Rb, DEK, MSL-3, HMGI(Y)/HMGA1, CtBP2, PGC-1

Transcription
coregulators
Signaling
mediators
DNA repair
enzyme

STAT3, Smad7, -catenin, IRS-1

Nuclear import

Rch1, importin- 7

Chaperon
proteins
Structural
protein
Inflammation
mediators

HSP90

Viral proteins

E1A, L-HDAg, S-HDAg, T antigen, HIV Tat

Ku70, WRN, TDG, NEIL2, FEN1

-Tubulin
HMGB1

Modified from Oncogene 26:5542
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Table 3: HDACI in clinical trials

Class

Compound

HDAC target

Hydroxamate

SAHA
(Zolinza,
vorinostat)
LBH589
PXD101
ITF2357
PCI-24781
FK228

Classes I, II

M

Classes I, II
Classes I, II
Classes I, II
Classes I, II
HDAC1, 2

nM
M
nM
NA
nM

Phase I
Phase II
Phase I
Phase I
Phase II

MS-275

HDAC1, 2, 3

M

Phase II

MGCD0103
Phenylbutyrate

Class I
Classes I, IIa

NA
Mm

Phase II
Phase II

Cyclic
peptide
Benzamide
Aliphatic
acid

Potency
(cells)

Stage of
development
FDA approved
for CTCL

Valproic acid
Classes I, IIa
mM
Phase II
AN-9
NA
M
Phase II
Baceca
Classes I
NA
Phase II
Savicol
NA
NA
Phase II
Abbreviations: CTCL, cutaneous T-cell lymphoma; FDA, Food and Drug
Administration; HDACI, histone deacetylase inhibitors; NA, not available.
Modified from Oncogene 26:5543
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Table 4: Activation of Ras pathway in human bladder cancers

Gene

Mode

of Frequency in tumors Role in Tumorigenesis

Activation
H-ras

Mutation

30-40%

Genesis

H-ras

Over expression

50%

Genesis

FGFR3

Mutation

60-70%

Genesis

ERBB3

Over expression

ND

Genesis?

ERBB4

Over expression

ND

Genesis?

EGFR

Over expression

50%

Progression

ERBB2

Over expression

40-50%

Progression

EEBB2

Amplification

10%

Progression

EGFR: Epithelial Growth Factor Receptor; FGFR3: Fibroblast Growth Factor
Receptor 3; ERBB: Erythroblastosis oncogene B; ND: not determined

Modified from Nature Reviews Cancer 5:717
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(A)

CAAX motif

Prenylation

(B)

Proteolytic
cleavage

Carboxymethylation

Farnesyl pyrophosphate
moiety

Palmitoylation

Palmitoyl moiety

Modified from Nature Reviews Molecular Cell Biology 9, 523

Figure 1
Post-translational modifications of Ras proteins
(A) C-terminal sequences of Ras proteins
(B) C-terminal processing
See text for details
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Modified from Nature Reviews Molecular Cell Biology 9, 526

Figure 2
Ras signaling networks
See text for details
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Modified from Nature Reviews Cancer 1, 878

Figure 3
General overview of apoptosis
See text for details
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Modified from Nature Reviews Cancer 5, 195

Figure 4
Nucleosome and Chromatin remodelling
(A) The core nucleosome- DNA wraps around an octamer of histones
(B) Covalent modifications of amino-terminal tails of core histones. A, acetylation; C, carboxyl
terminus; E, glutamic acid; K, lysine; M,methylation; N, aminoterminus; P, phosphorylation; S,
serine; Ub, ubiquitination
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Inner
Mitochondrial
membrane

Rotenone

Figure 5
ROS generation during electron transport chain in the inner mitochondrial membrane
See text for details
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PART –II
PRO-APOPTOTIC ABILITY OF ONCOGENIC H-RAS TO
FACILITATE APOPTOSIS INDUCED BY HISTONE
DEACETYLASE INHIBITORS IN HUMAN CANCER
CELLS

56

Research described in this chapter is slightly modified version of an article that is published in
2007 in Molecular Cancer Thearpeutics by Shambhunath Choudhary and Hwa-Chain Robert
Wang.

Choudhary S, Wang HCR. Proapoptotic ability of oncogenic H-Ras to facilitate apoptosis
induced by histone deacetylase inhibitors in human cancer cells. Mol Cancer Ther 2007;6:1099111. Copyright © 2007 American Association for Cancer Research.

In this paper “our” and “we” refers to me and co-authors. My contribution in the paper includes
(1) Selection of the topic (2) Compiling and interpretation of the literature (3) Designing
experiments (4) understanding the literature and interpretation of the results (5) providing
comprehensive structure to the paper (6) Preparation of the graphs and figures (7) Writing and
editing

Abstract
More than 35% of human urinary bladder cancers involve oncogenic H-Ras activation.
In addition to tumorigenic ability, oncogenic H-Ras possesses a novel pro-apoptotic ability to
facilitate the induction of apoptosis by histone deacetylase inhibitors (HDACIs). HDACIs are a
new class of anticancer agents and are highly cytotoxic to transformed cells. To understand the
connection between the selectivity of HDACIs on transformed cells and the pro-apoptotic ability
of oncogenic H-Ras to facilitate HDACI-induced apoptosis, we introduced oncogenic H-Ras into
urinary bladder J82 cancer cells to mimic an acquisition of the H-ras gene activation in tumor
development. Expression of oncogenic H-Ras promoted J82 cells to acquire tumorigenic ability.
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Meanwhile, oncogenic H-Ras increased susceptibility of J82 cells to HDACIs, including
FR901228 and Trichostatin A (TSA), for inducing apoptosis. The caspase pathways, the B-Raf
and extracellular signal regulatory kinase (ERK) pathway, p21Cip1 and p27Kip1, and core
histone contents are regulated differently by FR901228 in oncogenic H-Ras-expressed J82 cells
than their counterparts in parental J82 cells, contributing to the increased susceptibility to the
induction of selective apoptosis. Our results lead us to a suggestion that HDACIs activate the
pro-apoptotic ability of oncogenic H-Ras, indicating a potential therapeutic value of this new
class of anticancer agents in the control of human urinary bladder cancer that has progressed to
acquire oncogenic H-Ras.
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Introduction
Activating mutations of ras genes are frequently found in human cancers (1-3). In fact,
mutation in codon 12 of the H-ras gene is detected in more than 35% of patients with urinary
bladder cancers (3). Expression of oncogenic Ras proteins results in cellular transformation and
promotes tumorigenesis accompanied by an aberrantly regulated, complex signaling circuitry,
such as constant activation of the extracellular signal regulatory kinase (ERK) pathway, which
consists of Raf, Mek, and Erk, and the phosphatidylinositol 3-kinase (PI3-K) pathway, which
consists of PI3-K, PDK, and Akt (4). In the quest to understand the roles of oncogenic Ras in
tumorigenesis, delineating Ras-induced signaling pathways has helped reveal many potential
targets for current therapeutic approaches focusing on inhibition of Ras protein synthesis and
functions (5).

It is important to identify anticancer agents and their molecular targets to

selectively induce apoptosis of Ras-related cancer cells in order to increase the effectiveness of
chemotherapy.
Histone deacetylase inhibitors (HDACIs), a new class of anticancer agents, have been
shown to exhibit antimetastatic and antiangiogenic activities toward malignantly transformed
cells in vitro and in vivo (6,7).

HDACI molecules are structurally diverse and include

depsipeptides such as FR901228 and hydoximates such as Trichostatin A (TSA) (6). We have
shown the ability of FR901228, also named FK228 (NSC-630176) (8-10), to induce apoptosis of
human breast cancer MCF7 and MDA-MB231 cells and to induce p21Cip1 expression in a p53independent manner (11).

We have also shown that FR901228 induces apoptosis in Ras-

transformed mouse embryo fibroblast 10T1/2 cells, whereas it induces growth arrest of nontransformed counterpart cells in the G0/G1 phase of the cell cycle (12,13). Caspase-3 plays an
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important role in FR901228-induced selective apoptosis of Ras-transformed 10T1/2 cells (1214). In the non-transformed 10T1/2 cells, p21Cip1 is induced by FR901228, but it is reduced in
Ras-transformed cells (12). In addition, although the ERK pathway plays an anti-apoptotic role
in parental 10T1/2 cells, it plays a pro-apoptotic role in FR901228-induced cell death of Rastransformed cells (13). Raf-1 in the ERK pathway is particularly reduced by FR901228 in Rastransformed 10T1/2 cells (12). The PI3-K pathway plays an anti-apoptotic role, whereas the
stress-activated protein kinase p38 (p38/SAPK) pathway plays a pro-apoptotic role in
FR901228-induced apoptosis of both Ras-transformed and parental 10T1/2 cells (13). Our
studies indicate a pro-apoptotic role of oncogenic H-Ras in the FR901228-induced apoptosis in
mouse cells. The novel pro-apoptotic ability of oncogenic H-Ras to increase cell susceptibility
to selected anticancer agents, such as FR901228, should be seriously considered in developing
anticancer therapeutics against Ras-related cancers. However, the values of the ERK, PI3-K,
p38/SAPK, and caspase pathways, as well as Cdk inhibitors as therapeutic targets need to be
validated in all types of human cancer cells subjected to FR901228 treatment.
Here, we present evidence that expression of oncogenic H-Ras resulted in increased
susceptibility of human cancer J82 cells to both FR901228- and TSA-induced apoptosis. The
J82 human urinary bladder transitional carcinoma cell line hosts wild-type ras and the inactive
mutant Rb and p53 genes with deletion of the pTEN gene (15,16). Expression of oncogenic HRas promoted J82cells to acquire tumorigenicity, mimicking an acquisition of H-ras gene
activation in tumor development. Meanwhile, expression of oncogenic H-Ras facilitated the
induction of apoptosis by FR901228, and reduced clonogenic resistance to FR901228. Our
studies revealed both commonality and discrepancy in modulation of signaling pathways
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associated with cell growth, survival, growth arrest, and apoptosis between oncogenic H-Rasexpressed and parental J82 cells. The discrepancies, which may contribute to the ability of
FR901228 to selectively induce apoptosis in oncogenic H-Ras-expressed cells, should be
considered in the selection of therapeutic targets for Ras-related human urinary bladder cancers.

Materials and Methods
Cell Cultures, Transfection, and Reagents
Human urinary bladder transitional carcinoma J82 and T24 cell lines (ATCC, Rockville,
MD) and oncogenic H-Ras-expressed J82 cells were maintained in DMEM supplemented with
10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37oC. To generate
oncogenic H-Ras-expressed J82 cells, we used a previously constructed pcDNA4/TO-E-H-ras
plasmid (17), which carries the oncogenic H-ras (V12) gene. Cells in a 35 mm culture dish were
transfected with 0.5 μg of pcDNA4/TO-E-H-ras plasmid DNA using PolyFect Transfection
Reagent (Qiagen, Valencia, CA). After 48 h of transfection, cells were subcultured and selected
in 100 μg/ml Zeocin (Invitrogen, Carlsbad, CA). Resistant cell clones were established as
candidate J82-Ras cell lines.

Stock aqueous solutions of FR901228 (obtained through a

collaboration with Dr. KK Chan at the Ohio State University), TSA (ICN, Aurora, OH), U0126
(Cell Signaling, Beverly, MA), LY294002, SB203580, SP600125, and Ac-Asp-Glu-Val-AspCHO (Ac-DEVD-CHO) (Alexis, San Diego, CA) were prepared in DMSO and diluted in culture
medium for assays.
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Flow cytometry
Attached cells were trypsinized from cultures, rinsed with Ca++ and Mg++ free
phosphate buffered saline, fixed in ethanol, and stained with propidium iodide for flow
cytometric analysis, as performed previously (13). Analysis of DNA content and determination
of the percentage of apoptotic cells and cells in each phase of the cell cycle were performed on
Multicycle software (Phoenix Flow System, San Diego, CA).

Cell growth and survival rate assay
Cells were seeded in 12-well culture plates and treated with FR901228. Every 24 h, attached
cells were trypsinized, washed, and then resuspended in culture medium containing 0.2% trypan
blue to stain dead cells. Live cells were counted in a hemocytometer to determine relative cell
growth and survival rate (12).

Cell growth inhibition assay
Inhibition of cell proliferation was determined by the inhibition of 5-bromo-2’-deoxyuridine
(BrdU) incorporation into cellular DNA, using the BrdU cell proliferation ELISA kit (Roche,
Indianapolis, IN). Five x 104 cells were seeded into each well of 96-well culture plates for 24 h.
After treatment with FR901228, cells were labeled with BrdU for 12 h, fixed, incubated with
peroxidase-conjugated BrdU-specific antibodies, and stained with peroxidase substrate.
Quantification of BrdU-labeled cells was determined with an ELISA reader (Bio-Tek, Winooski,
VT).
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Cell viability assay
A Methyl Thiazolyl Tetrazolium (MTT) assay kit (ATCC, Manassas, VA) was used to
measure cell viability in cultures. Five x 104 cells were seeded into each well of 96-well culture
plates for 24 h. After treatments with HDACIs and/or inhibitors, cells were incubated with MTT
Reagent for 4 h, followed by incubation with Detergent Reagent for 24 h. Reduced MTT reagent
in cultures was quantified with an ELISA reader.

Clonogenic assay
Triplicates of 1 x 104 cells were seeded in 100 mm culture dishes for 24 h. After
FR901228 treatment, cultures were rinsed and replaced with fresh medium. Growing colonies
(>30 cells) were identified and counted under an anatomical microscope. Adherent colonies in
untreated cultures were stained with crystal violet after 7 days, and FR901228-treated cultures
were stained after 14 days.

Anchorage-independent cell growth assay
The base layer consisted of 2% low gelling SeaPlaque agarose (Sigma, St Louis, MO) in
complete J82 culture medium. Soft agar consisting of 0.4% Sea Plaque agarose in a mixture
(1:1) of complete J82 culture medium with 3 day-conditioned medium prepared from J82
culture, was mixed with 3x103 cells and plated on top of the base layer in 60mm diameter
culture dishes. Soft-agar cultures were maintained at 37oC and observed microscopically for the
appearance of colonies. Growing colonies were identified, and the number of colonies that
reached 0.5 mm diameter by 14 days, was recorded.
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Tumorigenic and histopathological studies
Cells were prepared with Matrigel basement membrane matrix (13.35 mg/ml; BD
Biosciences), and 1x107 cells in 100 μL were injected subcutaneously into flanks of 5-week old
female athymic NCr-nu/nu mice (NCI, Frederick, MD). Four mice were used per group and
maintained under pathogen-free conditions. Animals were monitored weekly until tumors were
visible; then tumor growth was monitored every 3 days.

Xenograft tumor tissues were

immediately harvested after euthanasia by exposure to carbon dioxide. Tumor tissues were fixed
in neutral buffered formalin and embedded in paraffin for histopathological evaluation of 5-μm
hematoxylin and eosin (H&E) stained sections. Tumor tissues were also sliced into 1 mm3
cubes and incubated with FR901228 in culture medium to detect activation of caspases using
Western immunoblotting with specific antibodies. All animal procedures were approved by The
University of Tennessee Animal Care and Use Committee and were in accordance with the NIH
Guide for the Care and Use of Laboratory Animals (National Research Council, 1985).

Western Immunoblotting
To prepare cell lysates, cultured cells were lysed in a buffer (10 mM Tris-HCl, 150 mM NaCl,
1% Triton X-100, 5 mM EDTA, 10 mM sodium pyrophosphate, 10% glycerol, 0.1% Na3VO4,
50 mM NaF, pH 7.4) (12). Tumor tissues were sliced into 1 mm3 cubes, incubated with
FR901228 in culture medium, and lysed in the buffer above with 30 strokes of a loose-fitting
Dounce homogenizer. Cell lysates (S20) were isolated from the supernatants after centrifugation
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of crude cell or tissue lysates at 20,000 x g for 20 min. To prepare nuclear cell lysates containing
core histones, cells were lysed in a hypotonic buffer (10 mM KH2PO4, 1 mM EDTA, 5 mM
EGTA, 10 mM MgCl2, 50 mM β-glycerolphosphate, 1 mM Na3VO4, 2 mM dithiothreitol, pH
7.2) with 30 strokes of a tight-fitting Dounce homogenizer (18). After centrifugation of crude
lysates at 10,000 x g for 10 min, cell pellets containing nuclear histones were resuspended in
lysis buffer and sonicated for 10 min as nuclear lysates (P10). Protein concentrations in cell
lysates (S20) and nuclear lysates (P10) were measured using the BCA assay (Pierce, Rockford,
IL). Equal amounts of cellular proteins were resolved by electrophoresis in either 10% or 14%
SDS-polyacrylamide gels and transferred to nitrocellulose filters for Western immunoblotting, as
previously described (12-14). Antibodies specific to Akt, Raf-1, Mek1/2, p38, JNK, acetylated
H2A on Lys5, acetylated H2B on Lys12, H2B protein, acetylated H3 on Lys9, H3 protein,
acetylated H4 on Lys8, procaspase-3, active caspase-3, active caspase-7, active caspase-8, full
length and cleaved poly (ADP-ribose) polymerase (PARP; 89 kDa cleaved PARP and 116 kDa
full length PARP), and β-Actin were purchased from Cell Signaling Technology (Beverly, MA).
Specific antibodies to phosphorylated forms of Akt, Raf-1, B-Raf, Mek1/2, Erk1/2, p38, and
JNK were also purchased from Cell Signaling Technology. Specific antibodies to H-Ras, B-Raf,
Erk1/2, p53 (FL-393), p27Kip1, and p21Cip1 were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Antigen-antibody complexes on filters were detected by the SuperSignal
chemiluminescence kit (Pierce, Rockford, IL).
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Statistical Analysis
Statistical significance was analyzed by the Student’s t-test. A p-value ≤ 0.05 was
considered significant.

Results
Tumorigenicity of J82 cells was induced by oncogenic H-Ras
To determine the effects of oncogenic H-Ras on tumorigenic potential of human urinary
bladder J82 cancer cells, cell clones were stably transfected with the expression plasmid vector
pcDNA4/TO-E-H-ras. As shown in Fig. 1A, ectopic expression of oncogenic H-Ras in J82 cells
resulted in a distinctive morphological change from a round, ruffled edge morphology (panel a)
to an elongated, transformed morphology (panel b). Based on this change, the H-Ras expression
level, and an enhanced cancerous ability of anchorage-independent growth in soft-agar (19), we
developed a single-clonal J82-Ras cell line from selected cell clones. As shown in Fig. 1B-1,
J82-Ras cells (lane 2) expressed a level of oncogenic H-Ras comparable to the counterpart level
in the human bladder cancer T24 cell line (lane 3), which hosts the oncogenic H-ras mutant gene
(20). Colony formation in soft-agar showed an average of 45 colonies developed from 3,000 J82
cells, and an average of 90 colonies developed from 3,000 J82-Ras cells (Fig. 1C).

The

cancerous ability of anchorage-independent growth in J82 cells was increased by oncogenic HRas. To conclude if J82-Ras cells had acquired tumorigenic ability, we inoculated J82-Ras and
parental J82 cells into immunodeficient mice. Consistent with others’ report (21), animals
inoculated with parental J82 cells did not develop any xenograft tumors in 8 weeks. In contrast,
nude mice inoculated with J82-Ras cells developed visible xenograft tumors in 15 days; tumors
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developed to an average size of 0.3 cm diameter by 20 days and 1 cm by 30 days.
Histopathological evaluation of J82-Ras-derived xenograft tumor tissues revealed neoplastic
cells that invaded the adjacent skeletal muscle (Fig.1D, panel a) and a cohesive sheet of
neoplastic cells characterized by ill-defined cytoplasmic borders, abundant slightly vacuolated
eosinophilic cytoplasm, round to elongate nuclei, and multiple prominent nucleoli (panel b).
Additionally, marked anisokaryosis (panel b) and anisocytosis as well as numerous binucleate
and occasional multinucleate tumor giant cells were noted. The histopathological diagnosis
confirmed that expression of oncogenic H-Ras induced the tumorigenic ability of J82 cells to
produce poorly differentiated, xenograft adenocarcinoma in vivo.

Increased cell susceptibility to HDACIs by oncogenic H-Ras
To determine if expression of oncogenic H-Ras increased cell susceptibility to FR901228
for inducing cell death, we compared cell growth and survival rates of J82-Ras cells with
parental J82 cells responding to FR901228 treatment. We detected that expression of oncogenic
H-Ras did not result in any significant difference in the growth rate of J82-Ras cells versus
parental J82 cells (Fig. 2A, 0 nM control lines). Treatment with 1 nM FR901228 reduced cell
growth of both parental J82 and J82-Ras cells. Treatment with 5 nM FR901228 resulted in
growth inhibition of both parental J82 and J82-Ras cells in 24 h. In contrast to a modestly
reduced cell survival rate in parental J82 cultures, 5 nM FR901228 treatment significantly
reduced cell survival in J82-Ras cultures by 48 h, indicating significantly higher cell death in
J82-Ras cultures than in parental J82 cultures. Prolonged incubation with FR901228 at either 1
or 5 nM induced increased cell death in both parental J82 and J82-Ras cultures. We observed a
67

higher extent of apoptotic-like cell morphology with cell shrinkage and loss of cell contact
induced by FR901228 treatment in J82-Ras cultures than in parental J82 cultures (data not
shown). Although induction of apoptotic-like cell death by FR901228 was in a dose- and timedependent manner, FR901228 at 5 nM induced a distinguishable, higher level of apoptosis in
J82-Ras cultures than in parental J82 cells. Cell death by apoptosis in these cultures was verified
by flow cytometry. As shown in Table 1, apoptotic cell population in attached cells was higher
in J82-Ras cultures (increased from 2% to 7% and 24%) contrasted to parental J82 cultures
(increased from 2% to 4% and 13%) after FR901228 treatment.
We used a clonogenic assay (22) to further determine whether the increased cell
susceptibility to FR901228 by oncogenic H-Ras was attributed to a reduced resistance of
oncogenic H-Ras-expressed J82 cells. As shown in Fig. 2B, approximately 600 clones (>30
cells/colony) developed from 1 x 104 untreated J82 and J82-Ras cells in 7 days (control). After
48 h of FR901228 treatment, we detected that approximately 25 clones had grown slowly and
survived in J82 cultures (reached 30 cells/colony) by 14 days, and none survived in J82-Ras
cultures (Fig. 2B, FR).

Evidently, expression of oncogenic H-Ras in J82 cells increased

susceptibility and reduced cell resistance to FR901228-induced apoptosis.
To expand our investigation of the pro-apoptotic role of oncogenic H-Ras in increasing
cell susceptibility to HDACIs, we compared the susceptibility of J82 and J82-Ras to the
induction of apoptosis by FR901228 and TSA, with the susceptibility to the human bladder
cancer T24 cell line, which hosts the endogenous, oncogenic H-ras mutant gene (20). As shown
in Fig. 2C, FR901228 treatment at either 5 or 25 nM reduced cell viability of J82-Ras and T24
cells to higher degrees than in J82 cells. Both J82-Ras and T24 cells also showed a higher
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susceptibility than J82 cells to TSA-reduced cell viability in a dose-dependent manner (Fig. 2D).
Interestingly, T24 cells showed a susceptibility similar to J82-Ras cells in response to either
FR901228 or TSA treatment. Evidently, both FR901228 and TSA showed selectivity to induce
cell death of oncogenic H-Ras-expressed human urinary bladder cancer J82 and T24 cells.
Differential regulation of caspase pathways by FR901228
To detect the apoptotic pathway induced by FR901128 in selective apoptosis of J82-Ras
cells, we initially studied activation of executor caspase-3 by FR901228 in parental J82 and J82Ras cells. We observed a higher level of procaspase-3 in J82-Ras cells than in parental J82 cells
(Fig. 3A-1, lane 3 versus lane 1); FR901228 treatment increased the procaspase-3 protein level in
parental J82 cells (lane 2 versus lane 1), but decreased procaspase-3 in J82-Ras cells (lane 4
versus lane 3). FR901228 treatment resulted in a higher level of active caspase-3 in J82-Ras
cells (Fig. 3A-2, lane 4) than in parental J82 cells (lane 2). Studying the activation course of
caspase-3 in FR901228-induced apoptosis revealed that FR901228 treatment did not induce
detectable levels of active caspase-3 in J82 cells until 48 h (Fig. 3B-1, lane 3); in contrast, it
induced an early caspase-3 activation in J82-Ras cells in 24 h (lane 5). Accelerated caspase-7
activation by FR901228 was also detected in J82-Ras cells (Fig. 3B-2, lanes 5 and 6) compared
to parental J82 cells (lanes 2 and 3). Concomitantly, PARP, a downstream substrate of caspase-3
and -7 (23), was accordingly cleaved in parental J82 cells (Fig. 3B-3, lane 3) and J82-Ras cells
(lanes 5 and 6). Expression of oncogenic H-Ras in J82 cells appears to accelerate FR901228induced activation of caspase-3 and -7 and proteolysis of PARP.
To determine the upstream initiator caspases, which may contribute to the activation of
caspase-3 and -7, we detected that active caspase-8 was induced by FR901228 in parental J82
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cells by 48 hr (Fig. 3B-4, lane 3), and FR901228 treatment induced an early activation of
caspase-8 in J82-Ras cells (lanes 5 and 6). Interestingly, caspase-9 was induced by FR901228 in
J82-Ras cells (Fig. 3B-5, lanes 5 and 6) but was not induced in parental cells (lanes 1 to 3).
Accordingly, the caspase-8 to caspase-3 and -7 pathway was induced by FR901228 in parental
J82 cells. Both caspase-8 and -9 to caspase-3 and -7 pathways were induced by FR901228 in
J82-Ras cells.

The caspase-9 pathway appears to be potentiated by oncogenic H-Ras for

activation in FR901228-induced selective apoptosis of J82-Ras cells.
To verify the role of caspase-3 and -7 in FR901228-induced cell death, J82 and J82-Ras
cells were pretreated with the potent inhibitor Ac-DEVD-CHO to specifically inhibit caspase-3
and -7 (24), followed by FR901228 treatment. Pretreating cells with Ac-DEVD-CHO reduced
FR901228-induced cleavage of PARP in both parental J82 (Fig. 3C-1, lane 4 versus lane 3) and
J82-Ras (lane 8 versus lane 7) cells. Although treatment of cells with Ac-DEVD-CHO alone did
not induce any detectable cleaved PARP (Fig. 3C-1, lanes 2 and 6), the treatment resulted in a
modest reduction of cell viability (Fig. 3C-2).

Pretreatment with Ac-DEVD-CHO did not

significantly reverse the low degree of FR901228-reduced viability of J82 cells, but it
significantly attenuated the FR901228-reduced viability of J82-Ras cells (Fig. 3C-2). We also
used AEBSF-HCl (25), a serine protease inhibitor, in a similar study, but pretreatment with
AEBSF-HCl did not enhance or suppress any FR901228-reduced cell viability (data not shown).
These results indicate that caspase-3 and -7 played important roles in the FR901228-induced
selective apoptosis of oncogenic H-Ras-expressed J82 cells. In addition, we treated xenograft
tumor tissues of J82-Ras cells with FR901228 in vitro and detected active caspase-3, caspase-7,
and cleaved PARP (Fig. 3D-1 to 3D-3, lanes 2 and 3); this result verified that the FR90122870

induced caspase activation also occurred in a three-dimensional tumor tissue-structural
environment.

Regulation of Cdk inhibitors, p53, and histones by FR901228
FR901228 treatment induces growth arrest of human breast cancer MCF7 and MDAMB231 cells in the G2/M phase of the cell cycle (11). However, FR901228 treatment growtharrests mouse 10T1/2 cells and Ras-expressed 10T1/2 cells in the G0/G1 phase of the cell cycle
(12,13). To study if growth arrest contributed to FR901228-induced growth inhibition of J82
and J82-Ras cells, we initially verified that cell proliferation in both parental J82 and J82-Ras
cultures was suppressed by FR901228 treatment in 24 h (Fig. 4A).

Subsequently, flow

cytometric analysis revealed that FR901228 treatment of either J82 or J82-Ras cultures resulted
in decreased cell populations in the G0/G1 phase, substantially decreased cell populations in the
S phase, and significantly increased cell populations in the G2/M phase (Table 1). A higher
population of J82-Ras cells than parental J82 cells (p < 0.05) accumulated in the G2/M phase
after FR901228 treatment.
To pursue the involvement of Cdk inhibitors in FR901228-induced cell growth arrest, we
detected that p21Cip1 was induced by FR901228 in J82 (Fig. 4B-1, lanes 2 and 3) and J82-Ras
(lanes 5 and 6) cells. Adjusted by β-Actin levels (Fig. 4B-4), the induced p21Cip1 was reduced
in J82-Ras cells undergoing apoptosis induced by FR901228 (lane 6). We also detected that
p27Kip1 was increasingly induced by FR901228 in J82 (Fig. 4B-2, lanes 2 and 3) and J82-Ras
(lanes 5 and 6) cells. Induction of p21Cip1 appears to correlate with induction of growth
inhibition, and p27Kip1 induction appears to correlate with completion of cell growth arrest by
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FR901228 in the G2/M phase of the cell cycle (Table 1). In addition, we detected that the
mutant p53 was progressively reduced by FR901228 in J82 (Fig. 4B-3, lanes 2 and 3) and J82Ras (lanes 5 and 6) cells. The reduction of the mutant p53 was correlated with FR901228induced apoptosis.
Modification of core histones through acetylation has been reported to play a critical role
in the growth arrest of cell proliferation (26,27). We detected that acetylation of core histones
H2A on Lys5 (Fig. 4C-1), H2B on Lys12 (Fig. 4C-2), H3 on Lys9 (Fig. 4C-3), and H4 on Lys8
(Fig. 4C-4) was profoundly increased by FR901228 treatment in both parental J82 (lane 2) and
J82-Ras (lane 5) cells by 24 h; however, acetylation was substantially reduced in cells treated
with FR901228 for 48 h (lanes 3 and 6). The H2B protein level was reduced by FR901228
treatment in both parental J82 and J82-Ras cells (Fig. 4C-5, lanes 3 and 6).

FR901228

progressively reduced the H3 protein level in J82-Ras cells undergoing apoptosis (Fig. 4C-6,
lanes 5 and 6) than in parental J82 cells mainly undergoing growth arrest (lanes 2 and 3).
However, we were unable to detect H2A and H4 protein with two commercially available
specific antibodies. These results indicate a novel effect of oncogenic H-Ras on the reduction of
histone contents induced by extended treatment with FR901228.
Roles of the ERK, PI3-K, and p38/SAPK pathways in FR901228-induced apoptosis
The ERK, PI3-K, and p38/SAPK pathways are modulated by FR901228 to play different
roles in apoptosis of H-Ras-transformed and non-transformed mouse 10T1/2 cells (12,13). To
investigate the role the ERK pathways may play in J82-Ras and parental J82 cells undergoing
FR901228-induced selective apoptosis, we used U0126 to specifically inhibit Mek1/2 activity
(13,14,28). As shown in Fig. 5A-1, treatments with U0126 alone for 48 h modestly reduced cell
72

viability in cultures of J82 and J82-Ras. Although U0126 treatment failed to affect FR901228reduced viability in parental J82 cells, it enhanced FR901228-reduced viability of J82-Ras cells.
Thus, expression of oncogenic H-Ras induced the survival role of the ERK pathway in J82-Ras
cells responding to the FR901228-induced apoptosis. To identify targets in the ERK pathway for
reducing

cell

viability,

we

studied

FR901228-induced

effects

on

activation-related

phosphorylation and protein levels of ERK pathway kinases B-Raf, Raf-1, Mek1/2, and Erk1/2.
We detected that protein levels of oncogenic H-Ras were not affected by FR901228 treatment
(Fig. 5A-2). The overall phosphorylation level of B-Raf was elevated in J82-Ras cells (Fig. 5A3, lane 4), compared to the counterpart phosphorylated kinase in parental J82 cells (lane 1).
FR901228 treatment increased the overall phosphorylation of B-Raf in parental J82 cells (Fig.
5A-3, lanes 2 and 3), but reduced both the overall phosphorylation and cognate protein levels of
B-Raf in J82-Ras cells (Fig. 5A-3 and 5A-4, lanes 5 and 6). Although B-Raf protein levels may
vary slightly between experiments, in general, they were unchanged in parental J82 cells treated
with FR901228. Adjusted by the cognate protein level of B-Raf, the specific phosphorylation
level of B-Raf (p/B-Raf) was elevated by FR901228 treatment in both parental J82 and J82-Ras
cells. Adjusted with β-Actin levels (Fig. 5A-11), FR901228 treatment resulted in significant
reduction of B-Raf protein in J82-Ras cells. B-Raf protein appears to be a distinct target for
FR901228-induced reduction in J82-Ras cells, but not in parental J82 cells.
Expression

of

oncogenic

H-Ras

also

elevated

the

overall

activation-related

phosphorylation level of Raf-1 in J82-Ras compared to parental J82 cells (Fig. 5A-5, lane 4
versus lane 1). FR901228 treatment resulted in reduction of the overall phosphorylation and
protein levels of Raf-1 in both J82 and J82-Ras cells (Fig. 5A-5 and 5A-6, lanes 2, 3, 5, and 6);
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based on the cognate Raf-1 protein level, the specific phosphorylation level of Raf-1 (p/Raf-1)
was slightly increased in parental J82 cells and reduced in J82-Ras cells. Adjusted with β-Actin
levels, FR901228 treatment resulted in significant reduction of Raf-1 protein (Raf-1/Actin) in
both parental J82 and J82-Ras cells. Thus, Raf-1 protein appears to be a common target for
FR901228-induced reduction in J82 and J82-Ras cells.
To further investigate the ERK downstream pathway from Raf regulated in FR901128treated cells, we detected that phosphorylation levels of Mek1/2 (Fig. 5A-7) and Erk1/2 (Fig.
5A-9) were not noticeably increased in J82-Ras cells (lane 4 versus lane 1). Although treatment
of J82-Ras cells with FR901228 suppressed the overall phosphorylation and protein levels of BRaf (Fig. 5A-3 and 5A-4, lanes 5 and 6) and Raf-1 (Fig. 5A-5 and -5A-6), it increased
phosphorylation of Mek1/2 (Fig. 5A-7) and Erk1/2 (Fig. 5A-9). In contrast, FR901228 treatment
did not induce any noticeable change in phosphorylation of Mek1/2 and Erk1/2 in parental J82
cells (Fig. 5A-7 and 5A-9, lanes 2 and 3). Increased phosphorylation/activation of Mek1/2 and
Erk1/2 appears to correlate with increased specific phosphorylation of B-Raf in J82-Ras cells.
Expression of oncogenic H-Ras in J82 cells appears to potentiate the ERK downstream kinases
for activation in response to FR901228 treatment.
While investigating the PI3-K, the p38/SAPK, and the JNK/SAPK pathways involved in
FR901228-induced cell death, we detected that expression of oncogenic H-Ras in J82 cells (lanes
4 versus 1) did not increase the phosphorylation of Akt (Fig. 5B-1) and p38 (Fig. 5B-3), but
changed the phosphorylation profiles of JNK (Fig. 5B-5). FR901228 treatment did not result in
any significant change in the overall phosphorylation of Akt in either J82 (Fig. 5B-1 and 5B-2,
lanes 2 and 3) or J82-Ras (lanes 5 and 6) cells. Interestingly, FR901228 treatment profoundly
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reduced phosphorylation of p38 in parental J82 cells (Fig. 5B-3, lanes 2 and 3), but it did not
result in any change in phosphorylation of p38 in J82-Ras cells (lanes 5 and 6). Thus, expression
of oncogenic H-Ras prevented p38 from dephosphorylation induced by FR901228. On the other
hand, FR901228 treatment profoundly reduced phosphorylation of JNK but not cognate protein
in parental J82 cells (Fig. 5B-5 and -6, lanes 2 and 3) and in J82-Ras cells (lane 6). In pursuing
the role the PI3-K, the p38/SAPK, and the JNK/SAPK pathways may play in FR901228-induced
cell death, we detected that treatments with LY294002, which specifically inhibits PI3-K activity
(13,29), alone modestly reduced cell viability in cultures of J82 and J82-Ras, but it failed to
result in any significant change in the FR901228-reduced viability (Fig. 5C-1). The PI3-K
pathway was unlikely to play a role in the FR901228-induced growth inhibition or apoptosis of
J82 and J82-Ras cells. After using SB203580, which specifically inhibits p38 activity (13,30), to
block the p38/SAPK pathway, we detected that SB203580 treatment attenuated FR901228reduced viability in J82-Ras cells, but not in parental J82 cells (Fig. 5C-2). Therefore, the
p38/SAPK pathway appears to be differentially maintained by oncogenic H-Ras and to play a
pro-apoptotic role in FR901228-induced apoptosis of J82-Ras cells. Using SP600125, which
specifically inhibits JNK activity (31,32), to block the JNK/SAPK pathway, we detected that
J82-Ras cells were less susceptible to SP600125 treatment than parental J82 cells, and SP600125
treatment additionally enhanced FR901228-reduced viability in parental J82 cells, but not in J82Ras cells (Fig. 5C-3). The JNK/SAPK pathway appears to play a survival role in parental J82
cells. Although expression of oncogenic H-Ras induced phosphorylation of both p54 and p48
JNK and induced resistance to SP600125, suppression of the JNK/SAPK pathway by FR901228
treatment may still contribute to the induction of cell death in J82-Ras cells.
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Discussion
Understanding the pro-apoptotic ability of oncogenic H-Ras to enhance the cytotoxicity
of anticancer agents in order to induce selective apoptosis provides cellular and molecular bases
for developing therapeutic strategies to target Ras-related human cancers. In our previous
studies (12-14), we showed that expression of oncogenic H-Ras in mouse 10T1/2 cells increases
susceptibility to FR901228 but not the potent apoptosis inducer staurosporine, for inducing
selective apoptosis. In this report, we present evidence to verify selectivity of HDACIs to target
human bladder cancer cells associated with oncogenic H-Ras expression, as summarized in
Fig.6.
The human urinary bladder carcinoma J82 cell line hosts wild-type ras genes, and is not
tumorigenic to immune-deficient mice (15,16,21). In our studies, introduction of the oncogenic
H-ras gene into J82 cells promoted cells to acquire the tumorigenic ability to develop xenograft
tumors in immune-deficient mice; however, it was also accompanied by the novel pro-apoptotic
property for FR901228 and TSA to induce selective apoptosis. The human urinary bladder
carcinoma T24 cell line, in which oncogenic H-Ras is endogenously expressed (20), showed a
comparable level of susceptibility with J82-Ras cells to both FR901228 and TSA for inducing
cell death. However, expression of oncogenic H-Ras in J82 cells did not increase susceptibility
to other agents, including U0126, LY294002, SB203580, SP600125, and Ac-DEVD-CHO,
which is consistent with our results from studying mouse fibroblasts (13). The pro-apoptotic
ability of oncogenic H-Ras that facilitates agents to induce cell death is HDACI-specific, but is
not a cell type-specific property. HDACIs may activate the pro-apoptotic potential of oncogenic
H-Ras. In addition, expression of the oncogenic v-src gene in 10T1/2 cells resulted in cellular
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transformation but did not increase cell susceptibility to FR901228 for inducing apoptosis (result
not shown). Whether the selectivity of HDACIs to induce cell death of oncogenic H-Rasexpressed cells is applicable to other oncogene-expressed cells needs to be broadly investigated.
Caspase pathways were differentially induced by FR901228 between oncogenic H-Rasexpressed and parental J82 cells. Previously, we reported that caspase-3 plays an important role
in FR901228-induced selective apoptosis of Ras-transformed 10T1/2 cells (12-14). Here, we
detected that FR901228 not only induced accelerated caspase-3 activity but also caspase-7 in the
selective apoptosis of oncogenic H-Ras-expressed J82 cells as compared to parental J82 cells.
Inhibition of caspase-3 and -7 alleviated FR901228-reduced cell viability, which clearly verified
the contributing role of these caspases in the induction of apoptosis by FR901228. Investigating
their upstream caspase pathways, we detected that both the caspase-8 and caspase-9 pathways
were activated in oncogenic H-Ras-expressed J82 cells, but only the caspase-8 pathway was
induced in parental counterpart J82 cells after FR901228 treatment. Other studies have shown
that FR901228 treatment induces the extrinsic Fas pathway-dependent activation of caspase-8
and -3 in human osteosarcoma and leukemia cells (33,34), and induces the intrinsic
mitochondrial pathway-dependent activation of caspase-9 and -3, but not caspase-8, in lung
cancer cells (35). Either the extrinsic caspase-8 or the intrinsic caspase-9 initiator pathway is
reportedly sufficient to activate its downstream executioners, caspase-3 and -7 (36). Whether the
additional activation of caspase-9 in J82-Ras cells, but not in parental J82 cells, plays an
enhancing role in the accelerated induction of selective apoptosis in J82-Ras needs to be
clarified.
Expression of oncogenic H-Ras in J82 cells resulted in an increased cell population in the
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G2/M phase of the cell cycle in response to FR901228-induced cell growth arrest. Studies of
Cdk inhibitors revealed distinct regulation of p21Cip1 and p27Kip1 in the course of FR901228induced cell growth arrest of J82 cells. High levels of p21Cip1 were initially induced in 24 h
and subsequently reduced by 48 h in both parental J82 and J82-Ras cells, whereas the p27Kip1
level was continuously increased in the course of FR901228 treatment. Increased expression of
p27Kip1 has been postulated to play a role in complete suppression of human cancer cell growth
(37). In fact, FR901228 induced growth inhibition of both parental J82 and J82-Ras cells in 24
h. Accordingly, an early induction of p21Cip1 plus a progressive induction of p27Kip1 may be
required to growth-arrest J82 and J82-Ras cells.

Both p21Cip1 and p27Kip1 have been

postulated to play multiple roles in the regulation of apoptosis, protein assembly, and gene
transcription in addition to inhibitors of the cell cycle (38). The significance of the distinctive,
sequential regulation of p21Cip1 and p27Kip1 in FR901228-induced cell growth arrest and
apoptosis remains to be determined. On the other hand, it is interesting that in J82-Ras cells, a
lower level of p21Cip1 and a higher level of p27Kip1 were induced compared to parental J82
cells undergoing FR901228-induced growth arrest. We reported previously that FR901228
treatment induces p21Cip1 expression in non-transformed 10T1/2 cultures in which cells are
mainly arrested in the G0/G1 phase of the cell cycle; in contrast, FR901228 treatment reduces
the basal level of p21Cip1 in Ras-transformed 10T1/2 cultures in which significant apoptosis is
induced (12). We did not detect any induction of p27Kip1 in either non-transformed or Rastransformed 10T1/2 cultures after FR901228 treatment (data not shown). Sandor et al. observed
that human colon cancer HCT116-derived cell clones lacking p21Cip1 are not arrested in the G1
phase, but are arrested in the G2/M phase of the cell cycle following FR901228 treatment; they
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suggested that p21Cip1 is required for FR901228-induced G1 arrest, and G2/M arrest in the
absence of p21Cip1 is associated with increased cell death induced by FR901228 (39). In
addition, expression of p21Cip1 is induced by FR901228 in a p53-independent manner, but
expression of p21Cip1 has been suggested to play a role in degrading mutant p53 in FR901228treated cells (40). J82 cells host the mutant p53 gene (15), and the mutant p53 protein was
progressively and substantially reduced in J82 and J82-Ras cells undergoing FR901228-induced
growth arrest followed by apoptosis. It has been suggested that FR901228 induces a novel p53related feedback activity that results in depletion of mutant p53 protein in association with
increased cytotoxicity of FR901228 to tumor cells (40,41). Accordingly, enhanced reduction of
p21Cip1 and depletion of mutant p53 conceivably contribute to FR901228-induced selective
apoptosis of oncogenic H-Ras-expressed J82 cells.
It was expected that FR901228 treatment induced profound acetylation of core histones
H2A, H2B, H3, and H4 in both J82 and J82-Ras cells. However, it was unexpected that
acetylated histones and their protein contents were subsequently reduced in cells undergoing
FR901228-induced growth inhibition or apoptosis. Particularly, reduction of H3 content by
FR901228 appears to be accelerated by expression of oncogenic H-Ras in J82 cells in association
with enhanced cell death. Modification of core histones through acetylation has been reported to
play a critical role in the growth arrest of cell proliferation (26,27). It is possible that oncogenic
H-Ras-induced modification of histones in conjunction with apoptosis-related chromosomal
DNA fragmentation contribute to the enhanced histone reduction in J82-Ras cells undergoing
FR901228-induced cell death. However, the mechanism for reducing histone content and the
role of reduced histones in FR901228-induced apoptosis remain to be clarified.
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The ERK pathway was targeted by FR901228 treatment in both parental and oncogenic
H-Ras-expressed J82 cells.

FR901228 treatment resulted in substantial reduction of Raf-1

protein in both parental J82 and J82-Ras cells, a result consistent to the outcome of substantially
reduced Raf-1 protein in FR901228-treated mouse 10T1/2 cells (12). It has been suggested that
FR901228 treatment results in destabilization of Raf-1 protein due to dissociation from Hsp90
(42,43). Possibly, the association between Raf-1 and Hsp90 is a target for FR901228 to reduce
Raf-1 protein in J82 and 10T1/2 cells, regardless of Ras activation.

On the other hand,

expression of oncogenic H-Ras increased phosphorylation/activation of B-Raf. It has been
suggested that Ras-activated B-Raf, but not inactive B-Raf, is subjected to regulation by Hsp90,
and inhibition of Hsp90 activity destabilizes activated B-Raf for degradation (44). Therefore,
activated B-Raf may become susceptible to the Hsp90-involved degradation induced by
FR901228 treatment in J82-Ras cells. Raf family members have been reportedly involved in cell
survival (45). In contrast to a maintained, unchanged B-Raf level and a reduced Raf-1 level in
parental J82 cells, reduction of both Raf-1 and B-Raf conceivably contributed to the increased
susceptibility of J82-Ras cells to FR901228-induced apoptosis.
FR901228 treatment stimulated the survival role of the ERK pathway in J82-Ras cells,
but not in parental J82 cells. Although expression of oncogenic H-Ras in J82 cells increased
phosphorylation of both B-Raf and Raf-1, it did not lead to significant phosphorylation of
downstream kinases Mek1/2 and Erk1/2 until FR901228 treatment.

FR901228 treatment

resulted in reduction of both overall phosphorylated B-Raf and B-Raf protein in J82-Ras cells;
however, the specific phosphorylation of B-Raf was highly increased. Possibly, the FR901228increased specific phosphorylation contributed to the increased specific kinase activity of B-Raf,
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leading to the induction of downstream kinases Mek1/2 and Erk1/2 in J82-Ras cells. In contrast,
Mek1/2 and Erk1/2 were not activated by FR901228 in parental J82 cells. Consequently,
blockage of the ERK pathway by inhibition of Mek1/2 activation resulted in enhanced cell death
in FR901228-treated J82-Ras cells, but not in parental J82 cells. Thus, the downstream ERK
pathway plays an anti-apoptotic role in FR901228-induced apoptosis of J82-Ras cells.
Accordingly, suppression of the downstream ERK pathway enhanced the FR901228-induced
selective apoptosis of J82-Ras cells.
The PI3-K pathway, in addition to the ERK pathway, was also unconventionally
regulated in J82 cells. Akt is downstream from PI3-K and pTEN, and its activation is positively
regulated by PI3-K and negatively regulated by pTEN (46).

Previously, we showed that

expression of oncogenic H-Ras in 10T1/2 cells induces the PI3-K pathway to activate Akt, and
blockage of PI3-K activity enhances FR901228-induced apoptosis in both non-transformed and
Ras-transformed 10T1/2 cells (13). Clearly, the PI3-K pathway plays an anti-apoptotic role in
FR901228-induced cell death of mouse cells. Here, expression of oncogenic H-Ras in J82 cells,
in which the pTEN gene is deleted (16), did not increase phosphorylation of Akt. Suppression of
PI3-K activity did not change FR901228-reduced cell viability. Thus, the PI3-K pathway is
unlikely to play a role in FR901228-induced cell death of either J82 or J82-Ras cells. On the
other hand, the p38/SAPK pathway was also not induced by oncogenic H-Ras in J82 cells.
However, in contrast to a suppression of the p38/SAPK pathway induced by FR901228 in
parental J82 cells, FR901228 did not suppress the p38/SAPK pathway in J82-Ras cells.
Inhibition of p38 activity attenuated the FR901228-reduced cell viability in J82-Ras cells, but not
in parental J82 cells, indicating that a pro-apoptotic role of the p38/SAPK pathway was induced
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in J82-Ras cells responding to FR901228-induced apoptosis. On the other hand, inhibition of
JNK activity enhanced the FR901228-reduced cell viability in parental J82 cells, but not in J82Ras cells, indicating a survival role of the JNK/SAPK pathway in parental J82 cells responding
to FR901228-induced apoptosis. Possibly, expression of oncogenic H-Ras in J82 cells had
suppressed the survival JNK activity; FR901228 treatment further reduced JNK phosphorylation
as a contributing factor to the resulting cell death. These unconventionally regulated pathways
may indicate an outcome from multiple mutations occurring in human cancers.
Current Ras-targeted anticancer approaches mainly focus on inhibition of Ras protein
synthesis, interference with Ras processing to functional sites, or blockage of downstream Ras
effectors, approaches based on understanding the roles of oncogenic Ras in tumorigenesis (5).
Growing evidence indicates transformed cells are much more sensitive than normal cells to
growth-inhibitory and apoptotic effects of HDACIs (6,47). Other evidence has shown that
anticancer agents, including 5-fluorouracil (48), etoposide VP16 (49), cisplatin (50), lovastatin
(51), and arsenic (52) selectively induce apoptosis of oncogenic H-Ras-expressed cells. Our
studies verified the pro-apoptotic activity of oncogenic H-Ras that facilitated HDACIs to induce
cell death of human urinary bladder cancer J82 cells. Our results suggest a potential value of
HDACIs in treating human cancers involving activation of H-Ras. However, whether human
cancers involving H-Ras overexpression are potential targets for HDACI therapy needs to be
studied. Although the precise role of H-Ras activation in urinary bladder tumorigenesis remains
controversial, clinical and basic studies have suggested that activation of H-Ras accompanied by
inactivation of tumor suppressor p53 play important roles in tumorigenesis to high-grade
invasive urothelial tumors (53,54). Our previous studies showed that expression of oncogenic H82

Ras alone in mouse embryo fibroblasts induces cellular transformation and tumorigenicity in
immune-deficient mice, and increases cell susceptibility to FR901228 for inducing apoptosis
(12-14). Our current report indicates that expression of oncogenic H-Ras in bladder tumor J82
cells, which host mutant p53, Rb, and pTEN genes, promotes tumorigenesis and increases cell
susceptibility to HDACIs for inducing apoptosis. Possibly, HDACI therapy may be applicable to
human cancers that acquire oncogenic H-Ras mutation at various stages of tumorigenesis, but
that possibility needs to be verified clinically. FR901228 has been shown to exhibit strong
activities inhibiting Class I HDAC-1 and HDAC-2, mild activity inhibiting Class II HDAC-4,
and weak activity inhibiting Class II HDAC-6, assayed in vitro (55).

Some studies have

suggested that Class I HDACs are important in the regulation of proliferation and survival in
cancer cells (56-58).

Selective inhibition of Class I HDACs by FR901228 conceivably

contributes to its selectivity in control of cancer cells. In addition, a recent report showed that
ectopic expression of oncogenic H-Ras elevates reactive oxygen species (ROS) in ovarian
epithelial cells (59).

Two HDACIs, SAHA and MS-275, have been shown to cause an

accumulation of ROS in transformed cells but not in normal cells (60). Whether expression of
oncogenic H-Ras and FR901228 treatment additively increased ROS in the selective induction of
apoptosis of J82-Ras cells needs to be clarified. Multiple mutations occur within human cancer
cells; consequently affected signaling pathways are unconventionally regulated. It is important
that the values of individual molecular targets need to be considered in individual cases for
designing therapeutic protocols using HDACIs in combination with other agents to treat human
urinary bladder cancers involving H-Ras activation.
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Table
Table 1. Flow cytometric analysis of FR901228-treated cells
J82
J82-Ras
Treatment (h):
0
24
48
0
24
2±1
4±2
13±7
2±1
7±3
Apoptotic (%):

48
24±7

Live (%):
G0/G1:

52±2

51±6

45±10

53±4

46±12

32±11

S:

22±1

5±1

4±1

22±1

5±1

6±1

G2/M:

26±3

44±3

51±3a

25±2

48±12

61±4b

J82 and J82-Ras cultures were treated with 5 nM FR901228 for 0, 24, and 48 h.
Anchored cells were trypsinized from cultures, and cell populations were analyzed by flow
cytometry to detect apoptotic cell population and live cells in each phase of the cell cycle. Each
value represents a mean of results from two independent experiments ± standard deviation. The
Student’s t-test was used to analyze statistical significance of b versus a (p < 0.05).
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Figure 1. Tumorigenicity of J82 cells induced by oncogenic H-Ras. (A) Morphological
features of J82 (panel a) and J82-Ras (panel b) cells in cultures. (B-1 and B-2) Lysates of
growing J82, J82-Ras, and T24 cells were analyzed with Western immunoblotting using specific
antibodies to detect levels of H-Ras and β-Actin. (C) Triplicates of 3 x 103 J82 and J82-Ras
cells were seeded in soft-agar in 60 mm diameter culture dishes. By 14 days, cell colony
formation (≥0.5 mm diameter) was counted microscopically and averaged ± standard deviation.
(D) H&E stained histologic sections revealed cohesive sheets of neoplastic cells with anaplastic
features of J82-Ras-derived xenograft tumor tissues. White arrows indicate J82-Ras xenograft
tumor cells invaded adjacent host mouse skeletal muscle, and asterisks indicate skeletal
myofibers (panel a). Black arrows indicate anisokaryosis and multiple prominent nucleoli (panel
b). Scale bars are shown at 200 and 50 µm in panel a and b, respectively.
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Figure 2. Increased cell susceptibility to HDACIs by oncogenic H-Ras. (A) J82 and J82-Ras
cells were treated with 0, 0.2, 1, and 5 nM FR901228 (FR) for 0, 24, and 48 h. Every 24 h, live
cells were counted in a hemocytometer. Relative cell growth and survival rates in cultures were
normalized by the number of live cells determined at 0 hour, set as 100%. Each value represents
a mean of triplicates, and error bars represent standard deviation. (B) Triplicates of 1 x 104 J82
and J82-Ras cells were seeded in 100 mm diameter culture dishes. After 24 h, the cells were
treated with 5 nM FR901228 for 48 h. Then, cultures were replaced with fresh medium. By 7
days, control untreated cultures were stained with crystal violet. By 14 days, FR901228-treated
cultures were stained with crystal violet. Cell colonies (> 30 cells) were counted microscopically
and averaged ± standard deviation. (C and D) J82, J82-Ras, and T24 cells were treated with 0,
1, 5, and 25 nM FR901228 for 36 h or TSA at 0, 1, 5, and 25 nM for 48 h. Quantification of cell
viability in these cultures was determined with an MTT assay kit. Relative cell viability was
normalized by the value determined in untreated cells, set as 100%. Each value represents a
mean of tetraplicates, and error bars represent standard deviation.
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Figure 3. FR901228-induced apoptotic caspase pathway facilitated by oncogenic H-Ras.
(A-1 and A-2) J82 and J82-Ras cells were treated with 0 and 5 nM FR901228 for 48 h. (B-1 to
B-6) J82 and J82-Ras cells were treated with 5 nM FR901228 for 0 (lanes 1 and 4), 24 (lanes 2
and 5), and 48 (lanes 3 and 6) h. (C-1 and C-2) J82 and J82-Ras cells were pretreated with 100
μM of the caspase-3 and -7 inhibitor Ac-DEVD-CHO (CI) for 6 h. Then, J82 and J82-Ras
cultures were treated with 5 nM FR901228 for 48 h. Cell lysates were prepared from these
cultures and analyzed by Western immunoblotting using specific antibodies to detect levels of
procaspase-3 (A-1), active caspase-3 (A-2 and B-1), active caspase-7 (B-2), full length and
cleaved PARP (B-3), active caspase-8 (B-4), active caspase-9 (B-5), β-Actin (B-6), and cleaved
PARP (C-1).

Levels of cleaved caspase-9 (B-5) and β-Actin (B-6) were quantified by

densitometry.

The relative protein levels of caspase-9 (C-9/Actin) were calculated by

normalizing the levels of caspase-9 with the levels of β-Actin, and then were normalized by the
level in untreated J82 cells (lane 1), set as 1 (X, arbitrary unit). (C-2) Quantification of cell
viability was determined with an MTT assay kit. Relative cell viability was normalized by the
value determined in untreated cells, set as 100%. Each value represents a mean of tetraplicates,
and error bars represent standard deviation. (D-1 to D-4) Xenograft tumor tissues of J82-Ras
cells were sliced to 1 mm3 cubes and incubated with 0, 5, and 25 nM FR901228 for 48 h.
Lysates were analyzed by Western immunoblotting using specific antibodies to detect levels of
active caspase-3, active caspase-7, full length and cleaved PARP, and β-Actin.
indicates the full length PARP.

98

Asterisk

J82
FR: 0

J82-Ras

5

0

5

(nM)

A-1.

Procaspase-3

A-2.

Caspase-3

(35 kDa)

1
FR: 0

2

J82
24

3
48

(19/17 kDa)

4
0

J82-Ras
24

48 (h)

Caspase-3

B-1.

(19/17 kDa)

B-2.

Caspase-7

B-3.

PARP
*(116/89
kDa)

B-4.

Caspase-8

B-5.

Caspase-9

(20 kDa)

(18 kDa)

C-9/Actin:( 1 : 1 : 1 : 1 : 7 : 4 )(X)

(35 kDa)

β-Actin

B-6.
1

2

3

4

5

J82

FR:
CI:

6

(45 kDa)

J82-Ras

C-1.

PARP

1

Cell Viability

C-2.

2

3

4

5

J82

(%)
100

6

7

8

J82-Ras

80
60
40
20
0
FR:
CI:

J82-Ras tumor
FR: 0

5

25

(nM)

D-1.

Caspase-3

D-2.
D-3.

Caspase-7

(19 kDa)
(20 kDa)

PARP
*(116/89
kDa)
β-Actin

D-4.
1

2

3

99

(45 kDa)

(89 kDa)

Figure 4. Regulation of CDK inhibitors, mutant p53, and histones in FR901228-treated
cells. (A) J82 and J82-Ras cells were treated with 5 nM FR901228 for 24 h. Inhibition of cell
growth by FR901228 was determined by the blockage of BrdU incorporation into cellular DNA.
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growth rate was normalized by the value of BrdU detected in untreated cells, set as 100%. Each
value represents a mean of tetraplicates, and error bars represent standard deviation. (B-1 to B-4
and C-1 to C-6) J82 and J82-Ras cultures were treated with 5 nM FR901228 for 0 (lanes 1 and
4), 24 (lanes 2 and 5), and 48 (lanes 3 and 6) h. Western immunoblotting with specific
antibodies was used to detect p21Cip1, p27Kip1, p53, and β-Actin in cell lysates (B-1 to B-4), and
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Figure 5. Roles of the ERK, PI3-K, p38/SAPK, and JNK/SAPK pathways in FR901228induced apoptosis. (A-1, C-1, C-2, and C-3) J82 and J82-Ras cultures were treated with 5 nM
FR901228 in the presence and absence of 20 µM U0126 (U0), 1 µM LY294002 (LY), 1 µM
SB203580 (SB), or 30 µM SP600125 for 36 h. Quantification of cell viability in these cultures
was determined with an MTT assay kit. Relative cell viability was normalized by the value
determined in untreated cells, set as 100%. Each value represents a mean of tetraplicates, and
error bars represent standard deviation. The Student’s t-test was used to analyze statistical
significance of b versus a (p < 0.01), d versus c (p < 0.01), and f versus e (p < 0.01). (A-2 to A11, and B-1 to B-7) J82 and J82-Ras cultures were treated with 5 nM FR901228 for 0 (lanes 1
and 4), 24 (lanes 2 and 5), and 48 (lanes 3 and 6) h. Cell lysates were analyzed with Western
immunoblotting using specific antibodies to detect levels of H-Ras, phosphorylated B-Raf (p-BRaf), total B-Raf protein, phosphorylated Raf-1 (p-Raf-1), total Raf-1 protein, phosphorylated
Mek1/2 (p-Mek1/2), total Mek1/2 proteins, phosphorylated Erk1/2 (p-Erk1/2), total Erk1/2
proteins, β-Actin, phosphorylated Akt (p-Akt), total Akt protein, phosphorylated p38 (p-p38),
total p38 protein, phosphorylated JNK (p-JNK), total JNK protein, and β-Actin. Levels of p-BRaf, B-Raf, p-Raf-1, Raf-1, and β-Actin were quantified by densitometry. The relative levels of
specific phosphorylation of B-Raf (p/B-Raf) and Raf-1 (p/Raf-1) were calculated by normalizing
the levels of p-B-Raf (A-3) and p-Raf-1 (A-5) with the levels of their cognate proteins (A-4 and
A-6), and then were normalized by the level in parental J82 cells (lane 1), set as 1 (X, arbitrary
unit).

The relative protein levels of B-Raf (B-Raf/Actin) and Raf-1 (Raf-1/Actin) were

calculated by normalizing the levels of B-Raf (A-4) and Raf-1 (A-6) with the levels of β-Actin
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(A-11), and then were normalized by the level in untreated J82 cells (lane 1) and J82-Ras (lane
4), set as 1 (X, arbitrary unit).
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PART –III
PRO-APOPTOTIC ACTIVITY OF ONCOGENIC H-RAS
FOR HISTONE DEACETYLASE INHIBITOR TO
INDUCE APOPTOSIS OF HUMAN CANCER HT29
CELLS
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This chapter is a slight modification of the research paper published in 2007 in Journal of Cancer
Research and Clinical Oncology by Shambhunath Choudhary and Hwa-Chain Robert Wang.

Choudhary S, Wang HCR. Pro-apoptotic activity of oncogenic H-Ras for histone deacetylase
inhibitor to induce apoptosis of human cancer HT29 cells. J Cancer Res Clin Oncol
2007;133:725-39. Copyright © Springer-Verlag 2007.

In this paper “our” and “we” refers to me and co-authors. My contribution in the paper includes
(1)Selection of the topic (2) Compiling and interpretation of the literature (3) Designing
experiments (4)understanding the literature and interpretation of the results (5) providing
comprehensive structure to the paper (6) Preparation of the graphs and figures (7) Writing and
editing

Abstract
Purpose

To verify the pro-apoptotic activity of oncogenic H-Ras in the increased

susceptibility of human cancer cells to histone deacetylase inhibitor (HDACI).
Methods

The pro-apoptotic activity of oncogenic H-Ras(V12) was verified by its ability to

increase susceptibility of human colorectal adenocarcinoma HT29 cells to HDACI for inducing
apoptosis and growth inhibition, assayed by various methods. The mode of action of HDACI
FR901228 was studied by its ability to modulate protein phosphorylation, acetylation, and
expression levels in various signaling pathways, measured by Western blot analysis.
Results Activation of caspase-3, -7, and -8, and serine protease by FR901228 was facilitated by
oncogenic H-Ras to induce apoptosis.

Expression of H-Ras(V12) changed the intrinsic
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modulation of Raf in cells responding to FR901228 treatment. Both p21Cip1 and p27Kip1 were
induced in FR901228-treated cells arrested in either the G0/G1 or G2/M phase of the cell cycle.
Deacetylation of FR901228-induced acetylation of core histones was accelerated by H-Ras(V12)
in cells undergoing apoptosis.
Conclusion

Expression of H-Ras(V12) increased susceptibility of HT29 cells to HDACI

FR901228 and Trichostatin A for inducing apoptosis. The pro-apoptotic activity of H-Ras(V12)
responding to HDACI indicates a potential value of this new class of anticancer agents in
treating Ras-related human cancers.

Keywords: Pro-apoptosis, Ras, HDACI, Depsipeptide, Signaling pathway
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Introduction
Evidence has shown pro-apoptotic activity of oncogenic H-Ras in the increased cell
susceptibility to anticancer agents, including 5-fluorouracil (1), etoposide VP16 (2), cisplatin (3),
lovastatin (4) and arsenic (5). We have shown the pro-apoptotic activity of oncogenic HRas(V12) that allows HDACI FR901228 to induce selective apoptosis of mouse embryo
fibroblast 10T1/2 cells (6, 7,8). However, the pro-apoptotic ability of H-Ras(V12) to increase
the susceptibility of human cells to HDACI for inducing apoptosis has not yet been studied. It is
important to verify the pro-apoptotic activity of oncogenic H-Ras in human cells that allows
HDACI to induce selective cell death; the result will indicate if a potential value of HDACI can
be recognized for treating human cancers related to Ras activation.
Oncogenic Ras is widely involved in human cancers (9). Expression of oncogenic Ras
proteins results in cellular transformation and promotes tumorigenesis accompanied by an
aberrantly regulated, complex signaling circuitry, including constant activation of the
extracellular signal regulatory kinase (ERK) and phosphatidylinositol 3-kinase (PI3-K) pathways
(10,11). Constant activation of the ERK pathway (which consists of Raf, Mek, and Erk) and the
PI3-K pathway (which consists of PI3-K, PDK, and Akt) contributes to cellular transformation
and suppression of apoptosis (10). In addition, expression of oncogenic H-Ras(V12) induces
CBP/p300 degradation in NIH3T3 cells (12). The CBP and p300 co-activators exhibit both
histone and non-histone protein acetylase activities (13).

Thus, constant activation of Ras

proteins not only result in significant changes in protein phosphorylation but also in protein
acetylation.

We have shown that FR901228 induces apoptosis in H-Ras(V12)-transformed

10T1/2 cells, whereas it induces growth arrest of non-transformed counterpart cells in the G0/G1
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phase of the cell cycle (6,8). Thus, FR901228 exhibits a selectivity to induce apoptosis of Rastransformed 10T1/2 cells.

FR901228, also named FK228, (NSC-630176), is a bicyclic

depsipeptide isolated from cultures of Chromobacterium violaceum (14-17). FR901228 is a prodrug and has a stable molecular hydrophobic structure that facilitates its entry through cell
membrane into cells. Its internal disulfide bond can be reduced by intracellular glutathione to
form two free sulfhydryl groups that are active to chelate the zinc in the HDAC active site (18).
Increased intracellular glutathione is associated with multidrug resistance; therefore, FR901228
is potentially effective for treating tumor cells with glutathione-mediated drug resistance.
HDACI contains a structurally diverse group of molecules that include hydroxamates such as
Trichostatin A (TSA), aliphatic acids such as phenyl butyrate, benzamides such as MS-275, and
electrophilic ketones such as trifluoromethyl ketones in addition to depsipeptides (19). Growing
evidence indicates transformed cells are much more sensitive than normal cells to the growthinhibitory and apoptotic effects of HDACI (19-21). Hence, it is important to understand if
expression of oncogenic H-Ras in human cancer cells will increase susceptibility to HDACI for
inducing cell death.
We have shown that caspase-3 plays an important role in FR901228-induced selective
apoptosis of Ras-transformed 10T1/2 cells (6-8). FR901228 also induces p21Cip1 expression in
non-transformed 10T1/2 cells growth-arrested by FR901228 in the G0/G1 phase of the cell
cycle, but it reduces p21Cip1 levels in Ras-transformed 10T1/2 cells undergoing FR901228induced apoptosis (6).

Raf-1 is particularly reduced in Ras-transformed 10T1/2 cultures

undergoing FR901228-induced apoptosis (6). Interestingly, we detected that the ERK pathway
plays an anti-apoptotic role in parental 10T1/2 cells, but it plays a pro-apoptotic role in
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FR901228-induced apoptosis of H-Ras(V12)-expressed 10T1/2 cells (8). The PI3-K pathway
plays an anti-apoptotic role in both H-Ras(V12)-expressed and parental 10T1/2 cells (8).
However, the question of whether oncogenic-H-Ras may exhibit pro-apoptotic activity that will
allow FR901228 to induce selective apoptosis of human cancer cells remains unanswered.
Concomitantly, the roles of the ERK and PI3-K pathways as well as caspase and Cdk inhibitors
in human cells also need to be verified for delineating signaling pathways involved in
FR901228-induced apoptosis and growth arrest.
In this communication, we present new evidence that expression of H-Ras(V12) resulted
in increased susceptibility of human cancer HT29 cells to both HDACI FR901228- and TSAinduced apoptosis. The HT29 human colorectal adenocarcinoma cell line hosts wild-type ras,
active mutant B-raf, wild-type raf-1, and the inactive mutant p53 genes (22). Accordingly, the
ERK signaling pathway, including Mek and Erk, downstream from active B-Raf is activated.
Therefore, expression of H-Ras(V12) in HT29 cells was expected to reveal activities other than
the induction of the ERK pathway to facilitate or attenuate FR901228-induced apoptosis.
Surprisingly, expression of H-Ras(V12) in HT29 cells did not protect the activated ERK pathway
from suppression by FR901228 treatment. FR901228 treatment differentially modulated Raf-1
phosphorylation in H-Ras(V12)-expressed cells from its counterpart in parental HT29 cells.
Expression of H-Ras(V12) facilitated the induction of the apoptotic pathway by FR901228.
Regarding the regulation of signaling pathways associated with cell growth, survival, growth
arrest, and apoptosis, our studies revealed both commonalities and discrepancies between HRas(V12)-expressed cells and parental HT29 cells that may contribute to the pro-apoptotic
activity of H-Ras(V12) that allows FR901228 to selectively induce apoptosis.
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Materials and methods
Cell cultures, transfection, and reagents
HT29 (ATCC, Rockville, MD) and its derived cell lines, a human colon adenocarcinoma cell
line SW480 (obtained through a collaboration with Dr S. Baek at The University of Tennessee),
as well as a human urinary bladder cancer J82 cell line (ATCC) were maintained in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum, 100 U/ml
penicillin, and 100 μg/ml streptomycin.

10T1/2-TR-H-ras cells were maintained in Basal

Medium Eagle medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and
100 μg/ml streptomycin (6-8,23).

These cultures were incubated at 37°C and routinely

subcultured every 2 to 3 days. To generate H-Ras(V12)-expressed HT29 cells, cells in a 35 mm
culture dish were transfected with 0.5 μg of pcDNA4/TO-E-H-ras plasmid DNA, which carries
the H-Ras(V12) gene (23), using PolyFect Transfection Reagent (Qiagen, Valencia, CA). After
48 h of transfection, cells were subcultured and selected in 100 μg/ml Zeocin (Invitrogen,
Carlsbad, CA). Resistant cell clones were established to HT29-Ras cell lines. Stock aqueous
solutions of FR901228 (obtained through a collaboration with Dr. KK Chan at the Ohio State
University), TSA (ICN, Aurora, OH), U0126 (Cell Signaling, Beverly, MA), and Ac-Asp-GluVal-Asp-CHO (Ac-DEVD-CHO) (Alexis, San Diego, CA) were prepared in DMSO and diluted
in culture medium for assays. The 4-(2-Aminoethyl)benzenesulfonylfluoride-HCl (AEBSF-HCl)
(Acros, Fair Lawn, NJ) was prepared in H2O and diluted in the culture medium for assays.
Recombinant human TRAIL/Apo2L, FasL, and TNF-α (PeproTech, Rocky Hill, NJ) were
prepared in distilled water and diluted in culture medium for assays.
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Cell growth and survival Assay
Cells were seeded in 12-well culture plates. Every 24 h after treatments with FR901228 and
TSA, cells were trypsinized, washed, and then resuspended in culture medium containing 0.2%
trypan blue for 2 min to stain dead cells. Live cells were counted in a hemocytometer to
determine relative cell growth and survival rate (6,7).

Cell proliferation inhibition assay
Inhibition of cell proliferation was determined by the inhibition of 5-bromo-2’-deoxyuridine
(BrdU) incorporation into cellular DNA (7), using the BrdU cell proliferation ELISA kit (Roche,
Indianapolis, IN). Five x 104 cells were seeded into each well of 96-well culture plates for 24 h.
After treatment with FR901228, cells were labeled with BrdU for 12 h, fixed, incubated with
peroxidase-conjugated BrdU-specific antibodies, and stained with peroxidase substrate.
Quantification of BrdU-labeled cells was determined with an ELISA reader (Bio-Tek, Winooski,
VT).

Apoptotic-like cell death assay
Apoptotic-like cell death in cultures was quantified using a Cell Death Detection ELISA kit
(Roche, Indianapolis, IN) (8). After FR901228 treatments, cell lysates were incubated with antihistone antibodies.

Fragmented DNA in the complexes of nucleosomes with histone was

detected with peroxidase-conjugated anti-DNA antibody and stained with peroxidase substrate
2,2’-azino-bis-(3-ethylbenzthiazoline-6-sulfonic acid).
determined with an ELISA reader.
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Quantification of cell death was

Cell viability assay
A Methyl Thiazolyl Tetrazolium (MTT) assay kit (ATCC, Manassas, VA) was used to measure
cell survivability in cultures. Five x 104 cells were seeded into each well of 96-well culture
plates for 24 h. After treatments with HDACI and inhibitors to caspases, serine protease, or
kinases, cells were incubated with MTT Reagent for 4 h, followed by incubation with Detergent
Reagent for 24 h. Reduced MTT reagent in cultures was quantified with an ELISA reader.

Flow cytometric analysis of cell growth arrest and cell death
Cells were trypsinized from cultures, rinsed with Ca++ and Mg++ free phosphate buffered
saline, fixed in ethanol, and stained with propidium iodide (6,8,23).

Subsequently, flow

cytometric analysis was performed on the Coulter EPICS Elite Cytometer (Hialeah, FL) by using
a 15 milliwatt air-cooled argon laser to produce 488 nm light. Fluorescent light emission was
collected with a 610LPDC filter. Analysis of DNA content and determination of the percentage
of cells in each phase of the cell cycle were performed on Multicycle software (Phoenix Flow
System, San Diego, CA).
An Annexin-V-FITC Apoptosis Detection Kit with propidium iodide (BD Biosciences,
San Jose, CA) was also used to detect cell death by flow cytometry. In brief, FR901228-treated
cells were trypsinized from cultures, rinsed with phosphate buffered saline, and stained with
annexin-V-FITC and propidium iodide. Flow cytometric analysis was performed on the Coulter
EPICS Elite Cytometer (Hialeah, FL). FITC and propidium iodide fluorescent light emission
were collected with 550 nm and 645 nm band pass filters, respectively, and analyzed using
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Multicycle software (Phoenix Flow System, San Diego, CA).

Western immunoblotting
To prepare cell lysates containing Ras, Rap1, Akt, B-Raf, Raf-1, Mek1/2, Erk1/2, Fas, FasL,
caspase-3, caspase-7, caspase-8, poly (ADP-ribose) polymerase (PARP), Bad, p53, p21Cip1,
p27Kip1, and β-Actin, cells were lysed in a buffer (10 mM Tris-HCl, 150 mM NaCl, 1% Triton
X-100, 5 mM EDTA, 10 mM sodium pyrophosphate, 10% glycerol, 0.1% Na3VO4, 50 mM
NaF, pH 7.4) (6). Cell lysates (S20) were isolated from the supernatants after centrifugation of
crude lysates at 20,000 x g for 20 min. To prepare cell lysates containing nuclear core histones,
cells were lysed in a hypotonic buffer (10 mM KH2PO4, 1 mM EDTA, 5 mM EGTA, 10 mM
MgCl2, 50 mM β-glycerolphosphate, 1 mM Na3VO4, 2 mM dithiothreitol, pH 7.2) with 30
strokes of a tight-fitting Dounce homogenizer. After centrifugation of crude lysates at 10,000 x g
for 10 min, cell pellets (P10) containing nuclear histones were resuspended in lysis buffer and
sonicated for 10 min as nuclear lysates. Protein concentrations in cell lysates (S20) and nuclear
lysates (P10) were measured using the BCA assay (Pierce, Rockford, IL). Equal amounts of
cellular proteins were resolved by electrophoresis in either 10% or 14% SDS-polyacrylamide
gels and transferred to nitrocellulose filters for Western immunoblotting, as previously described
(6,7,8). Antibodies specific to Akt, Raf-1, Mek1/2, Bad, acetylated H2B on Lys12, H2B protein,
acetylated H3 on Lys9, H3 protein, active caspase-3, active caspase-7, active caspase-8, PARP,
and β-Actin; and specific antibodies to phosphorylated forms of Akt, Raf-1, B-Raf, Mek1/2,
Erk1/2, and Bad (Ser112) were purchased from Cell Signaling Technology (Beverly, MA).
Specific antibodies to H-Ras, Rap1, B-Raf, Erk1/2, Fas, FasL, p53, p27Kip1, and p21Cip1 were
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purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antigen-antibody complexes on
filters were detected by the SuperSignal chemiluminescence kit (Pierce, Rockford, IL).

Statistical analysis
Statistical significance was analyzed by the Student’s t-test. A p-value ≤ 0.05 was considered
significant.

Results

Increased susceptibility of HT29 cells to FR901228 by oncogenic H-Ras
To determine whether expression of oncogenic H-Ras in human cancer cells may facilitate
FR901228-induced apoptosis, HT29 cells were stably transfected with the expression plasmid
vector pcDNA4/TO-E-H-ras, which carries the oncogenic H-ras(V12) gene (23).

Two H-

ras(V12)-transfected HT29 cell lines, HT29-Ras-1 and -2, were established based on their
distinct H-Ras expression levels (Fig. 1a). H-Ras protein was expressed by approximately 4- and
9-fold in HT29-Ras-1 and HT29-Ras-2 cells, respectively, as compared to its endogenous
counterpart protein in parental HT29 cells. Expression of H-Ras(V12) did not result in any
noticeable difference in cell growth rate (Fig. 1b, HT29-Ras-1 and HT29-Ras-2, 0 nM control
lines) or visible difference in cell morphology (data not shown) compared to parental HT29 cells.
To detect any change in susceptibility of HT29-Ras-1 and HT29-Ras-2 cells to FR901228 for
inducing cell death, cultures were treated with FR901228 at various concentrations for 48 h. As
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shown in Fig. 1b, treatment of parental HT29 and HT29-Ras-1 cells with 1 nM FR901228
resulted in growth inhibition in 24 h and 48 h. In contrast, treatment of HT29-Ras-2 cells with 1
nM FR901228 induced growth inhibition in 24 h and significant cell death in 48 h. Treatment
with 5 nM FR901228 resulted in growth inhibition of all these cultures in 24 h, and it induced
modest cell death in parental HT29 and HT29-Ras-1 cultures and profound cell death of HT29Ras-2 cells by 48 h. Induction of cell death by FR901229 was in a dose- and time-dependent
manner. FR901228 induced cell death of HT29-Ras-2 cells at a discriminating concentration of
1 nM, whereas this concentration mainly induced growth inhibition of parental HT29 and HT29Ras-1 cells in 48 h. A threshold of oncogenic H-Ras expression appeared to be involved in the
increased susceptibility of HT29 cells to FR901228 for inducing cell death.

Flow cytometric analysis of apoptosis and cell growth arrest by FR901228
To further analyze FR901228-induced growth inhibition and cell death, we used flow cytometry
to detect populations of cells undergoing apoptosis and growth arrest in the cultures of HT29 and
HT29-Ras-2 cells. As indicated in Table 1, treatment with FR901228 at 1 nM for 48 h induced a
modest population of apoptotic cells in parental HT29 cultures (increased from <1% to 4%), in
contrast to a significantly increased population of apoptotic cells in HT29-Ras-2 cultures
(increased from <1% to 20%). We also used an Annexin-V-FITC Apoptosis Detection Kit with
propidium iodide (BD Biosciences, San Jose, CA) to detect phosphatidylserine externalization in
cell population undergoing cell death by flow cytometry. As shown in Fig. 1c, FR901228
treatment resulted in higher populations of cells that were undergoing cell death (3% and 9.3%)
and apoptotic cells (7% and 29%) in HT29-Ras cultures than their counterpart cell population in
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parental HT29 cultures (1.8 and 3%; 2% and 8%) by 24 and 36 h. Cell population in HT29-Ras2 cultures was induced by FR901228 to increasingly undergo apoptosis to a higher level than the
apoptotic cell level induced in parental HT29 cultures. Apparently, expression of H-Ras(V12) in
HT29 cells facilitated the induction of apoptosis by FR901228.
Analysis of the live cell population throughout the cell cycle showed an increased
population in the G0/G1 phase and a substantially reduced population in the S phase in cultures
of parental HT29 cells after FR901228 treatment for 24 h (Table 1). In contrast, FR901228
treatment of HT29-Ras-2 cells resulted in a substantially reduced population in the S phase and
an increased cell population in the G2/M phase. Thus, expression of H-Ras(V12) in HT29 cells
appeared to change their susceptibility to FR901228 for growth arrest from the G0/G1 to G2/M
phase of the cell cycle.

Apoptotic pathways induced by FR901228
To further verify that the FR901228 induced apoptosis of HT29 cells, we measured the level of
fragmented DNA in the complexes of nucleosomes with histones induced by FR901228 in
cultures of HT29 and HT29-Ras-2 cells. As shown in Fig. 2a, the FR901228-induced apoptotic
DNA fragmentation was profoundly higher in HT29-Ras-2 cultures than in parental HT29
cultures. Studying the involved caspases in the FR901228-induced apoptosis, we detected that
higher levels of active caspase-3 were induced in HT29-Ras-2 cells (Fig. 2b, lanes 5 and 6) than
in parental counterpart HT29 cells (lanes 2 and 3) by 48 h in a dose-dependent manner. In
addition, higher levels of active caspase-3 (Fig. 2c-1), active caspase-7 (Fig. 2c-2), and
proteolytically modified, downstream substrate PARP (Fig. 2c-3), were induced in HT29-Ras-2
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cells (lanes 5 and 6) than in parental HT29 cells (lanes 2 and 3) in a time-dependent manner. To
determine the upstream caspases, which may contribute to the activation of caspase-3 and
caspse-7, we detected that active caspase-8 was induced to higher levels in HT29-Ras-2 cells
(Fig. 2c-4, lanes 5 and 6) than in parental HT29 cells (lanes 2 and 3). However, we did not
detect any differential induction of caspase-9 in these cells (data not shown). Accordingly, the
caspase-8 to caspase-3 and -7 pathway was induced by FR901228 treatment in HT29 cells.
Induction of caspase-3, caspase-7, and caspase-8 activation by FR901228 was enhanced by
expression of H-Ras(V12) in HT29 cells.
To determine the role of caspase-3 and -7 activation in FR901228-induced cell death,
HT29 and HT29-Ras-2 cells were pre-treated with the potent caspase-3 and -7 inhibitor, AcDEVD-CHO (8,24), followed by FR901228 treatment for 48 h. As shown in Fig. 2d, treatment
of cells with Ac-DEVD-CHO alone resulted in a modest reduction of cell viability in both HT29
and HT29-Ras-2 cultures. A modest reduction of cell viability was also detected in parental
HT29 cultures treated with FR901228 alone, and the Ac-DEVD-CHO pretreatment did not result
in a significant reversal of the FR901228-reduced cell viability. In contrast, FR901228 treatment
resulted in a profound reduction of cell viability in HT29-Ras-2 cultures, and the Ac-DEVDCHO pretreatment attenuated the FR901228-reduced cell viability. Accordingly, the role of
caspase-3 and -7 activation was evident in oncogenic Ras-expressed HT29 cells undergoing
FR901228-induced apoptosis, but was not clear in parental HT29 cells under FR901228
treatment.
To investigate other proteases involved in FR901228-induced cell death, we pre-treated
cells with AEBSF-HCl (24), a serine protease inhibitor. Treatment with AEBSF-HCl alone
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induced a modest reduction of cell viability in both HT29 and HT29-Ras-2 cultures (Fig. 2d).
Pre-treatment with AEBSF-HCl did not reverse FR901228-reduced cell viability in parental
HT29 cultures, but it alleviated FR901228-reduced cell viability in HT29-Ras-2 cultures. Again,
the role of serine protease activation was evident in H-Ras(V12)-expressed HT29 cells
undergoing FR901228-induced apoptosis, but was not clear in parental HT29 cells under
FR901228 treatment. These results taken together indicate that caspase-3, caspase-7, and serine
protease(s) were differentially induced by FR901228 to play roles in inducing apoptosis of
HT29-Ras-2 cells.
To pursue the involvement of death receptor family in FR901228-induced differential
cell death of HT29-Ras-2 cells, we studied the activity of TRAIL and FasL, and TNFα in
FR901228-induced cell death. As shown in Fig. 3a, 3b, and 3c, expression of oncogenic HRas(V12) increased cell susceptibility to TRAIL and FasL, but not TNFα, for inducing cell
death. Co-treatment with either TRAIL or FasL profoundly enhanced FR901228-induced cell
death of both HT29 and HT29-Ras-2 cells, regardless of H-Ras(V12) expression (Fig. 3a and
3b). Although expression o f H-Ras(V12) did not increase cell susceptibility to TNFα, cotreatment with TNFα also enhanced FR901228-induced cell death modestly in HT29 cells and
significantly in HT29-Ras-2 cell (Fig. 3c). Accordingly, these results indicate that H-Ras(V12)
expression played a role in differentially potentiating TRAIL and FasL pathways in cells for
FR901228-induced cell death; therefore, activation of the death receptor family pathways by
their ligands predominantly promoted the ability of FR901228 to induce cell death. We also
detected that the expression levels of FasL and Fas were differentially increased by FR901228
treatment in HT29 and HT29-Ras-2 cells. As shown in Fig. 3d-1, Fas expression was induced by
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FR901228 to a higher level in HT29-Ras-2 cells by 24 h (lane 5) than in HT29 cells (lane 2).
FR901228-induced expression of FasL was maintained to a higher level in HT29-Ras-2 cells by
48 h (Fig. 3d-2, lane 5) than in HT29 cells (lane 2). These results indicate that H-Ras(V12)
expression played a role in differentially potentiating both FasL and Fas for FR901228-induced
expression.

Induction of Cdk inhibitors in cell growth arrest by FR901228
To investigate FR901228-induced cell growth inhibition, we verified the ability of FR901228 to
inhibit cell proliferation by detecting the inhibition of BrdU uptake into cells. As shown in Fig.
4a, cell proliferation in both parental HT29 and HT29-Ras-2 cultures was suppressed by
FR901228 treatment in 24 h. To pursue the involvement of Cdk inhibitors in FR901228-induced
cell growth inhibition, we detected the induction of p21Cip1 and p27Kip1 in FR901228-treated
cells. As shown in Fig. 4b, p21Cip1 expression was induced by FR901228 in HT29 (lanes 2 and
3) and HT29-Ras-2 (lanes 5 and 6) cultures. The level of p21Cip1 was induced in growthinhibited HT29 cells by FR901228 in 24 h (lane 2) and unchanged by 48 h (lane 3). The level of
p21Cip1 was induced in HT29-Ras-2 cells by FR901228 in 24 h (lane 5), but reduced by 48 h
(lane 6) when cells underwent significant apoptosis. The mutant p53 was also reduced in HT29
(Fig. 4c, lane 3) and HT29-Ras-2 (lane 6) cells after FR901228 treatment for 48 h. Interestingly,
another Cdk inhibitor, p27Kip1, was not induced until 48 h after FR901228 treatment of HT29
(Fig. 4d, lane 3) and HT29-Ras-2 (lane 6) cells. It appeared that p21Cip1 expression was
correlated with an early growth arrest, and p27Kip1 expression was correlated with either a
complete growth arrest or induction of apoptosis by FR901228 in both HT29 and HT29-Ras-2
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cells.

Target in the ERK pathway by FR901228
To investigate the role the ERK pathway may play in HT29 and HT29-Ras-2 cells undergoing
FR901228 treatment, we used kinase inhibitor U0126 to specifically suppress Mek1/2 activity
(7,8,26). As shown in Fig. 5a, treatments with U0126 alone for 48 h modestly reduced cell
viability in cultures of HT29 and HT29-Ras-2.

However, U0126 treatment significantly

decreased the FR901228-reduced viability of parental HT29 cells. The significantly reduced cell
viability by FR901228 in HT29-Ras-2 cultures was additionally decreased by U0126 treatment.
Thus, the ERK pathway played a survival role in both HT29 and HT29-Ras-2 cells responding to
the FR901228 treatment.
To detect if the ERK pathway was targeted by FR901228 to reduce cell viability, we
studied FR901228-induced effects on activation-related phosphorylation and protein levels of
ERK pathway kinases B-Raf, Raf-1, Mek1/2, and Erk1/2. Equal amounts of cellular proteins
isolated from treated and control cultures were analyzed by Western immunoblotting with
specific antibodies. We detected that the overall phosphorylation level of B-Raf was elevated in
HT29-Ras-2 cells (Fig, 5b-1, lane 4), compared to its counterpart kinase in parental HT29 cells
(lane 1). FR901228 treatment reduced the overall phosphorylation and cognate protein levels of
B-Raf in HT29-Ras-2 cells (Fig, 5b-1, 5b-2, lanes 5 and 6) in contrast to the unchanged
counterpart levels in parental HT29 cells (lanes 2 and 3). Based on the cognate protein level of
B-Raf, the specific phosphorylation level of B-Raf (p/B-Raf) was elevated in HT29-Ras-2 cells
(approximately 2-fold), compared to its counterpart in parental HT29 cells. FR901228 treatment
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reversed the increased, specific phosphorylation level of B-Raf in HT29-Ras-2 cells to a level
maintained in parental HT29 cells.
Expression

of

H-Ras(V12)

modestly

elevated

the

overall

activation-related

phosphorylation level and protein level of Raf-1 in HT29 cells (Fig, 5c-1, 5c-2, lane 4 versus
lane 1); accordingly, its specific phosphorylation was unchanged. FR901228 treatment resulted
in a profound reduction of the protein level of Raf-1 in both HT29 and HT29-Ras-2 cells (Fig,
5c-2, lanes 2, 3, 5, and 6); however, the overall phosphorylation level of Raf-1 was not
accordingly reduced in either parental HT29 or HT29-Ras-2 cells (Fig, 5c-1). Adjusted with βActin levels (Fig. 5d), we detected that Raf-1 protein was reduced by FR901228 to lower levels
in parental HT29 cells (Raf-1/Actin, reduced from 1X to 0.3 and 0.1X) (Fig. 5c-2, lanes 2 and 3)
than in HT29-Ras-2 cells (reduced from 2.9 X to 0.8 and 0.4 X) (lanes 5 and 6), but the reduction
rate of Raf-1 protein in HT29 cells was similar to the rate in HT29-Ras-2 cells (approximately
reduced 1X to 0.3 and 0.1X). Based on the cognate protein levels of Raf-1, the specific
phosphorylation level of Raf-1 (p/Raf-1) was highly elevated to approximately 13-fold (Fig, 5c-1
and 4c-2, lane 3) in parental HT29 cells, but only elevated approximately 2-fold in HT29-Ras-2
cells (lane 6). It appeared that an intrinsic mechanism was involved in increasing the specific
phosphorylation of Raf-1 in order to maintain the overall level of activation/phosphorylation in
both HT29 and HT29-Ras-2 cells in response to FR901228-reduced Raf-1 protein. Raf-1 protein
was a target in FR901228-treated cells.

It has been suggested that FR901228-induced

upregulation of Rap1 plays a role in suppression of the Ras-Raf-Erk kinase signaling pathway
(27). We also detected increased expression of Rap1 induced by FR901228 in both HT29 and
HT29-Ras-2 cells, and a higher level of Rap1 was induced by FR901228 in HT29 cells (Fig. 5e,
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lanes 2 and 3 )than in HT29-Ras-2 cells (lanes 5 and 6). The increased levels of Rap1 may play
a role in regulating Raf-1 and B-Raf in both HT29 and HT29-Ras-2 cells.
HT29 cells host the active mutant B-raf gene (22). The downstream kinases Mek1/2 and
Erk1/2 were highly phosphorylated/activated in HT29 cells (Fig, 5f-1, 5g-1, lane 1), compared to
their counterpart kinases in human urinary bladder carcinoma J82 cells in which the ERK
pathway is not constitutively active (lane 7). FR901228 treatment reduced the activation-related
phosphorylation of both Mek1/2 and Erk1/2 in both HT29 (Fig, 5f-1, 5g-1, lanes 2 and 3) and
HT29-Ras-2 (lanes 5 and 6) cells. Protein levels of Mek1/2 and Erk1/2 were not significantly
changed by FR901228 treatment in either HT29 or HT29-Ras-2 cells (Fig, 5f-2, 5g-2). Reduced
phosphorylation of Mek1/2 and Erk1/2 appeared to correlate with the reduced Raf-1 protein,
regardless of the maintained overall phosphorylation of Raf-1 in FR901228-treated cells.
While investigating the role the PI3-K pathway plays in FR901228-induced apoptosis of
HT29 and HT29-Ras-2 cells, we observed that protein phosphorylation of Akt was not detectable
in HT29 and HT29-Ras-2 cells (Fig. 5h-1, lanes 1 to 6), as compared to its counterpart kinase in
J82 cells (lane 7). Expression of H-Ras(V12) in HT29 cells failed to conventionally activate the
PI3-K pathway (lane 4). Although the PI3-K pathway is a known downstream pathway of Ras
(10), the dissociation of the PI3-K pathway from Ras in HT29 cells remains to be clarified. To
clarify a target role the PI3-K pathway may play in HT29 and HT29-Ras-2 cells treated with
FR901228, we used kinase inhibitor LY294002 to specifically suppress PI3-K activity (20, 28).
We detected that LY294002 treatment did not enhance or decrease any FR901228-reduced cell
viability in either HT29 or HT29-Ras-2 cultures (data not shown). Thus, the PI3-K pathway was
unlikely to play any target role for FR901228 in the induction of apoptosis in either HT29 or
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HT29-Ras-2 cells.
To further investigate the effect of the suppressed ERK pathway on the cross-talk to
apoptotic pathway, we investigated regulation of Bcl-2 family members in FR901228-treated
cells. We detected that the overall phosphorylation level of Bad on Ser112 was lower in HT29Ras-2 cells (Fig. 5i-1, lane 4) than in parental HT29 cells (lane 1).

FR901228 treatment

increased the overall phosphorylation of Bad in both parental (Fig. 5i-1, lanes 2 and 3) and
HT29-Ras-2 (lanes 5 and 6) cells, but the induced overall phosphorylation levels were noticeably
lower in HT29-Ras-2 cells than in parental HT29 cells. Adjusted by their cognate protein levels
(Fig. 5i-2), the specific phosphorylation of Bad was significantly lower in HT29-Ras-2 cells
(p/Bad, lanes 4 to 6, approximately 0.5- to 0.9-fold) than its counterpart level in parental HT29
cells (lanes 1 to 3, 1- to 2.9-fold). Increased phosphorylation of Bad on Ser112 by Raf-1 has
been reported to deactivate Bad (29-31). FR901228-increased phosphorylation of Bad is likely
to be attributed to the increased specific phosphorylation/activation of Raf-1.
We also studied the role of JNK/SAPK and p38/SAPK in FR901228-induced cell death.
Blockage of JNK and p38 by their specific inhibitors, SP600125 (32) and SB203580 (33), did
not result in any detectable changes in FR901228-induced cell death (data not shown).
Therefore, these SAPK pathways may not be involved in FR901228-induced cell death of HT29
and HT29-Ras-2 cells.

Acetylation of core histones induced by FR901228
While verifying the effect of FR901228 on modulating histone acetylation in equal amounts of
nuclear proteins isolated from HT29 and HT29-Ras-2 cells, we detected that acetylation of core
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histones H2B on Lys-12 (Fig. 6a-1) and H3 on Lys-9 (Fig. 6b-1) was substantially induced by
FR901228 treatment in both HT29 (lane 2) and HT29-Ras-2 (lane 5) cells by 24 h. However,
histone acetylation was reduced in cells treated with FR901228 for 48 h (lanes 3 and 6).
Acetylated histones (Fig. 6a-1, 6b-1) and their cognate protein levels (Fig. 6a-2, 6b-2) were
reduced by FR901228 treatment to lower levels in HT29-Ras-2 undergoing apoptosis (lane 6)
than their counterparts in parental HT29 cells mainly undergoing growth arrest (lane 3).
Reduction of H2B and H3 contents by extended FR901228 treatment appeared to be enhanced
by expression of H-Ras(V12) in cells undergoing apoptosis.

Pro-apoptotic susceptibility of oncogenic Ras to HDACI
To further investigation of oncogenic Ras in cell susceptibility to HDACI, we included a human
colon adenocarcinoma cell line SW480 that carries oncogenic K-ras4B gene and wild-type raf
genes (34) in our studies. HT29, HT29-Ras-2, and SW480 cells were treated with FR901228
and a FR901228-unrelated HDACI, TSA, followed by determining cell viability in treated
cultures. As shown in Fig. 7a, FR901228 treatment of HT29-Ras-2 cells at concentrations of 1,
5, and 25 nM and FR901228 treatment of SW480 cells at concentrations of 5 and 25 nM reduced
viability to higher degrees than the reduced viability in counterpart HT29 cells. TSA treatment
at concentrations of 25 and 100 nM reduced viability of both HT29-Ras-2 and SW480 cells to
higher degrees than the reduced viability of parental counterpart HT29 cells (Fig. 7b).
Apparently, the increased susceptibility to HDACI by oncogenic Ras in human colorectal
adenocarcinoma cells is not cell line-limited and is also not limited to depsipeptide FR901228,
but also includes TSA.
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To verify that increased cell susceptibility to TSA by expression of oncogenic Ras is not
limited to human colorectal adenocarcinoma cells, we tested whether TSA was able to
selectively induce cell death in Ras-transformed 10T1/2 cells. 10T1/2-TR-H-ras cultures, in
which ectopic expression of H-Ras(V12) is controlled by tetracycline (7, 8, 23), were treated
with TSA at a discriminating concentration of 5 nM for 72 h in the absence and presence of
tetracycline induction. As shown in Fig. 7c, TSA treatment of 10T1/2-TR-H-ras cultures, in
which oncogenic Ras was not induced, resulted in reduction of the relative cell growth rate in 24
h and inhibition of cell growth by 72 h. In contrast, TSA treatment of 10T1/2-TR-H-ras
cultures, in which expression of oncogenic Ras was induced by tetracycline, reduced the relative
cell growth rate in 24 h, inhibited cell growth in 48 h, and induced cell death by 72 h. The
selectivity of TSA to induce cell growth inhibition and cell death of Ras-expressed cells is not a
cell type-specific event.

Discussion
Investigation of the pro-apoptotic activity of H-Ras(V12) in human cancer cells that
allows HDACI to induce apoptosis provides cellular bases for developing therapeutic strategies
to target Ras-related human cancers. Previously, we reported that expression of H-Ras(V12) in
mouse 10T1/2 cells increases susceptibility to FR901228, but not the potent apoptosis inducer
staurosporine (6-8). In contrast, expression of the oncogenic v-src gene in 10T1/2 cells showed
no pro-apoptotic activity in FR901228-induced apoptosis (result not shown). In this report, we
present evidence that expression of H-Ras(V12) in human cancer HT29 cells resulted in
increased susceptibility to cell death induced after treatment with FR901228 and a structurally
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unrelated HDACI, TSA. We also verified TSA’s ability to selectively induce cell death of HRas(V12)-expressed 10T1/2 cells. In addition, expression of H-Ras(V12) in either HT29 or
10T1/2 cells did not result in increased cell susceptibility to other agents, including U0126,
LY294002, Ac-DEVD-CHO, and AEBSF-HCl. Therefore, the pro-apoptotic activity of HRas(V12) that allows agents to induce cell death is an HDACI-specific, but is not a cell typespecific property. Although the selectivity of HDACI to induce cell death of H-Ras(V12)expressed cells may not be applicable to other Ras-unrelated oncogene-expressed cells, it may be
applicable to other Ras family, such as K-Ras, as evident with a high susceptibility of SW480
cell line, which hosts the oncogenic K-ras gene, to both FR901228 and TSA for inducing cell
death.
Both an enhanced induction of caspase-3 and caspase-7 activation and an induced serine
protease activity evidently play important roles in the increased cell susceptibility to FR901228
for inducing cell death of oncogenic-H-Ras-expressed cells.

Previously, we reported that

expression of H-Ras(V12) in mouse 10T1/2 cells not only increases procaspase-3 expression
level, but also facilitates FR901228-induced activation of caspase-3 for inducing cell death (7).
Although the procaspase-3 protein level was not noticeably increased by expression of HRas(V12) in HT29 cells, activation of caspase-3 by FR901228 was enhanced in HT29-Ras-2
cells for inducing apoptosis. In addition to caspase-3 and caspase-7 activation, serine protease
activity was detected in HT29-Ras-2 cells, but not in parental HT29 cells, was also likely to play
a role in the induction of apoptosis by FR901228. Thus, caspase-3, caspase-7, and serine
protease were differentially induced by FR901228 in H-Ras(V12)-expressed HT29 cells to play
roles in FR901228-induced selective apoptosis. Both the extrinsic caspase-8 and the intrinsic
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caspase-9 initiator pathways have been postulated to activate the executioner caspase-3 and
caspase-7 (35). Studies have shown that FR901228 treatment induces a Fas pathway-dependent
activation of caspase-8 and caspase-3 in human osteosarcoma and leukemia cells (36-38), and
induces mitochondrial pathway-dependent activation of caspase-9 and caspase-3, but not
caspase-8, in lung cancer cells (39). Our study indicated the extrinsic caspase-8 initiator caspase
pathway, but not the intrinsic caspase-9 pathway, was induced by FR901228 in both HT29 and
HT29-Ras-2 cells. Activation of caspase-3 and caspase-7 by FR901228 in HT29 cells appears to
be independent from caspase-9 activity.
In pursuing the involvement of the death receptor family pathways in FR901228-induced
cell death of HT29 and HT29-Ras-2 cells, we detected that H-Ras(V12) expression played a role
in differentially potentiating TRAIL- and FasL-induced death receptor pathways for FR901228induced cell death.

Activation of the death receptor pathways by TRAIL and FasL

predominantly promoted the ability of FR901228 to induce cell death of both HT29 and HT29Ras-2 cells. It has been reported that HDACI enhances the susceptibility of brain tumor cells to
TRAIL-induced cell death (40), and TRAIL-induced activation of caspase-8 is enhanced by
expression of oncogenic H-Ras (41). FR901228 treatment induces FasL expression, leading to
activation of caspase-8 and -3 in human osteosarcoma cells (38). We detected that FR901228
treatment not only increased expression level of FasL, but also Fas in HT29 and HT29-Ras-2
cells; higher levels of FasL and Fas were induced by FR901228 in HT29-Ras-2 cells than in
HT29 cells. In addition, we detected that activation of TNFα-induced death receptor pathway
promoted the ability of FR901228 to induce cell death in HT29-Ras-2 cells. Oncogenic H-Rasexpression induces susceptibility of 10T1/2 cells to TNFα-induced apoptosis (42). Apparently,
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these death receptor family pathways were potentiated by H-Ras(V12) expression to facilitate
FR901228-induced cell death in HT29-Ras-2 cells.
Profound acetylation of core histones H2B and H3 was expected in HT29 and HT29-Ras2 cells treated with FR901228. Unexpectedly, within equal amounts of isolated nuclear proteins,
we detected that acetylated histones and their protein contents were reduced in cells undergoing
growth inhibition or apoptosis. Particularly, reduction of H2B and H3 contents by FR901228
appears to be accelerated by expression of H-Ras(V12) in HT29 cells in association with an
enhanced cell death. It is possible that H-Ras(V12)-induced modification of core histones in
conjunction with apoptosis-related chromosomal DNA fragmentation contribute to the enhanced
histone reduction in HT29-Ras-2 cells undergoing FR901228-induced cell death. Modification
of core histones through acetylation has been reported to play a critical role in the growth arrest
of cell proliferation (43, 44). However, the mechanism for reducing histone content and the role
of reduced histones in FR901228-induced apoptosis remain to be clarified.
Investigation of Cdk inhibitors involved in FR901228-induced cell growth arrest revealed
that p21Cip1 was initially and p27Kip1 was subsequently induced by FR901228 treatment in
both oncogenic Ras-expressed and parental HT29 cells. Up-regulation of p27Kip1 has been
postulated to play a role in complete growth suppression of human cancer cells, in which the
constitutively activated ERK pathway is suppressed (45). The ERK pathway is constantly
activated in parental HT29 cells.
suppressed the ERK pathway.

FR901228 treatment of HT29 and HT29-Ras-2 cells

Accordingly, subsequent to p21Cip1 expression, p27Kip1

expression may contribute to a complete growth inhibition of HT29 and HT29-Ras-2 cells by
FR901228. FR901228 treatment induces p21Cip1 expression, but not p27Kip1 (data not shown),
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in non-transformed 10T1/2 cultures in which cells are mainly arrested in the G0/G1 phase of the
cell cycle; in contrast, FR901228 treatment reduces the basal level of p21Cip1 in Rastransformed 10T1/2 cultures in which significant apoptosis is induced (6). Sandor et al. observed
that human colon cancer HCT116-derived cell clones lacking p21Cip1 are not arrested in the G1
phase, but are arrested in the G2/M phase of the cell cycle following FR901228 treatment; they
suggested that p21Cip1 is required for FR901228-induced G1 arrest, and G2/M arrest in the
absence of p21Cip1 is associated with increased cell death induced by FR901228 (46). We
observed that expression of H-Ras(V12) in HT29 cells changed the susceptibility to FR901228
for growth-arresting cells from the G0/G1 to G2/M phase of the cell cycle. Possibly, decreased
p21Cip1 protein content in HT29-Ras cells plays a role in the increased susceptibility to
FR901228-induced apoptosis. Both p21Cip1 and p27Kip1 have been postulated to play multiple
roles in the regulation of apoptosis, protein assembly, and gene transcription in addition to
inhibitors of the cell cycle (47). The roles of sequential expression of p21Cip1 and p27Kip1 as
well as down-regulation of p21Cip1 in FR901228-induced cell growth arrest and apoptosis
remain to be clarified.
The ERK pathway was targeted and suppressed by FR901228 treatment in both parental
and H-Ras(V12)-expressed HT29 cells. Blocking the ERK pathway resulted in an enhancement
of FR901228-induced apoptosis; thus, the ERK pathway plays an anti-apoptotic role in
FR901228-induced apoptosis of both parental and H-Ras(V12)-expressed HT29 cells.
FR901228 treatment resulted in substantial reduction of Raf-1 protein in both parental HT29 and
HT29-Ras-2 cells, a result consistent to the outcome of substantially reduced Raf-1 protein in
FR901228-treated mouse 10T1/2 cells (6). It has been suggested that FR901228 treatment
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results in destabilization of Raf-1 protein due to dissociation from Hsp90 (48, 49). Possibly, the
association between Raf-1 and Hsp90 is a target for FR901228 to reduce Raf-1 protein in HT29
and 10T1/2 cells, regardless of Ras activation. Recently, it has been suggested that FR901228induced upregulation of Rap1 plays a role in suppression of the Ras-Raf-Erk kinase signaling
pathway (27). We detected an increased level of Rap1 induced by FR901228 in both HT29 and
HT29-Ras-2 cells. FR901228-increased Rap1 expression may play a role in regulating Raf-1
and B-Raf in both HT29 and HT29-Ras-2 cells; however, the effect of H-Ras(V12) expression
on the role of Rap1 in FR901228-induced cell death remains to be determined. Based on the
reduced cognate Raf-1 protein levels in FR901228-treated cells, the specific phosphorylation of
Raf-1 was highly increased by FR901228 in parental HT29 cells and was modestly increased in
HT29-Ras-2 cells. It appears that a novel mechanism is involved in increasing the specific
phosphorylation/activation of Raf-1 in order to maintain the overall level of phosphorylated Raf1.

The specific phosphorylation of Raf-1 may contribute to its specific kinase activity in

phosphorylating Bad on Ser112 and suppressing the apoptotic activity of Bad (29-31). It is
highly possible that suppression of Bad contributes to suppression of the mitochondrial caspase9-inovolved pathway in FR901228-treated cells. Whether the less phosphorylated/inhibited Bad
in H-Ras(V12)-expressed HT29 cells than in parental HT29 cells plays a role in the selective
apoptosis induced by FR901228 remains to be clarified. On the other hand, phosphorylation
levels of Mek1/2 and Erk1/2 were profoundly suppressed by FR901228 in both parental HT29
and HT29-Ras-2 cells. Apparently, maintenance of the overall phosphorylation and the increases
in specific phosphorylation of Raf-1 may not be sufficient to prevent the downstream Mek1/2
and Erk1/2 from down-regulation by FR901228 treatment. Possibly, the protein level of Raf-1
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plays an important role in maintaining the activity of Mek1/2 and Erk1/2. A question of whether
the reduction of the Raf-1 protein level by FR901228 treatment is sufficient to block signals for
phosphorylation/activation of downstream Mek1/2 and Erk1/2 needs to be addressed.

In

addition, although differential modulation in phosphorylation and protein levels of B-Raf and
Raf-1 by FR901228 treatment was detectable in between HT29 and HT29-Ras-2 cells,
phosphorylation of the downstream Mek1/2 and Erk1/2 was down-regulated in both HT29 and
HT29-Ras-2 cells. The role FR901228-induced differential modulation of B-Raf and Raf-1,
which may involve induction of pro-apoptotic pathways such as Mst2 (50), may play in selective
induction of cell death HT29-Ras-2 cells remains to be clarified.
The HT29 cell line hosts the active B-raf mutant gene (22), and contains constantly
activated downstream Mek1/2 and Erk1/2. Expression of H-Ras(V12) in HT29 cells appears to
slightly enhance the ERK pathway. Possibly, an intrinsic, feedback signaling circuit is involved
in the constant regulation of the constitutively B-Raf-activated ERK pathway in HT29 cells. The
HT29 cell line also hosts the inactive p53 mutant gene (22). FR901228 treatment resulted in
reduction of mutant p53 in both parental and H-Ras(V12)-expressed HT29 cells. Apparently,
FR901228’s ability to induce cell death is not dependent on p53 function. In addition, Akt
phosphorylation was not detectable in HT29 cells; and expression of oncogenic H-Ras failed to
induce phosphorylation of Akt. The PI3-K pathway appears to be aberrantly inhibited in HT29
cells and plays no role in FR901228-induced cell death. In general, mutation of either the ras
gene or the B-raf gene may be sufficient for human cancer development (51, 52). Our studies
using HT29 cells as hosts to express oncogenic H-Ras revealed that H-Ras(V12) may possess an
additional, pro-apoptotic activity affecting oncogenic B-Raf in response to HDACI-induced
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selective cell death.
Current Ras-targeted anticancer approaches mainly focus on inhibition of Ras protein
synthesis, interference with Ras processing to functional sites, or blockage of downstream Ras
effectors, approaches based on understanding the roles of oncogenic Ras in tumorigenesis (51).
However, agents targeting the pro-apoptotic activity of oncogenic Ras are still overlooked. Our
studies verified the pro-apoptotic activity of oncogenic H-Ras that allows HDACI to induce cell
death of human cancer HT29 cells. Our results indicate the ability of HDACI to discriminate
between oncogenic H-Ras-expressed and counterpart human cells, and suggest a potential value
of HDACI in treating Ras-related human cancers. The values of the ERK and PI3-K pathways,
the death receptor family pathways, caspase-3, caspase-7, and caspase-8, and Cdk inhibitors as
molecular targets need to be considered individually for designing therapeutic protocols using
HDACI in combination with other agents to assure the effectiveness of target therapies for treat
human cancer involving Ras or Raf activation.
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Table
Table 1. Flow cytometric analysis of FR901228-treated cells
0 hr

HT29
24 hr

48 hr

<1

1

4±1

Live (%):
G0/G1:

60±8

72±4

S:

17±2

G2/M:

23±7

Treatment:
Apoptotic (%):

0 hr

HT29-Ras
24 hr

48 hr

<1

4±2

20±2

75±2a

59±6

57±11

57±6b

3±1

4±1

12±3

3±1

5±2

25±3

21±1c

29±10

40±13

38±3d

HT29 and HT29-Ras cultures were treated with 1 nM FR901228 for 0, 24, and 48 hours.
Anchored cells were trypsinized from cultures, and cell populations were analyzed by flow
cytometry to detect apoptotic cell population and live cells in each phase of the cell cycle. Each
value represents a mean of results from two independent experiments ± standard deviation.
Student’s t-test was used to analyze statistical significance of b versus a (p < 0.01) and d versus c
(p < 0.001).
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Fig. 1 Increased cell susceptibility to FR901228 by oncogenic H-Ras. (a) Expression levels of
H-Ras and β-Actin in HT29, HT29-Ras-1, and HT29-Ras-2 cells were determined by Western
immunoblotting with antibodies specific to H-Ras and β-Actin. Detected levels of H-Ras and βActin on radiograms were quantified by densitometry. The levels of H-Ras were normalized by
the cognate levels of β-Actin, and then the relative levels of H-Ras in HT29-Ras-1 and -2 cells
were normalized by the level of endogenous H-Ras determined in parental HT29 cells, set as 1
(X, arbitrary unit), as shown in parentheses. (b) HT29, HT29-Ras-1, and HT29-Ras-2 cells were
treated with 0, 0.2, 1, and 5 nM FR901228 (FR) for 0, 24, and 48 h. Relative cell growth and
survival rates in cultures were normalized by the number of live cells determined at 0 h, set as
100%. Each value represents a mean of triplicates, and error bars represent standard deviation.
The Student’s t-test was used to analyze statistical significance of ii versus i (p < 0.001). (c)
HT29-Ras-2 and HT29 cells were treated with 1 nM FR901228 for 0, 12, 24, and 36 h. Then,
cell death in the population of attached cells was assessed by flow cytometry with an AnnexinV-FITC Apoptosis Detection Kit with propidium iodide.
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Fig. 2 Apoptotic pathways in FR901228-induced cell death. (a) Quantification of apoptotic-like
cell death in cultures of HT29 and HT29-Ras-2 that were treated with 1 nM FR901228 for 48 h
was determined using a Cell Death Detection ELISA kit. Relative cell death, as fold induction
(X, arbitrary unit), was normalized by the value determined in untreated cells, set as 1. Each
value represents a mean of triplicates, and error bars represent standard deviation. (b) HT29 and
HT29-Ras-2 cultures were treated with 0 (lanes 1 and 4), 1 (lanes 2 and 5), and 5 (lanes 3 and 6)
nM FR901228 for 48 h. Equal amounts of cellular proteins prepared from cell lysates were
analyzed by Western immunoblotting using a specific antibody to detect levels of cleaved, active
caspase-3. (c-1 to c-5) HT29 and HT29-Ras-2 cultures were treated with 1 nM FR901228 for 0
(lanes 1 and 4), 24 (lanes 2 and 5), and 48 (lanes 3 and 6) h. Equal amounts of cellular proteins
prepared from cell lysates were analyzed by Western immunoblotting using specific antibodies
to detect levels of cleaved, active caspase-3 (c-1), active caspase-7 (c-2), cleaved PARP
fragments (c-3), active caspase-8 (c-4), and β-Actin (c-5). (d) HT29 and HT29-Ras-2 cells were
pretreated with 100 μM of caspase-3/-7 inhibitor Ac-DEVD-CHO (CI) or 100 μM of serine
protease inhibitor AEBSF-HCl (SI) for 6 h. Then, HT29 and HT29-Ras-2 cultures were treated
with 1 nM FR901228 for 48 h. Quantification of cell viability in these cultures was determined
with an MTT assay kit. Relative cell viability was normalized by the value determined in
untreated cells, set as 100%. Each value represents a mean of triplicates, and error bars represent
standard deviation. The Student’s t-test was used to analyze statistical significance of ii and iii
versus i (p < 0.01). * indicates a non-specific protein.
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Fig. 3 Death receptor family pathways involved in FR901228-induced cell death. HT29 and
HT29-Ras-2 cells were treated with TRAIL (a), FasL (b), and TNFα (c) at indicated
concentrations in the absence and presence of 1 nM FR901228 for 48 h. Quantification of cell
viability in these cultures was determined with an MTT assay kit. Relative cell viability was
normalized by the value determined in untreated cells, set as 100%. Each value represents a
mean of triplicates, and error bars represent standard deviation. (d-1 to d-3) HT29 and HT29Ras-2 cells were treated with 1 nM FR901228 for 0 (lanes 1 and 4), 24 (lanes 2 and 5), and 48
(lanes 3 and 6) h. Equal amounts of cellular proteins prepared from cell lysates were analyzed
by Western immunoblotting using specific antibodies to detect levels of Fas (d-1) and FasL (d-2)
with β-Actin (d-3) as a control.
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Fig. 4 Induction of CDK inhibitors in FR901228-arrested cells. (a) Inhibition of cell growth
induced by FR901228 was determined by the blockage of BrdU incorporation into cellular DNA.
HT29 and HT29-Ras-2 cells were treated with 1 nM FR901228 for 24 h. Cells were labeled with
BrdU, incubated with peroxidase-conjugated BrdU-specific antibodies, and stained with
peroxidase substrate. Relative cell growth rate was normalized by the value of BrdU detected in
untreated cells, set as 100%. Each value represents a mean of triplicates, and error bars represent
standard deviation. (b to e) HT29 and HT29-Ras-2 cells were treated with 1 nM FR901228 for 0
(lanes 1 and 4), 24 (lanes 2 and 5), and 48 (lanes 3 and 6) h. Equal amounts of cellular proteins
prepared from cell lysates were analyzed by Western immunoblotting using specific antibodies
to detect levels of p21Cip1 (b), p53 (c), and p27Kip1 (d), with β-Actin (e) as a control.
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Fig. 5 Modulation of the ERK and PI3-K pathways in FR901228-treated cells. (a) HT29 and
HT29-Ras-2 cells were treated with 20 µM U0126 (U0) in the presence and absence of 1 nM
FR901228 for 48 h. Quantification of cell viability was determined with an MTT assay kit.
Relative cell viability was normalized by the value determined in untreated cells, set as 100%.
Each value represents a mean of triplicates, and error bars represent standard deviation. The
Student’s t-test was used to analyze statistical significance of ii versus i (p < 0.001). (b to i) Cell
lysates were prepared from HT29 and HT29-Ras-2 cells treated with 1 nM FR901228 for 0
(lanes 1 and 4), 24 (lanes 2 and 5), and 48 (lanes 3 and 6) h. Cell lysates were also prepared
from growing J82 cultures for a comparison (f to h, lane 7). Equal amounts of cellular proteins
prepared from cell lysates were analyzed by Western immunoblotting with specific antibodies to
detect levels of phosphorylated B-Raf (b-1) and total B-Raf protein (b-2) , phosphorylated Raf-1
(c-1) and total Raf-1 protein (c-2), β-Actin (d), Rap1 (e), phosphorylated Mek1/2 (f-1) and total
Mek1/2 proteins (f-2), phosphorylated Erk1/2 (g-1) and total Erk1/2 proteins (g-2),
phosphorylated Akt (h-1) and total Akt proteins (h-2), and phosphorylated Bad (i-1) and total
Bad protein (i-2). Levels of p-B-Raf, B-Raf, p-Raf-1, Raf-1, p-Bad, Bad, and β-Actin on
radiograms were quantified by densitometry. The relative levels of specific phosphorylation of
B-Raf (p/B-Raf), Raf-1 (p/Raf-1), and Bad (p/Bad) were calculated by normalizing the levels of
p-B-Raf , p-Raf-1, and p-Bad with the levels of their cognate proteins, and then were normalized
by the level in parental HT29 cells (lane 1), set as 1 (X, arbitrary unit). The relative levels of
Raf-1 protein (Raf-1/Actin) were calculated by normalizing the levels of Raf-1 with the levels of
β-Actin, and then were normalized by the level in parental HT29 cells (lane 1), set as 1 (X,
arbitrary unit). The ratio of p/Bad in FR90122-treated HT29-Ras-2 cells (i, lanes 5 and 6) to
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untreated cells (lane 4) was also calculated as shown in parenthesis.
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Fig. 6 Histone modulation in FR901228-treated cells. HT29 and HT29-Ras-2 cells were treated
with 1 nM FR901228 for 0 (lanes 1 and 4), 24 (lanes 2 and 5), and 48 (lanes 3 and 6) h. Nuclear
lysates were prepared, and equal amounts of cellular proteins in these nuclear lysates were
analyzed by Western immunoblotting with specific antibodies to detect levels of acetylated H2B
(a-1) and total H2B protein (a-2), and acetylated H3 (b-1) and total H3 protein (b-2).
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Fig. 7 Cell susceptibility to HDACI. HT29, HT29-Ras-2, and SW480 cells were treated with 0,
0.2, 1, 5, and 25 nM FR901228 (a) and 0, 1, 5, 25, and 100 nM TSA (b) for 48 h. Quantification
of cell viability was determined with an MTT assay kit. Relative cell viability was normalized
by the value determined in untreated cells, set as 100%. Each value represents a mean of
triplicates, and error bars represent standard deviation. (c) 10T1/2-TR-H-ras cells were treated
with 100 ng/ml tetracycline (Tet) to induce expression of H-Ras and cellular transformation for
72 h in the absence (-) and presence of 5 nM TSA. Every 24 h, live cells were counted in a
hemocytometer. Relative cell growth and survival rates in cultures were normalized by the
number of live cells determined at 0 hour, set as 100%. Each value represents a mean of
triplicates, and error bars represent standard deviation. The Student’s t-test was used to analyze
statistical significance of ii versus i (p < 0.001).
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PART –IV
ROLE OF REACTIVE OXYGEN SPECIES IN THE
ABILITY OF H-RAS TO ENHANCE CELL DEATH
INDUCED BY HISTONE DEACETYLASE INHIBITORS
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Research described in this chapter is slightly modified version of an article that is submitted for
publication in International Journal of Cancer by Shambhunath Choudhary, Kusum Rathore,
Xiaoyu Song, and Hwa-Chain Robert Wang.

Shambhunath Choudhary, Kusum Rathore, Xiaoyu Song, and Hwa-Chain Robert Wang. Role of
reactive oxygen species in the ability of H-Ras to enhance cell death induced by histone
deacetylase inhibitors (International Journal of Cancer-Submitted)

In this paper “our” and “we” refers to me and co-authors. My contribution in the paper includes
(1) Selection of the topic (2) Compiling and interpretation of the literature (3) Designing
experiments (4) understanding the literature and interpretation of the results (5) providing
comprehensive structure to the paper (6) Preparation of the graphs and figures (7) Writing and
editing

Abstract
Oncogenic induction of the ras genes is widely involved in human cancers. Expression
of oncogenic H-Ras increases susceptibility of human and mouse cells to histone deacetylase
inhibitors (HDACIs), such as FK228 and trichostatin A, for inducing caspase activation and
selective apoptosis. HDACIs make up a new class of structurally diverse anticancer agents and
have been shown to exhibit antimetastatic and antiangiogenic activities toward malignantly
transformed cells. To understand the mechanisms behind the proapoptotic ability of oncogenic
H-Ras to enhance cell susceptibility to HDACIs, we detected that expression of oncogenic H-Ras
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potentiated intracellular reactive oxygen species (ROS) in human urinary bladder cancer J82,
human colorectal cancer HT29, and mouse embryo fibroblast 10T1/2 cells to enhance HDACIinduced ROS, thereby contributing to the induction of selective apoptosis and caspase activation.
Expression of oncogenic H-Ras also increased cell susceptibility to hydrogen peroxide (H2O2)
for inducing apoptosis and caspase activation. By studying IC50 values of FK228 and H2O2 for
oncogenic H-Ras-expressing and parental cells and by quantifying cell death and caspase
activation induced by FK228 and H2O2, we demonstrated evidence to indicate, for the first time,
that intracellular ROS was cooperatively up-regulated by oncogenic H-Ras and FK228 treatment
to induce apoptosis and caspase activation in a dose-dependent manner. Considering the role of
intracellular ROS as a potential target of the novel proapoptotic activity of oncogenic H-Ras is
important in developing therapeutic strategies to control oncogenic H-Ras-involved human
cancers.
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Introduction
Induction of ras genes is frequently detected in human cancers (1). Both clinical and
basic studies suggest that activation of H-Ras accompanied by inactivation of tumor suppressor
p53 may play important roles in tumorigenesis in high-grade, invasive urothelial tumors (2,3). In
fact, an activating mutation in codon 12 of the H-ras gene is detected in more than 35% of
patients with urinary bladder cancers (1). The human urinary bladder transitional carcinoma J82
cell line hosts wild-type ras and the inactive mutant Rb and p53 genes with deletion of the pTEN
gene (4,5). We have shown that ectopic expression of oncogenic H-Ras promotes acquired
tumorigenicity in J82 cells, mimicking an acquisition of H-ras gene activation in tumor
development (6). We have also shown that expression of oncogenic H-Ras in J82 (6), human
colorectal adenocarcinoma HT29 (7), and mouse embryo fibroblast 10T1/2 (8,9) cells increases
their susceptibility to the histone deacetylase inhibitors (HDACIs) FK228 and trichostatin A
(TSA) for inducing apoptosis.

Expression of oncogenic H-Ras also results in reducing

clonogenic resistance of J82 cells to HDACIs (6). Our results of the ability of oncogenic H-Ras
to increase cell susceptibility to HDACIs for inducing selective apoptosis lead us to suggest that
oncogenic H-Ras possesses a proapoptotic ability to facilitate HDACI-induced apoptosis.
Ectopic expression of oncogenic H-Ras has been shown to elevate intracellular ROS,
including superoxide and H2O2, in mouse and rat fibroblast cells (10,11) and ovarian epithelial
cells (12). Several studies have indicated that the Ras-induced membrane NADPH-oxidase
complex plays an important role in producing ROS for Ras-induced transformation phenotypes
(13-18). Increased ROS reportedly mediates changes of cell morphology and motility in Rastransformed fibroblast cells (11), and increased ROS is required for Ras-induced cell growth
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(10,19) and DNA repair (13) in mouse embryo fibroblast cells. In addition, oncogenic Rasincreased ROS may cause DNA damage, contributing to Ras-induced mutagenesis in cells
lacking the tumor suppressor p53 (20). On the other hand, increased intracellular ROS has been
postulated to play a role in the increased susceptibility of H-Ras-expressing ovarian and breast
epithelial cells to β-phenylethyl isothiocyanate (12) and to capsaicin (21) for inducing cell death,
respectively.

However, whether increased ROS may also play a role in the increased

susceptibility of H-Ras-expressing human cancer cells to HDACIs for inducing selective
apoptosis remains to be clarified.
HDACIs make up a new class of structurally diverse anticancer agents and have been
shown to exhibit antimetastatic and antiangiogenic activities toward malignantly transformed
cells in vitro and in vivo (22,23). Growing evidence indicates transformed cells are much more
sensitive than normal cells to growth-inhibitory and apoptotic effects of HDACIs (22,24). Some
studies have suggested that Class I histone deacetylases (HDACs) are important in the regulation
of proliferation and survival in cancer cells (23,25,26). FK228, a depsipeptide also known as
FR901228 and romidepsin (NSC-630176) (27), has been shown to exhibit strong activity
inhibiting Class I HDAC-1 and HDAC-2, mild activity inhibiting Class II HDAC-4, and weak
activity inhibiting Class II HDAC-6, assayed in vitro (28). Selective inhibition of Class I
HDACs by FK228 may contribute to its selectivity in control of cancer cells. In addition, FK228
treatment has been shown to result in elevated ROS in gastrointestinal cancer cells for inducing
cell death (29). However, whether FK228 treatment is able to induce elevated ROS contributing
to selective apoptosis of oncogenic H-Ras-expressing human cancer cells remains to be clarified.
In this report, we present evidence to reveal, for the first time, that intracellular ROS was
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cooperatively increased by ectopic expression of oncogenic H-Ras and FK228 treatment in
increasing cell susceptibility for inducing selective apoptosis and profound caspase activation in
oncogenic H-Ras-expressing cells versus parental cells in a dose-dependent manner. Our results
show the contributing role of elevated ROS in the proapoptotic ability of oncogenic H-Ras to
increase susceptibilities of human urinary bladder and colorectal cancer cells as well as mouse
embryo fibroblast cells to HDACIs for inducing selective apoptosis.

Materials and Methods
Cell Cultures and Reagents
J82 and HT29 cells (ATCC, Rockville, MD) and oncogenic H-Ras-expressing, J82-Ras (6) and
HT29-Ras (7) cells were maintained in DMEM supplemented with 10% fetal bovine serum.
10T1/2 and oncogenic H-Ras-expressing, 10T1/2-Ras cells (8) were maintained in Basal
Medium Eagle supplemented with 10% fetal bovine serum. All cultures were maintained in
medium supplemented with 100 U/ml penicillin and 100 μg/ml streptomycin in 7% CO2 at 37oC
and routinely subcultured every 2 to 3 days. Stock aqueous solutions of FK228 (National Cancer
Institute, Chemistry and Synthesis Branch, collaboration with Dr. KK Chan, The Ohio State
University),

chloromethyl-dichlorodihydrofluorescein-diacetate

(CM-H2DCF-DA)

(Invitrogen/Molecular Probes, Carlsbad, CA), rhodamine-123 (Rho-123), rotenone (ROT)
(Sigma, St. Louis, MO), and TSA (Wako, Richmond, VA) were prepared in DMSO and diluted
in culture medium for assays. Stock aqueous solutions of N-acetyl-L-cysteine (NAC) (Alexis,
San Diego, CA) and 10-N-nonyl acridine orange (NAO) (Sigma) were prepared in distilled water
and diluted in culture media for assays. Stock aqueous solution of H2O2 (Cumberland Swan,
163

Smyrna, TN) was diluted directly in culture medium for assays.

Cell Viability Assay
A Methyl Thiazolyl Tetrazolium (MTT) assay kit (ATCC) was used to measure cell
viability in cultures (6,7). Five x 104 cells were seeded into each well of 96-well culture plates
for 24 h. After indicated treatments, cells were incubated with MTT reagent for 4 h, followed by
incubation with detergent reagent for 24 h. Reduced MTT reagent in cultures was quantified
with an ELISA reader (Bio-Tek, Winooski, VT).

Annexin-V Apoptosis Assay
An annexin-V-fluorescein isothiocyanate (FITC) apoptosis detection kit with propidium iodide
(BD Biosciences, San Jose, CA) was used to detect apoptotic cell death by flow cytometry (6,7).
In brief, cells were collected after trypsinization and washed with PBS.

Cells were then

incubated with annexin V-FITC and propidium iodide in a binding buffer (10 mmol/L HepesKOH, pH 7.4, 150 mmol/L NaCl, 1.8 mmol/L CaCl2) for 20 min at ambient temperature in the
dark. Flow cytometric analysis was performed on the Coulter EPICS Elite Cytometer (Hialeah,
FL) at the excitation and emission wavelengths of 488 and 550 nm, respectively, for FITC
measurements, and at 488 and 645 nm for propidium iodide measurements. Both subpopulations
of annexin V-FITC-labeled cells and propidium iodide-labeled cells were considered together to
determine the percentage of cells undergoing apoptotic cell death using Multicycle software.
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Measurement of Intracellular ROS
To measure intracellular ROS levels, cells were incubated with 5 µmol/L CM-H2DCF-DA in 7%
CO2 at 37ºC for 1 h (12). Cells were rinsed with Ca++ and Mg++ free PBS, trypsinized from
cultures, and resuspended in PBS for analysis of intracellular ROS by flow cytometry. Flow
cytometric analysis was performed, as described above (6,7), by using a 15 milliwatt air-cooled
argon laser to produce 488 nm light. DCF fluorescence emission was collected with a 529 nm
band pass filter.

The mean fluorescence intensity of 2 x 104 cells was quantified using

Multicycle software (Phoenix Flow System, San Diego, CA).

Measurement of Mitochondrial Membrane Potential (∆ψm) and Mitochondrial Membrane
Lipid Peroxidation
To measure mitochondrial membrane potential, cells were incubated with 1 µmol/L Rho-123 in
7% CO2 at 37ºC for 1 h (12). To measure mitochondrial membrane lipid peroxidation, cells
were incubated with 50 nmol/L NAO in 7% CO2 at 37ºC for 15 min (12). Cells were rinsed
with PBS, trypsinized from cultures, and resuspended in PBS for flow cytometric analysis, as
described above, at the excitation and emission wavelengths of 488 and 529 nm, respectively, for
Rho-123 or NAO fluorescence measurements.

Determination of Caspase Activity by Luminescence Spectroscopy
Caspase-3/7 activity was measured using a Caspase-Glo assay kit (Promega, Madison,
WI). Cells were lysed in a buffer (10 mmol/L Tris–HCl, 150 mmol/L NaCl, 1% Triton X-100, 5
mmol/L EDTA, 10 mmol/L sodium pyrophosphate, 10% glycerol, 0.1% Na3VO4, 50 mmol/L
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NaF, pH 7.4) (6,7). Whole cell lysates were isolated from the supernatants after centrifugation
of crude cell lysates at 20,000 x g for 20 min. Protein concentrations in cell lysates were
measured using the BCA assay (Pierce, Rockford, IL). Cell lysates containing 30 µg of protein
were incubated with a proluminescent substrate specific for caspase-3/7 in white-walled 384well plates at ambient temperature for 1 h. The released luminescence in each reaction was
measured in a luminometer plate-reader (Bio-Tek).

Statistical Analysis
Statistical significance was analyzed by the Student t test. A P-value of ≤ 0.05 was
considered significant.

Results
Intracellular ROS Increase by Oncogenic H-Ras and HDACIs in Human Urinary Bladder
Cancer Cells
To determine whether expression of oncogenic H-Ras and HDACI treatment resulted in
increasing intracellular ROS contributing to selective apoptosis of human cancer cells, we used
CM-H2DCF-DA (30) to measure the overall intracellular ROS levels by flow cytometry in
FK228-treated cells. As shown in Fig. 1A, FK228 treatment significantly increased ROS in both
parental J82 and J82-Ras cells, and co-treatment of cells with the antioxidant NAC (11,12,31)
significantly reduced FK228-induced ROS. The basal level of ROS was detectably higher in
J82-Ras cells than in J82 cells, and FK228 treatment induced significantly higher levels of ROS
in J82-Ras cells compared to J82 cells in a time-dependent manner (Fig. 1B). These results
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verified that expression of oncogenic H-Ras or FK228 treatment resulted in increases of ROS;
expression of oncogenic H-Ras enhanced FK228-increased ROS in J82 cells. In addition, higher
levels of ROS (Fig. 1C) correlated with higher degrees of FK228-induced apoptosis (Fig. 1D) of
J82-Ras cells versus J82 cells. Reduction of FK228-induced ROS from approximately 1.9- to
1.4-fold and from approximately 3.3- to 2.4-fold by NAC (Fig. 1C) significantly reduced FK228induced apoptosis from approximately 14% to 10% and from approximately 37% to 27% in
parental J82 and J82-Ras cells (Fig. 1D), respectively, though NAC treatment was able to only
partially suppress FK228-induced ROS and apoptosis in J82 and J82-Ras cells.
Using another HDACI, TSA (22,23), which is structurally unrelated from depsipeptide
FK228, we detected that TSA treatment also induced significantly higher levels of ROS (Fig.
2A), apoptosis (Fig. 2B), and caspase-3/7 activity (Fig. 2C) in J82-Ras cells compared to J82
cells. Co-treatment with NAC resulted in a significant reduction of TSA-increased ROS from
approximately 1.6- to 1.3-fold and from approximately 2.7- to 1.9-fold (Fig. 2A), a reduction in
apoptosis from approximately 12% to 9% and from approximately 33% to 26% (Fig. 2B), and in
caspase-3/7 activity from approximately 2.7- to 2-fold and from approximately 9- to 5.9-fold
(Fig. 2C) in J82 and J82-Ras cells, respectively. Thus, increased intracellular ROS played an
important role in selective apoptosis of oncogenic H-Ras-expressing, J82-Ras versus parental J82
cells induced by both HDACIs FK228 and TSA. In addition, using an unbiased anticancer agent
to induce apoptosis of J82-Ras and parental J82 cells as a control, we did not detect any
differentially up-regulated ROS induced by 5-Fluorouracil in J82-Ras versus J82 cells (data not
shown).
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ROS-Mediated Oxidative Damage in FK228-Induced Cell Death
In investigating the involvement of mitochondrial membrane damage in FK228-induced
apoptosis, we labeled cells with Rho-123 to measure mitochondrial membrane potential in
FK228-treated cells. We detected that FK228 treatment resulted in reduction of mitochondrial
membrane potential, which was indicated by reduction of Rho-123 labeling down to
approximately 95% and 75% in J82 and J82-Ras cells, respectively (Fig. 3A), indicating a
possible mitochondrial membrane damage induced by FK228. To investigate whether FK228induced ROS was involved in mitochondrial membrane damage, we used NAO to measure lipid
peroxidation of mitochondrial membrane in FK228-treated cells. NAO has been shown to
specifically interact with a mitochondrial membrane lipid component cardiolipin; and cardiolipin
peroxidation induced by oxidative damage to mitochondrial membrane reduces the NAOlabeling of cardiolipin (32). As shown in Fig. 3B, FK228 treatment significantly reduced NAOlabeling to approximately 79% and 59% in parental J82 and J82-Ras cells, respectively; and, cotreatment with NAC significantly reversed the FK228-reduced NAO-labeling back to
approximately 92% and 83% in parental J82 and J82-Ras cells, respectively. FK228 treatment
appeared to result in higher oxidative damage to mitochondrial membrane in J82-Ras cells than
in parental J82 cells. Using rotenone to block mitochondrial ROS (33,34), we detected that
rotenone treatment resulted in modest but significant reduction of FK228-increased ROS from
approximately 1.3- to 1.1-fold and from approximately 2.2- to 1.9-fold (Fig. 3C) and resulted in
significant reversal of FK228-decreased cell viability from approximately 73% back to 86% and
from approximately 51% back to 72% (Fig. 3D) in parental J82 and J82-Ras cells, respectively.
Apparently, FK228-induced ROS was involved in mitochondrial membrane damage, and
reduction of FK228-induced mitochondrial ROS reduced FK228-induced cell death.
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Dose-Dependent Induction of Cell Death and Caspases by FK228 and ROS
To measure oncogenic H-Ras-enhanced susceptibility of J82 cells to FK228 for inducing
cell death, we compared IC50 values of FK228 for J82 and J82-Ras cells. As shown in Fig. 4A,
IC50 values of FK228 for J82 and J82-Ras cells were determined at concentrations of 500±50
nmol/L and 5±2 nmol/L, respectively. Accordingly, expression of oncogenic H-Ras in J82 cells
resulted in an approximate 100-fold increase of cell susceptibility to FK228 for inducing cell
death.
To measure ROS levels potentiated by oncogenic H-Ras for inducing cell death, we
compared IC50 values of H2O2 for J82-Ras and J82 cells. As shown in Fig. 4B, IC50 values of
H2O2 for J82 and J82-Ras cells were determined at concentrations of 2±0.15 mmol/L and
1±0.15 mmol/L, respectively. Accordingly, the result indicated that expression of oncogenic HRas-potentiated endogenous ROS resulted in an approximate 2-fold increase of cell susceptibility
to H2O2 for inducing cell death.
Combined results from the above studies indicated that expression of oncogenic H-Ras in
cells resulted in elevated ROS, enhanced FK228-induced ROS, and increased susceptibility to
H2O2 for inducing cell death. J82-Ras cells with a higher endogenous level of ROS than J82
cells required less H2O2 for inducing cell death. Based on IC50 values of FK228 and H2O2 for
J82 and J82-Ras cells, we tested whether distinguishable degrees of cell death and caspase
activation were induced by FK228 in combination with H2O2 in a dose-dependent manner. As
shown in Fig. 4C, treatment of J82 cells with FK228 at 5 nmol/L, which was the IC50 value of
FK228 for J82-Ras cells (column 8), reduced cell viability to approximately 70% (column 4).
Similarly, treatment of J82 cells with H2O2 at 1 mmol/L, which was the IC50 value of H2O2 for
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J82-Ras cells (column 9), reduced cell viability to approximately 70% (column 5). Noteworthy
is the difference between IC50 values of H2O2 for J82 (2 mmol/L) and J82-Ras (1 mmol/L): 1
mmol/L. The additional 1 mmol/L H2O2 appeared to be sufficient to enhance the activity of 5
nmol/L FK228 to reduce cell viability to 50% (column 6), as induced by 500 nmol/L FK228 in
J82 cells (column 2). Accordingly, H2O2 was able to enhance FK228-induced cell death in a
dose-dependent manner; treatment with both FK228 and H2O2 cooperatively induced death of
J82 cells.
To verify whether caspase-3/7 activity was increased by the addition of H2O2 to FK228
treatment, we treated J82 and J82-Ras cells with FK228 in the presence of additional H2O2. As
shown in Fig. 4D, treatment of J82 cells with FK228 at 500 nmol/L (column 3) or H2O2 at 2
mmol/L (column 5) significantly induced caspase-3/7 activity to approximately 8- and 6-fold,
respectively. Treatment of J82 cells with FK228 at 5 nmol/L (column 7) or H2O2 at 1 mmol/L
(column 9) significantly induced an approximate 3-fold increase in caspase-3/7 activity.
Interestingly, treatment of J82 cells with 5 nmol/L FK228 and an additional 1 mmol/L H2O2
significantly induced an increase in caspase-3/7 activity by approximately 7-fold (column 11);
thus, treating cells with FK228 and H2O2 additively increased caspase-3/7 activity in J82 cells.
The additional 1 mmol/L H2O2 appeared to be sufficient to enhance the activity of 5 nmol/L
FK228 to induce caspase activity to a level similar to that induced by 500 nmol/L FK228 in J82
cells. In contrast, treating J82-Ras cells with 5 nmol/L FK228 (column 15) or 1 mmol/L H2O2
(column 17) alone significantly induced an increase in caspase-3/7 activity by approximately 9and 11-fold, respectively.

All FK228- and/or H2O2-increased caspase-3/7 activity was
170

significantly suppressed by co-treatment with the antioxidant NAC (even columns). H2O2induced cell death was also significantly suppressed by NAC (data not shown). Accordingly,
H2O2 was able to play a contributing role in FK228-induced activation of caspases for inducing
cell death in a dose-dependent manner. Oncogenic H-Ras-increased susceptibility of J82 cells to
FK228 from IC50 values of 500 nmol/L to 5 nmol/L could be alternately achieved by an
additional 1-fold increase of 1 mmol/L H2O2. These results indicated that differentially upregulated ROS quantitatively contributed to the proapoptotic ability of oncogenic H-Ras to
enhance FK228-induced cell death and caspase activation.

ROS Increase by Oncogenic H-Ras and FK228 in Human Colorectal Cancer Cells and
Mouse Embryo Fibroblast Cells
To determine whether increases of ROS also played an important role in FK228-induced
selective apoptosis of human cancer cells other than J82 cells, we treated human colorectal
adenocarcinoma HT29 cells and oncogenic H-Ras-expressing, HT29-Ras cells (7) with FK228 in
the presence of NAC (Fig. 5A to 5C). To determine whether an increase of ROS played an
important role in FK228-induced selective apoptosis of cells other than human cells, we treated
mouse embryo fibroblast 10T1/2 cells and oncogenic H-Ras-expressing, 10T1/2-Ras cells (8)
with FK228 in the presence of NAC (Fig. 6A to 6C). We detected that FK228 treatment induced
significantly higher levels of ROS to approximately 2.7- and 2.4-fold (Fig. 5A and 6A),
apoptosis to approximately 40% and 37% (Fig. 5B and 6B), and caspase-3/7 activity to
approximately 8- and 9-fold (Fig. 5C and 6C) in HT29-Ras and 10T1/2-Ras cells, respectively,
compared to the FK228-induced ROS to approximately 1.6- and 1.4-fold (Fig. 5A and 6A),
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apoptosis to approximately 13% and 11% (Fig. 5B and 6B), and caspase-3/7 activity to
approximately 3-fold (Fig. 5C and 6C) in parental HT29 and 10T1/2 cells, respectively. NAC
treatment resulted in a significant reduction of FK228-increased ROS down to approximately
1.8-fold (Fig. 5A and 6A) and apoptosis down to approximately 28% (Fig. 5B and 6B) in both
oncogenic H-Ras-expressing, HT29-Ras and 10T1/2-Ras cells, and a significant reduction of
caspase-3/7 activity down to approximately 4.4- and 5.7-fold (Fig. 5C and 6C) in HT29-Ras and
10T1/2-Ras cells, respectively. In addition, NAC treatment resulted in a significant reduction of
FK228-increased ROS down to approximately 1.3- and 1.2-fold (Fig. 5A and 6A), apoptosis
down to approximately 9% and 8% (Fig. 5B and 6B) in parental HT29 and 10T1/2 cells,
respectively, and caspase-3/7 activity down to approximately 2-fold (Fig. 5C and 6C) in both
types of cells. Accordingly, increased intracellular ROS also played an important role in FK228induced selective apoptosis of oncogenic H-Ras-expressing human colorectal cancer cells and
oncogenic H-Ras-expressing mouse embryo fibroblast cells versus their parental counterpart
cells in addition to human urinary bladder cancer cells.

Discussion
In this communication, our studies show that differentially up-regulated intracellular
ROS played a pivotal role in selective apoptosis induced by the HDACIs FK228 and TSA and
profound activation of caspases in oncogenic H-Ras-expressing human urinary bladder cancer
J82, human colorectal cancer HT29, and mouse embryo fibroblast 10T1/2 cells versus their
parental counterpart cells. Expression of oncogenic H-Ras resulted in elevation of intracellular
ROS in cells, as did treatment of cells with HDACIs; as a result, expression of oncogenic H-Ras
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in cells and FK228 treatment resulted in cooperative elevation of intracellular ROS in cells.
FK228 treatment profoundly increased ROS in all the oncogenic H-Ras-expressing, J82-Ras,
HT29-Ras, and 10T1/2-Ras cells and modestly increased ROS in parental counterpart cells,
which led to induction of profound and modest mitochondrial membrane damage, caspases, and
apoptosis in oncogenic H-Ras-expressing cells and parental counterpart cells, respectively.
Blockage of ROS production resulted in suppression of FK228-induced mitochondrial membrane
damage, apoptosis, and caspase activation, indicating an important role of intracellular ROS in
FK228-induced selective apoptosis of oncogenic H-Ras-expressing cells versus their parental
counterpart cells. Although ROS has been reportedly shown to induce DNA damage through
p53 activity, leading to apoptosis (35), it is unlikely to be involved in HDACI-induced cell death
of either J82 or HT29 cells, which host the inactive mutant p53 genes (4, 36).
Expression of oncogenic H-Ras in J82 cells increased cell susceptibility not only to
HDACIs but also to H2O2 for inducing apoptosis and caspase activation. Elevation of H2O2 has
been postulated to facilitate apoptosis (37,38). It has also been postulated that the high levels of
H2O2 frequently detected in cancer cells may potentiate cancer cells to be more susceptible to
H2O2-induced apoptosis than normal counterpart cells (39). Our studies showed that expression
of oncogenic H-Ras in J82 cells resulted in a 100-fold increase of cell susceptibility to FK228
and a 2-fold increase of cell susceptibility to H2O2 for inducing cell death. The IC50 values of
FK228 for J82 and J82-Ras were 500 and 5 nmol/L, respectively. The difference between IC50
values of H2O2 for J82 (2 mmol/L) and J82-Ras (1 mmol/L) was 1 mmol/L. Treatment of J82
cells with FK228 at 5 nmol/L or H2O2 at 1 mmol/L alone resulted in a reduction of cell viability
to 70%. Treatment with 5 nmol/L FK228 and an additional 1 mmol/L H2O2 resulted in a
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reduction of cell viability to 50% and was sufficient to induce activation of caspases to levels
similar to those induced by either 500 nmol/L FK228 or 2 mmol/L H2O2 alone. Thus, the
oncogenic H-Ras-increased susceptibility of J82 cells to FK228 from IC50 values of 500 nmol/L
to 5 nmol/L could be alternately achieved by an additional 1-fold increase of 1 mmol/L H2O2.
Our semi-quantitative study verified that differentially up-regulated intracellular ROS played a
contributing role in the proapoptotic ability of oncogenic H-Ras to increase cell susceptibility to
HDACIs for inducing apoptosis and caspase activation in a dose-dependent manner.
Although differential regulation of ROS played an important role, other mechanisms are
also involved in HDACI-induced selective apoptosis of oncogenic H-Ras-expressing cells versus
parental counterpart cells. Previously, we reported that differential regulation of the caspase
pathways, the Raf and ERK pathway, the p38/SAPK pathway, p21Cip1 and p27Kip1, and core
histone contents contributes to FK228-induced selective apoptosis of oncogenic H-Rasexpressing, J82-Ras, HT29-Ras, and 10T1/2-Ras cells versus their parental counterpart cells (69), though some discrepancies in regulation of the downstream ERK pathway and PI3K pathway
are detectable between these cell lines. As a consequence, reduction of ROS by either NAC or
rotenone may not be able to completely suppress FK228-induced cell death. However, we also
experienced incomplete blockage of FK228-induced ROS by using NAC and rotenone, though
both NAC and rotenone are recognized to exhibit potent activity in blocking intracellular ROS
(40). Whether complete blockage of FK228-induced ROS may result in completely suppressing
FK228-induced cell death remains to be clarified.
NAC, a precursor of glutathione (40), was able to significantly reduce FK228- and TSAinduced ROS and apoptosis in oncogenic H-Ras-expressing and parental counterpart cells.
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HDACIs have been shown to deplete cellular glutathione (41), depletion of cellular glutathione
results in ROS accumulation (12,41), and NAC is able to suppress glutathione depletion and
ROS accumulation (12).

HDACI has also been shown to up-regulate thioredoxin-binding

protein-2, resulting in suppression of thioredoxin, which is a major intracellular scavenger of
ROS, and leading to excessive accumulation of intracellular ROS (42). Whether depletion of
cellular glutathione, up-regulation of thioredoxin-binding protein-2, and down-regulation of
thiroredoxin are involved in profound increases of ROS by FK228 as well as TSA in selective
induction of apoptosis in oncogenic H-Ras-expressing cells remains to be determined.
In conclusion, our study revealed profound increases of intracellular ROS cooperatively
induced by expression of oncogenic H-Ras and treatment with HDACIs FK228 and TSA,
leading to selective induction of apoptosis of oncogenic H-Ras-expressing cancer cells versus
their parental counterpart cells. It is important to utilize the cell killing potential of ROS in
control of oncogenic Ras-expressing cancer cells and any cancer cells with potential to generate
high levels of ROS by using ROS-inducing anticancer agents, such as HDACIs, to increase
intracellular ROS to induce selective cell death of target cancer cells. The proapoptotic ability of
oncogenic H-Ras, through increases of intracellular ROS, to increase cell susceptibility to
HDACIs should be seriously considered in developing anticancer therapeutics against Rasrelated human cancers and any other types of human cancers with intrinsic ability to generate
toxic levels of ROS induced by HDACIs.
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Figure 1. Oncogenic H-Ras- and FK228-induced ROS and apoptosis in human urinary bladder
cancer J82 cells. A, J82 and J82-Ras cells were treated with 0 and 5 nmol/L FK228 (FK) in the
presence or absence of 5 mmol/L NAC for 24 h. B, J82 and J82-Ras cells were treated with 5
nmol/L FK228 for 0, 12, 24, and 36 h. C and D, J82 (white columns) and J82-Ras (dark
columns) cells were treated with 5 nmol/L FK228 in the presence or absence of 5 mmol/L NAC
for 36 h. A, B, and C, cultures were then labeled with CM-H2DCF-DA for flow cytometric
analysis of intracellular ROS levels. Relative fluorescence intensity, as fold induction (X,
arbitrary unit), was normalized by the fluorescence intensity determined in the untreated J82
cells, set as 1. Points, mean of triplicates; bars, SD. D, apoptotic cell population (%) was
measured by flow cytometry with an Annexin-V-FITC Apoptosis Detection Kit. Columns, mean
of triplicates; bars, SD. The Student t test was used to analyze statistical significance, indicated
by * P<0.05, ** P<0.01, *** P<0.001. All results are representative of three independent
experiments.
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Figure 2. ROS in TSA-induced apoptosis of J82 and J82-Ras cells. J82 (white columns) and
J82-Ras (dark columns) cells were treated with 25 nmol/L TSA in the presence or absence of 5
mmol/L NAC for 48 h. A, cultures were then labeled with CM-H2DCF-DA for flow cytometric
analysis of intracellular ROS levels. Relative fluorescence intensity, as fold induction (X,
arbitrary unit), was normalized by the fluorescence intensity determined in the untreated J82
cells, set as 1. Columns, mean of triplicates; bars, SD. B, apoptotic cell population (%) was
measured by flow cytometry with an Annexin-V-FITC Apoptosis Detection Kit. Columns, mean
of triplicates; bars, SD. C, a Caspase-Glo luminescence assay kit was used to measure the
activity of caspase-3/7. Relative caspase activity, as fold induction (X, arbitrary unit), was
normalized by the values determined in the untreated counterpart J82 and J82-Ras cells, set as 1.
Columns, mean of triplicates; bars, SD. The Student t test was used to analyze statistical
significance, indicated by * P<0.05, ** P<0.01, *** P<0.001. All results are representative of
three independent experiments.
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Figure 3. ROS-mediated oxidative damage in FK228-induced cell death.

A, J82 (white

columns) and J82-Ras (dark columns) cells were treated with 0 and 5 nmol/L FK228 for 36 h.
Cultures were then labeled with Rho-123 for flow cytometric analysis of mitochondrial
membrane potential. Relative fluorescence intensities in FK228-treated J82 cells and J82-Ras
cells were normalized by the fluorescence intensities determined in the untreated counterpart J82
and J82-Ras cells, set as 100%. Columns, mean of triplicates; bars, SD. B, J82 and J82-Ras
cells were treated with 0 and 5 nmol/L FK228 in the presence or absence of 5 mmol/L NAC for
36 h. Cultures were then labeled with NAO for flow cytometric analysis of mitochondrial
membrane oxidative damage. Relative fluorescence intensities in FK228-treated J82 cells and
J82-Ras cells were normalized by the fluorescence intensities determined in the untreated
counterpart J82 and J82-Ras cells, set as 100%. Columns, mean of triplicates; bars, SD. C, J82
and J82-Ras cells were treated with 5 nmol/L FK228 in the presence or absence of 1 µmol/L
rotenone (ROT) for 24 h. Cultures were then labeled with CM-H2DCF-DA for flow cytometric
analysis of intracellular ROS levels. Relative fluorescence intensity, as fold induction (X,
arbitrary unit), was normalized by the fluorescence intensity determined in the untreated J82
cells, set as 1. Columns, mean of triplicates; bars, SD. D, J82 and J82-Ras cells were treated
with 5 nmol/L FK228 in the presence or absence of 1 µmol/L rotenone for 36 h. Quantification
of cell viability was determined with an MTT assay kit, and relative cell viability was normalized
by the value determined in untreated counterpart J82 and J82-Ras cells, set as 100%. Columns,
mean of tetraplicates; bars, SD. The Student t test was used to analyze statistical significance,
indicated by * P<0.05, ** P<0.01, *** P<0.001.
independent experiments.
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Figure 4. Dose-dependent enhancement of cell death and caspase activity by combined FK228
and H2O2. A, J82 and J82-Ras cells were treated with FK228 at a range of concentrations from
0.1 to 5000 nmol/L (nM) for 48 h, followed by MTT assay for revealing dose-response curves of
cell viability in response to FK228. B, J82 and J82-Ras cells were treated with H2O2 at a range
of concentrations from 0.1 to 500 mmol/L (mM) for 24 h, followed by MTT assay to reveal
dose-response curves of cell viability in response to H2O2. Points, mean of triplicates. IC50
values of FK228 at 500±50 nmol/L and 5±2 nmol/L and IC50 values of H2O2 at 2±0.15 mmol/L
and 1±0.15 mmol/L were determined for J82 and J82-Ras cells, respectively, from the semilogarithmic dose-response curves of cell viability.

All results are representative of three

independent experiments. C, J82 (columns 1 to 6) and J82-Ras (columns 7 to 9) cells were
treated with FK228 at 0, 5, or 500 nmol/L (nM) in the presence and absence of 1 or 2 mmol/L
(mM) H2O2 for 48 h. Cell viability was measured with an MTT assay kit, and relative cell
viability was normalized by the value determined in untreated counterpart J82 (column 1) and
J82-Ras (column 7) cells, set as 100%. Columns, mean of tetraplicates; bars, SD. D, J82
(columns 1 to 12) and J82-Ras (columns 13 to 18) cells were treated with FK228 at 0, 5, or 500
nmol/L in the presence and absence of 1 or 2 mmol/L H2O2 and 5 mmol/L NAC (even columns)
for 24 h. A Caspase-Glo luminescence assay kit was used to measure the activity of caspase-3/7.
Relative caspase activity, as fold induction (X, arbitrary unit), was normalized by the values
determined in the untreated counterpart J82 (column 1) and J82-Ras (column 13) cells, set as 1.
Columns, mean of triplicates; bars, SD. The Student t test was used to analyze statistical
significance, indicated by *** P<0.001. All results are representative of three independent
experiments.
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Figure 5. Oncogenic H-Ras- and FK228-induced ROS and apoptosis of human colorectal cancer
HT29 cells. HT29 (white columns) and HT29-Ras (dark columns) cells were treated with 1
nmol/L FK228 in the presence or absence of 5 mmol/L NAC for 48 h. A, cultures were then
labeled with CM-H2DCF-DA for flow cytometric analysis of ROS levels. Relative fluorescence
intensity, as fold induction (X, arbitrary unit), was normalized by the fluorescence intensity
determined in the untreated HT29 cells, set as 1. Columns, mean of triplicates; bars, SD. B,
apoptotic population (%) was measured by flow cytometry with an Annexin-V-FITC Apoptosis
Detection Kit. Columns, mean of triplicates; bars, SD. C, a Caspase-Glo luminescence assay kit
was used to measure the activity of caspase-3/7. Relative caspase activity, as fold induction (X,
arbitrary unit), was normalized by the values determined in the untreated counterpart HT29 and
HT29-Ras cells, set as 1. Columns, mean of triplicates; bars, SD. The Student t test was used to
analyze statistical significance, indicated by * P<0.05, ** P<0.01, *** P<0.001. All results are
representative of three independent experiments.
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Figure 6. Oncogenic H-Ras- and FK228-induced ROS and apoptosis of mouse embryo
fibroblast 10T1/2 cells. 10T1/2(white columns) and 10T1/2-Ras (dark columns) cells were
treated with 1 nmol/L FK228 in the presence or absence of 5 mmol/L NAC for 48 h. A, cultures
were then labeled with CM-H2DCF-DA for flow cytometric analysis of intracellular ROS levels.
Relative fluorescence intensity, as fold induction (X, arbitrary unit), was normalized by the
fluorescence intensity determined in the untreated 10T1/2 cells, set as 1. Columns, mean of
triplicates; bars, SD. B, apoptotic cell population (%) was measured by flow cytometry with an
Annexin-V-FITC Apoptosis Detection Kit. Columns, mean of triplicates; bars, SD.

C, a

Caspase-Glo luminescence assay kit was used to measure the activity of caspase-3/7. Relative
caspase activity, as fold induction (X, arbitrary unit), was normalized by the values determined
in the untreated counterpart 10T1/2 and 10T1/2-Ras cells, set as 1. Columns, mean of triplicates;
bars, SD. The Student t test was used to analyze statistical significance, indicated by * P<0.05,
** P<0.01, *** P<0.001. All results are representative of three independent experiments.
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General Discussion
The study presented in this dissertation was designed to (1) investigate the pro-apoptotic activity
of oncogenic H-Ras in human cancer cells that allows HDACIs to induce selective apoptosis
and, (2) show that elevated intracellular reactive oxygen species (ROS) play an important role in
the pro-apoptotic ability of oncogenic H-Ras to enhance cell death induced by HDACIs.

Importance of the novel pro-apoptotic ability of oncogenic H-Ras in developing anticancer
therapeutics against Ras-related cancers
Oncogenic Ras is widely involved in human cancers (1). Activating mutation of the Kras gene is frequently detected in pancreatic and colonic carcinomas. H-ras mutations are
commonly seen in bladder carcinomas, whereas lymphoid malignancies and melanomas
frequently harbor activating mutations of the N-ras gene (1,2). Hence, it is important develop
selective anticancer therapeutics against Ras-related human cancers by identifying anticancer
agents and their molecular targets to selectively induce apoptosis of Ras-related cancer cells to
increase the effectiveness of chemotherapy.
In our studies, introduction of the oncogenic H-ras gene into J82 cells promoted cells to
acquire the tumorigenic ability to develop xenograft tumors in immune-deficient mice; however,
it was also accompanied by the novel pro-apoptotic property which allowed FR901228 and TSA
to induce selective apoptosis in these cells. The human urinary bladder carcinoma T24 cell line,
in which oncogenic H-Ras is endogenously expressed (3), showed a comparable level of
susceptibility with J82-Ras cells to both FR901228 and TSA for inducing cell death. We have
also shown that expression of oncogenic H-Ras in human colorectal adenocarcinoma HT29, and
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mouse embryo fibroblast 10T1/2 cells increases their susceptibility to the HDACIs FR901228
and TSA for inducing apoptosis. The observed ability of oncogenic H-Ras to increase cell
susceptibility to HDACIs for inducing selective apoptosis lead us to suggest that oncogenic HRas possesses a pro-apoptotic ability to facilitate HDACI-induced apoptosis. However,
expression of oncogenic H-Ras in any of these cells did not increase susceptibility to other
agents, including U0126, LY294002, SB203580, SP600125, and Ac-DEVD-CHO. Therefore,
the pro-apoptotic ability of oncogenic H-Ras that facilitates agents to induce cell death is
HDACI-specific, but is not a cell type-specific property. In addition, our results also suggest that
selectivity of HDACI to induce cell death in oncogenic H-Ras-expressing cells may be
applicable to other Ras family proteins, such as K-Ras, as evident by a high susceptibility of
SW480 cell line, which hosts the oncogenic K-ras gene, to both FR901228 and TSA for
inducing cell death. However, whether the selectivity of HDACIs to induce cell death of
oncogenic H-Ras-expressed cells is applicable to human cancers involving H-Ras overexpression
or other oncogene-expressed cells needs to be broadly investigated.
Current Ras-targeted anticancer approaches are mainly based on understanding the roles
of oncogenic Ras in tumorigenesis, such as inhibition of Ras protein synthesis, interference with
Ras processing to functional sites, or blockage of downstream Ras effectors (4). However,
agents targeting the pro-apoptotic activity of oncogenic Ras are still overlooked. Our studies
verified the pro-apoptotic activity of oncogenic H-Ras that allows HDACIs to induce cell death
of human cancer cells. Our results indicate the ability of HDACIs to discriminate between
oncogenic H-Ras-expressed and counterpart human cells, and suggest a potential value of
HDACIs in treating Ras-related human cancers. The values of the ERK, p38/SAPK and PI3-K
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pathways, the death receptor family pathways, caspase-3, caspase-7, and caspase-8, and Cdk
inhibitors as molecular targets need to be considered individually for designing therapeutic
protocols using HDACI in combination with other agents to assure the effectiveness of target
therapies for treat human cancer involving Ras or Raf activation.

Elevated intracellular reactive oxygen species (ROS) has a pivotal role in the pro-apoptotic
ability of oncogenic H-Ras
Ectopic expression of oncogenic H-Ras has been shown to elevate intracellular ROS,
including superoxide and hydrogen peroxide. Increased ROS is reportedly required for the Rasinduced increase in cell growth (5,6) and DNA repair (7) in mouse embryo fibroblast NIH3T3
cells. On the other hand, increased intracellular ROS has been postulated to play a role in the
increased susceptibility of H-Ras-expressing ovarian and breast epithelial cells to β-phenylethyl
isothiocyanate (8) and to capsaicin (9) for inducing cell death, respectively. However, whether
increased ROS may also have played a role in the increased susceptibility of H-Ras-expressing
human cancer cells to HDACIs for inducing selective apoptosis remained to be clarified. In
addition, HDACIs treatment has been shown to result in elevated ROS in gastrointestinal cancer
cells for inducing cell death (4). However, whether HDACI treatment was able to induce
elevated ROS contributing to selective apoptosis of oncogenic H-Ras-expressing human cancer
cells remained to be clarified.
In our studies, HDACIs treatment significantly increased ROS in all the oncogenic HRas-expressing cells (J82-Ras, HT29-Ras, and 10T1/2-Ras cells) compared to their parental
counterpart cells. Severe accumulation of intracellular ROS in oncogenic H-Ras-expressing cells
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caused profound induction of mitochondrial membrane damage, caspases, and apoptosis. In
contrast, HDACIs treatment caused only modest increase in ROS insufficient to cause significant
apoptosis in parental counterpart cells. Blockage of ROS production resulted in suppression of
HDACI-induced mitochondrial membrane damage, apoptosis, and caspase activation, indicating
an important role of intracellular ROS in HDACI-induced selective apoptosis of oncogenic HRas-expressing cells versus their parental counterpart cells. Although ROS has been reportedly
shown to induce DNA damage through p53 activity, leading to apoptosis (10), it is unlikely to be
involved in HDACI-induced cell death of either J82 or HT29 cells, which host the inactive
mutant p53 genes (11,12).
In conclusion, our results show the contributing role of elevated ROS in the pro-apoptotic
ability of oncogenic H-Ras to increase susceptibilities of human urinary bladder and colorectal
cancer cells as well as mouse embryo fibroblast cells to HDACIs for inducing selective
apoptosis. It is important to utilize the cell killing potential of ROS in control of oncogenic Rasexpressing cancer cells and any cancer cells with potential to generate high levels of ROS by
using ROS-inducing anticancer agents, such as HDACIs, to increase intracellular ROS to induce
selective cell death of target cancer cells. The pro-apoptotic ability of oncogenic H-Ras, through
increases of intracellular ROS, to increase cell susceptibility to HDACIs should be seriously
considered in developing anticancer therapeutics against Ras-related human cancers and any
other types of human cancers with intrinsic ability to generate toxic levels of ROS induced by
HDACIs.
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Summary
These studies demonstrate that oncogenic H-Ras has a pro-apoptotic activity that allows
histone deacetylase inhibitors (HDACIs) to induce selective apoptosis of oncogenic H-Rasexpressed cells (J82-Ras, HT29-Ras, and 10T1/2-Ras). H-Ras-potentiated ROS plays a pivotal
role in the pro-apoptotic ability of oncogenic H-Ras to facilitate HDACI-induced, ROSdependent mitochondrial damage, activation of caspase pathways and selective apoptosis of
oncogenic H-Ras expressed cells. The interplay of above discussed factors can be summarized
by the scheme shown in Figure 1.
Data also indicate that besides differential regulation of ROS, other mechanisms such as
differential regulation of the caspase pathways, the Raf and ERK pathway, the p38/SAPK
pathway, p21Cip1 and p27Kip1, and core histone contents also contributes to FR901228-induced
selective apoptosis of oncogenic H-Ras-expressing, J82-Ras, HT29-Ras, and 10T1/2-Ras cells
versus their parental counterpart cells, though some discrepancies in regulation of the
downstream ERK pathway and PI3K pathway are detectable between these cell lines.

Prospects
Investigate the mechanisms for synergy between oncogenic H-Ras and HDACI in ROS
mediated dell death
Our study revealed significant increases of intracellular ROS cooperatively induced by
expression of oncogenic H-Ras and treatment with HDACIs FR901228 and TSA, leading to
selective induction of apoptosis of oncogenic H-Ras-expressing cancer cells versus their parental
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counterpart cells. However, a mechanism for synergy between oncogenic H-Ras and HDACI in
ROS mediated dell death is not clear and warrant further investigations.

(1) Investigating the antioxidant system of the cell. HDACIs have been shown to deplete
cellular glutathione (13), depletion of cellular glutathione results in ROS accumulation
(8,13). HDACI has also been shown to up-regulate thioredoxin-binding protein-2,
resulting in suppression of thioredoxin, which is a major intracellular scavenger of ROS,
and leading to excessive accumulation of intracellular ROS (14). Glutathione and
thioredoxin represents the two major antioxidant systems of the cells which neutralizes
the cytotoxic effects of ROS (15). Whether depletion of cellular glutathione, upregulation of thioredoxin-binding protein-2, and down-regulation of thiroredoxin are
involved in profound increases of ROS by HDACIs in selective induction of apoptosis in
oncogenic H-Ras-expressing cells remains to be determined.

(2) Investigating the connection between Ras signaling pathways and ROS. Our data
suggest that the Ras-Raf-MEK1/2-ERK1/2 and the p38/SAPK pathways are differentially
regulated in HDACI-induced selective apoptosis of oncogenic H-Ras-expressing cells.
HDACI treatment stimulated the survival role of the ERK pathway and pro-apoptotic role
of the p38/SAPK pathway in oncogenic H-Ras-expressing cells. Recent studies have
shown that ROS participate in both Ras-Raf-MEK1/2-ERK1/2 signaling and the p38
MAPK pathway. Increased intracellular levels of ROS, induced by the Ras-Raf-MEKERK signaling cascade, may mediate the activation of the p38 pathway and act as an
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intermediate signal between the MEK-ERK and MKK3/6-p38 pathways (16). On the
other hand, the activation of p38 mitogen-activated protein kinase (MAPK) has been
shown to be a prerequisite for ROS-mediated functions such as apoptotic cell death in
cancer cells (17). Whether ROS directly mediate the Ras-Raf-MEK1/2-ERK1/2 and p38
MAPK signaling pathways in HDACI-induced selective apoptosis of oncogenic H-Rasexpressing cells remains to be determined.
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Figure 1.
Hypothetical scheme of FR901228-induced ROS-dependent, oncogenic H-Ras-enhanced
caspase pathways for selective apoptosis.
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